U.S. patent application number 13/926481 was filed with the patent office on 2014-01-02 for sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug.
The applicant listed for this patent is Merck, Sharp & Dohme Corp.. Invention is credited to Craig A. Coburn, Chunsing Li, Yunfu Luo, Milana Maletic, Zhiqi Qi, Richard Soll.
Application Number | 20140005103 13/926481 |
Document ID | / |
Family ID | 48782629 |
Filed Date | 2014-01-02 |
United States Patent
Application |
20140005103 |
Kind Code |
A1 |
Coburn; Craig A. ; et
al. |
January 2, 2014 |
SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING
THE PHARMACOKINETICS OF A DRUG
Abstract
The present invention relates to Sulfonamide Derivatives of
Formula (I): ##STR00001## and pharmaceutically acceptable salts
thereof, wherein A, W, X, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and
R.sup.5 are as defined herein. The present invention also relates
to compositions comprising at least one Sulfonamide Derivative, and
methods of using the Sulfonamide Derivatives for improving the
pharmacokinetics of a drug.
Inventors: |
Coburn; Craig A.;
(Royersford, PA) ; Maletic; Milana; (Summit,
NJ) ; Soll; Richard; (Shanghai, CN) ; Li;
Chunsing; (Shanghai, CN) ; Luo; Yunfu;
(Shanghai, CN) ; Qi; Zhiqi; (Shanghai,
CN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Merck, Sharp & Dohme Corp. |
Rahway |
NJ |
US |
|
|
Family ID: |
48782629 |
Appl. No.: |
13/926481 |
Filed: |
June 25, 2013 |
Current U.S.
Class: |
514/4.1 ;
514/230.5; 514/235.8; 514/249; 514/252.11; 514/253.1; 544/105;
544/130; 544/230; 544/349; 544/350; 544/357 |
Current CPC
Class: |
C07D 417/14 20130101;
A61P 31/18 20180101; A61K 31/5383 20130101; A61K 31/4985 20130101;
C07D 487/04 20130101; C07D 401/14 20130101; A61P 43/00 20180101;
C07D 491/04 20130101; A61K 31/5377 20130101; A61K 31/4402 20130101;
C07D 471/10 20130101; A61K 38/05 20130101; A61K 31/513 20130101;
C07D 403/14 20130101; C07D 471/04 20130101; C07D 498/04 20130101;
A61K 31/496 20130101; A61K 45/06 20130101; C07D 417/12
20130101 |
Class at
Publication: |
514/4.1 ;
544/357; 514/252.11; 544/230; 514/253.1; 544/349; 514/249; 544/105;
514/230.5; 544/130; 514/235.8; 544/350 |
International
Class: |
A61K 31/496 20060101
A61K031/496; C07D 471/10 20060101 C07D471/10; C07D 471/04 20060101
C07D471/04; A61K 31/4985 20060101 A61K031/4985; A61K 38/05 20060101
A61K038/05; A61K 31/5383 20060101 A61K031/5383; A61K 31/5377
20060101 A61K031/5377; C07D 487/04 20060101 C07D487/04; A61K 31/513
20060101 A61K031/513; C07D 417/12 20060101 C07D417/12; C07D 498/04
20060101 C07D498/04 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 27, 2012 |
CN |
PCT/CN2011/077611 |
Claims
1. A compound having the formula (I): ##STR00176## or a
pharmaceutically acceptable salt thereof, wherein: A is a 5 or
6-membered heteroarylene group; W is N or --CH--; X is N or
--C(R.sup.3)--; R.sup.1 is selected from --(C.sub.1-C.sub.6
alkylene)-aryl, --(C.sub.1-C.sub.6 alkylene)-(5 or 6-membered
heteroaryl), --(C.sub.1-C.sub.6 alkylene)-O-aryl,
--(C.sub.1-C.sub.6 alkylene)-O-(5 or 6-membered heteroaryl) and
C.sub.3-C.sub.6 cycloalkyl, wherein any aryl, heteroaryl or
C.sub.3-C.sub.6 cycloalkyl group can be optionally substituted with
up to four R.sup.7 groups, which can be the same or different, and
wherein said C.sub.3-C.sub.6 cycloalkyl group can be fused to a
benzene ring and said fused benzene ring can be optionally
substituted with up to four R.sup.7 groups, which can be the same
or different; each occurrence of R.sup.2 is independently selected
from H, C.sub.1-C.sub.6 alkyl, --OH, --O--(C.sub.1-C.sub.6 alkyl)
and --(C.sub.1-C.sub.6 alkylene)-O--(C.sub.1-C.sub.6 alkyl);
R.sup.3 is selected from H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
hydroxyalkyl and --CN, or R.sup.3 and an R.sup.2 group, together
with the carbon atoms to which they are attached, can combine to
form a cyclopropyl ring; R.sup.4 is H, or R.sup.4 and an R.sup.2
group, can join to form a group selected from
--CH.sub.2--CH.sub.2--CH.sub.2--, --C(O)--O--CH.sub.2--,
--CH.sub.2--O--CH.sub.2-- and --CH.sub.2--N(R.sup.8)--CH.sub.2--;
R.sup.5 is --NH(R.sup.6), 5 or 6-membered monocyclic
heterocycloalkyl or 9 or 10-membered bicyclic heterocycloalkyl,
wherein said 5 or 6-membered monocyclic heterocycloalkyl group can
optionally form a spirocycle with a C.sub.3-C.sub.6 cycloalkyl
group or another 5 or 6-membered monocyclic heterocycloalkyl group,
and wherein said 5 or 6-membered monocyclic heterocycloalkyl group
and said 9 or 10-membered bicyclic heterocycloalkyl group can be
optionally substituted on one or more ring carbon atoms with up to
four R.sup.7 groups, which can be the same or different, and
wherein a ring carbon atom of a 5 or 6-membered monocyclic
heterocycloalkyl group may be functionalized as a carbonyl group
R.sup.6 is C.sub.1-C.sub.6 alkyl or 5 or 6-membered heteroaryl,
wherein said C.sub.1-C.sub.6 alkyl group is optionally substituted
with 1 or 2 groups, each independently being NH.sub.2 or halo, and
wherein said 5 or 6-membered heteroaryl group can be optionally
substituted with up to four R.sup.7 groups; each occurrence of
R.sup.7 is independently selected from C.sub.1-C.sub.6 alkyl, 5 or
6-membered heterocycloalkyl, C.sub.1-C.sub.6 hydroxyalkyl,
C.sub.1-C.sub.6 haloalkyl, halo, --CN, --N(R.sup.8).sub.2,
--CH.sub.2N(R.sup.8).sub.2, --OR.sup.8, --C(O)OR.sup.8, --SR.sup.8,
--S(O).sub.2R.sup.8 and --C(O)N(R.sup.8).sub.2, wherein said 5 or
6-membered heterocycloalkyl group can be optionally substituted
with a group selected from C.sub.1-C.sub.6 alkyl, halo,
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.6 haloalkyl, halo,
--CN, --N(R.sup.8).sub.2 and --OR.sup.8; and each occurrence of
R.sup.8 is independently H or C.sub.1-C.sub.6 alkyl.
2. The compound of claim 1, wherein A is thiazolyl, pyridyl or
pyrazinyl.
3. The compound of claim 1, having the formula (Ia): ##STR00177##
or a pharmaceutically acceptable salt thereof, wherein: R.sup.5 is
5 or 6-membered monocyclic heterocycloalkyl, 9 or 10-membered
bicyclic heterocycloalkyl, wherein said 5 or 6-membered monocyclic
heterocycloalkyl group can optionally form a spirocycle with a
C.sub.3-C.sub.6 cycloalkyl group or another 5 or 6-membered
monocyclic heterocycloalkyl group, and wherein said 5 or 6-membered
monocyclic heterocycloalkyl group, said 9 or 10-membered bicyclic
heterocycloalkyl and said spirocycle can be optionally substituted
on one ring carbon atom with C.sub.1-C.sub.6 alkyl or halo; and
each occurrence of R.sup.7 is independently selected from H,
C.sub.1-C.sub.6 alkyl or halo.
4. The compound of claim 3, wherein R.sup.5 is 5 or 6-membered
monocyclic heterocycloalkyl, which can optionally form a spirocycle
and/or be optionally substituted as described in claim 1.
5. The compound of claim 3, wherein R.sup.5 is 9 or 10-membered
bicyclic heterocycloalkyl, which can be optionally substituted as
described in claim 1.
6. The compound of claim 3, wherein R.sup.5 is selected from:
##STR00178##
7. The compound of claim 6, wherein R.sup.7 is halo.
8. The compound of claim 7, wherein R.sup.7 is F.
9. The compound of claim 1, having the structure: ##STR00179##
##STR00180## ##STR00181## ##STR00182## ##STR00183## ##STR00184##
##STR00185## ##STR00186## or a pharmaceutically acceptable salt
thereof.
10. A pharmaceutical composition comprising an effective amount of
a compound of claim 1 and a pharmaceutically acceptable
carrier.
11. The pharmaceutical composition of claim 10, further comprising
an anti-HIV drug.
12. The pharmaceutical composition of claim 11, wherein said
anti-HIV drug is selected from an HIV protease inhibitor, an HIV
integrase inhibitor, a nucleoside reverse transcriptase inhibitor
and a non-nucleoside reverse-transcriptase inhibitor.
13. The pharmaceutical composition of claim 12, wherein said
anti-HIV drug is selected from raltegravir, lamivudine, abacavir,
darunavir, ritonavir, dolutegravir, atazanavir, elvitegravir and
lopinavir.
14. The pharmaceutical composition of claim 13, further comprising
a second anti-HIV drug, which is selected from an HIV protease
inhibitor, an HIV integrase inhibitor, a nucleoside reverse
transcriptase inhibitor and a non-nucleoside reverse-transcriptase
inhibitor.
15. A method for inhibiting a CYP3A enzyme in a subject, comprising
administering to said subject a compound of claim 1, or
pharmaceutically acceptable salt thereof, in an amount that is
effective to inhibit a CYP3A enzyme in said subject.
16. The method of claim 15, wherein the CYP3A enzyme being
inhibited is CYP3A4.
17. A method for improving the pharmacokinetics of a therapeutic
compound that is metabolized by a CYP3A enzyme in subject, said
method comprising administering to said subject in need of such
treatment a combination of: (a) said therapeutic compound that is
metabolized by a CYP3A enzyme and (b) a compound of claim 1, or a
pharmaceutically acceptable salt thereof.
18. The method of claim 17, wherein said therapeutic compound is an
anti-HIV drug.
19. The method of claim 18, wherein said anti-HIV drug is selected
from an HIV protease inhibitor, an HIV integrase inhibitor, a
nucleoside reverse transcriptase inhibitor and a non-nucleoside
reverse-transcriptase inhibitor.
20. The method of claim 19, wherein said anti-HIV drug is selected
from raltegravir, lamivudine, abacavir, ritonavir, dolutegravir,
atazanavir, darunavir, elvitegravir and lopinavir.
21. The method of claim 20, wherein said anti-HIV drug is
raltegravir.
22. The method of claim 17, wherein the therapeutic compound of (a)
is metabolized by CYP3A4.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to Sulfonamide Derivatives,
compositions comprising at least one Sulfonamide Derivative, and
methods of using the Sulfonamide Derivatives for improving the
pharmacokinetics of a drug.
BACKGROUND OF THE INVENTION
[0002] The cytochrome P450 enzyme system (CYP450) is responsible
for the biotransformation of drugs from active substances to
inactive metabolites that can be excreted from the body. In
addition, the metabolism of certain drugs by CYP450 can alter their
PK profile and result in sub-therapeutic plasma levels of those
drugs over time. In the area of anti-viral therapy, this can lead
to resistance of the virus to the drug.
[0003] The virus causing acquired immunodeficiency syndrome (AIDS)
is know by various names, including human immunodeficiency virus
(HIV), of which two distinct families have been identified--HIV-1
and HIV-2. Many inhibitors of HIV, including HIV protease
inhibitors, HIV integrase inhibitors and non-nucleoside reverse
transcriptase inhibitors are metabolized by CYP450. This metabolic
activity can lead to unfavorable pharmacokinetics, requiring
administering more frequent and/or higher doses than are
optimal.
[0004] Many drugs, including some HIV protease inhibitors, are now
paired with other agents that improve exposure of the drug, with
the drug-drug interaction being commonly referred to as "boosting."
International Publication Nos. WO 2006/108879, WO 2007/034312 and
WO 2008/010921; U.S. Patent Publication No. US 2009/0175820; and
U.S. Pat. No. 7,919,488 describe compounds useful as
pharmacokinetic enhancers.
[0005] Ritonavir, a common boosting agent, is widely used with HIV
agents and is an HIV protease inhibitor itself that exerts its
boosting effect through inhibition of Cytochrome P450 3A4 (CYP3A4)
and p-glycoprotein drug transporters. Ritonavir, however, is
associated with certain risks, including hepatotoxicity,
hyperlipidemia and unfavorable gastrointestinal effects.
SUMMARY OF THE INVENTION
[0006] In one aspect, the present invention provides Compounds of
Formula (I):
##STR00002##
and pharmaceutically acceptable salts thereof, wherein:
[0007] A is a 5 or 6-membered heteroarylene group;
[0008] W is N or --CH--;
[0009] X is N or --C(R.sup.3)--;
[0010] R.sup.1 is selected from --(C.sub.1-C.sub.6 alkylene)-aryl,
--(C.sub.1-C.sub.6 alkylene)-(5 or 6-membered heteroaryl),
--(C.sub.1-C.sub.6 alkylene)-O-aryl, --(C.sub.1-C.sub.6
alkylene)-O-(5 or 6-membered heteroaryl) and C.sub.3-C.sub.6
cycloalkyl, wherein any aryl, heteroaryl or C.sub.3-C.sub.6
cycloalkyl group can be optionally substituted with up to four
R.sup.7 groups, which can be the same or different, and wherein
said C.sub.3-C.sub.6 cycloalkyl group can be fused to a benzene
ring and said fused benzene ring can be optionally substituted with
up to four R.sup.7 groups, which can be the same or different;
[0011] each occurrence of R.sup.2 is independently selected from H,
C.sub.1-C.sub.6 alkyl, --OH, --O--(C.sub.1-C.sub.6 alkyl) and
--(C.sub.1-C.sub.6 alkylene)-O--(C.sub.1-C.sub.6 alkyl);
[0012] R.sup.3 is selected from H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 hydroxyalkyl and --CN, or R.sup.3 and an R.sup.2
group, together with the carbon atoms to which they are attached,
can combine to form a cyclopropyl ring;
[0013] R.sup.4 is H, or R.sup.4 and an R.sup.2 group, can join to
form a group selected from --CH.sub.2--CH.sub.2--CH.sub.2--,
--C(O)--O--CH.sub.2--, --CH.sub.2--O--CH.sub.2-- and
--CH.sub.2--N(R.sup.8)--CH.sub.2--;
[0014] R.sup.5 is --NH(R.sup.6), 5 or 6-membered monocyclic
heterocycloalkyl or 9 or 10-membered bicyclic heterocycloalkyl,
wherein said 5 or 6-membered monocyclic heterocycloalkyl group can
optionally form a spirocycle with a C.sub.3-C.sub.6 cycloalkyl
group or another 5 or 6-membered monocyclic heterocycloalkyl group,
and wherein said 5 or 6-membered monocyclic heterocycloalkyl group
and said 9 or 10-membered bicyclic heterocycloalkyl group can be
optionally substituted on one or more ring carbon atoms with up to
four R.sup.7 groups, which can be the same or different, and
wherein a ring carbon atom of a 5 or 6-membered monocyclic
heterocycloalkyl group may be functionalized as a carbonyl
group
[0015] R.sup.6 is C.sub.1-C.sub.6 alkyl or 5 or 6-membered
heteroaryl, wherein said C.sub.1-C.sub.6 alkyl group is optionally
substituted with 1 or 2 groups, each independently being NH.sub.2
or halo, and wherein said 5 or 6-membered heteroaryl group can be
optionally substituted with up to four R.sup.7 groups;
[0016] each occurrence of R.sup.7 is independently selected from
C.sub.1-C.sub.6 alkyl, 5 or 6-membered heterocycloalkyl,
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.6 haloalkyl, halo,
--CN, --N(R.sup.8).sub.2, --CH.sub.2N(R.sup.8).sub.2, --OR.sup.8,
--C(O)OR.sup.8, --SR.sup.8, --S(O).sub.2R.sup.8 and
--C(O)N(R.sup.8).sub.2, wherein said 5 or 6-membered
heterocycloalkyl group can be optionally substituted with a group
selected from C.sub.1-C.sub.6 alkyl, halo, C.sub.1-C.sub.6
hydroxyalkyl, C.sub.1-C.sub.6 haloalkyl, halo, --CN,
--N(R.sup.8).sub.2 and --OR.sup.8; and
[0017] each occurrence of R.sup.8 is independently H or
C.sub.1-C.sub.6 alkyl.
[0018] The Compounds of Formula (I) (also referred to herein as the
"Sulfonamide Derivatives") and pharmaceutically acceptable salts
thereof can inhibit CYP3A4, and are also believed to be useful, for
example, for enhancing or improving the pharmacokinetics of a drug
that is metabolized by CYP3A4. Without being bound by any specific
theory, it is believed that the Sulfonamide Derivatives inhibit
CYP3A4, and possibly other members of the CYP3A family.
[0019] Accordingly, the present invention provides methods for
improving the pharmacokinetics of a therapeutic compound that is
metabolized by CYP3A4, the methods comprising administering to a
subject in need of such treatment an effective amount of a
combination of said drug and a compound of Formula (I) or a
pharmaceutically acceptable salt thereof.
[0020] The present invention also provides methods for inhibiting
CYP3A4 in a subject, comprising administering to said subject a
compound of Formula (I) or pharmaceutically acceptable salt
thereof, in an amount that is effective to inhibit CYP3A4 in said
subject.
[0021] The details of the invention are set forth in the
accompanying detailed description below.
[0022] Although any methods and materials similar to those
described herein can be used in the practice or testing of the
present invention, illustrative methods and materials are now
described. Other embodiments, aspects and features of the present
invention are either further described in or will be apparent from
the ensuing description, examples and appended claims.
DETAILED DESCRIPTION OF THE INVENTION
[0023] The present invention relates to Sulfonamide Derivatives,
compositions comprising at least one Sulfonamide Derivative, and
methods of using the Sulfonamide Derivatives for inhibiting CYP3A4
or for improving the pharmacokinetics of a therapeutic compound
that is metabolized by CYP3A4.
DEFINITIONS AND ABBREVIATIONS
[0024] The terms used herein have their ordinary meaning and the
meaning of such terms is independent at each occurrence thereof.
That notwithstanding and except where stated otherwise, the
following definitions apply throughout the specification and
claims. Chemical names, common names, and chemical structures may
be used interchangeably to describe the same structure. If a
chemical compound is referred to using both a chemical structure
and a chemical name and an ambiguity exists between the structure
and the name, the structure predominates. These definitions apply
regardless of whether a term is used by itself or in combination
with other terms, unless otherwise indicated. Hence, the definition
of "alkyl" applies to "alkyl" as well as the "alkyl" portions of
"hydroxyalkyl," "haloalkyl," "--O-alkyl," etc. . . .
[0025] As used herein, and throughout this disclosure, the
following terms, unless otherwise indicated, shall be understood to
have the following meanings:
[0026] A "subject" is a human or non-human mammal In one
embodiment, a subject is a human. In another embodiment, a subject
is a primate. In another embodiment, a subject is a monkey. In
still another embodiment, the subject is a dog, cat, horse, pig,
hamster or other companion animal.
[0027] The term "effective amount" as used herein, refers to: (i)
an amount administered of a Sulfonamide Derivative, or
pharmaceutically acceptable salt thereof, that is effective for
inhibiting CYP3A4 in a subject, (ii) the amounts administered of
each of a combination of: (A) a Sulfonamide Derivative, or
pharmaceutically acceptable salt thereof, and (B) a therapeutic
compound metabolized by CYP3A4 wherein the amounts administered are
together effective in producing the desired therapeutic,
ameliorative, inhibitory or preventative effect when administered
to a subject. In one embodiment the patient is suffering from HIV
infection or AIDS and the therapeutic compound is an anti-HIV
agent. In the combination therapies of the present invention, an
effective amount can refer to each individual agent or to the
combination as a whole, wherein the amounts of all agents
administered are together effective, but wherein the component
agent of the combination may not be present individually in an
effective amount.
[0028] The term "preventing," as used herein with respect to an HIV
viral infection or AIDS, refers to reducing the likelihood or
severity of HIV infection or AIDS.
[0029] The term "alkyl," as used herein, refers to an aliphatic
hydrocarbon group having one of its hydrogen atoms replaced with a
bond. An alkyl group may be straight or branched and contain from
about 1 to about 20 carbon atoms. In one embodiment, an alkyl group
contains from about 1 to about 12 carbon atoms. In different
embodiments, an alkyl group contains from 1 to 6 carbon atoms
(C.sub.1-C.sub.6 alkyl) or from about 1 to about 4 carbon atoms
(C.sub.1-C.sub.4 alkyl). Non-limiting examples of alkyl groups
include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,
isobutyl, tert-butyl, n-pentyl, neopentyl, isopentyl, n-hexyl,
isohexyl and neohexyl. An alkyl group may be unsubstituted or
substituted by one or more substituents which may be the same or
different, each substituent being independently selected from the
group consisting of halo, alkenyl, alkynyl, aryl, cycloalkyl,
cyano, hydroxy, --O-alkyl, --O-aryl, -alkylene-O-alkyl, alkylthio,
--NH.sub.2, --NH(alkyl), --N(alkyl).sub.2, --NH(cycloalkyl),
--O--C(O)-alkyl, --O--C(O)-aryl, --O--C(O)-cycloalkyl, --C(O)OH and
--C(O)O-alkyl. In one embodiment, an alkyl group is linear. In
another embodiment, an alkyl group is branched. Unless otherwise
indicated, an alkyl group is unsubstituted.
[0030] The term "alkenyl," as used herein, refers to an aliphatic
hydrocarbon group containing at least one carbon-carbon double bond
and having one of its hydrogen atoms replaced with a bond. An
alkenyl group may be straight or branched and contain from about 2
to about 15 carbon atoms. In one embodiment, an alkenyl group
contains from about 2 to about 12 carbon atoms. In another
embodiment, an alkenyl group contains from about 2 to about 6
carbon atoms. Non-limiting examples of alkenyl groups include
ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl,
octenyl and decenyl. An alkenyl group may be unsubstituted or
substituted by one or more substituents which may be the same or
different, each substituent being independently selected from the
group consisting of halo, alkenyl, alkynyl, aryl, cycloalkyl,
cyano, hydroxy, --O-alkyl, --O-aryl, -alkylene-O-alkyl, alkylthio,
--NH.sub.2, --NH(alkyl), --N(alkyl).sub.2, --NH(cycloalkyl),
--O--C(O)-alkyl, --O--C(O)-aryl, --O--C(O)-cycloalkyl, --C(O)OH and
--C(O)O-alkyl. The term "C.sub.2-C.sub.6 alkenyl" refers to an
alkenyl group having from 2 to 6 carbon atoms. Unless otherwise
indicated, an alkenyl group is unsubstituted.
[0031] The term "alkynyl," as used herein, refers to an aliphatic
hydrocarbon group containing at least one carbon-carbon triple bond
and having one of its hydrogen atoms replaced with a bond. An
alkynyl group may be straight or branched and contain from about 2
to about 15 carbon atoms. In one embodiment, an alkynyl group
contains from about 2 to about 12 carbon atoms. In another
embodiment, an alkynyl group contains from about 2 to about 6
carbon atoms. Non-limiting examples of alkynyl groups include
ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. An alkynyl group
may be unsubstituted or substituted by one or more substituents
which may be the same or different, each substituent being
independently selected from the group consisting of halo, alkenyl,
alkynyl, aryl, cycloalkyl, cyano, hydroxy, --O-alkyl, --O-aryl,
-alkylene-O-alkyl, alkylthio, --NH.sub.2, --NH(alkyl),
--N(alkyl).sub.2, --NH(cycloalkyl), --O--C(O)-alkyl,
--O--C(O)-aryl, --O--C(O)-cycloalkyl, --C(O)OH and --C(O)O-alkyl.
The term "C.sub.2-C.sub.6 alkynyl" refers to an alkynyl group
having from 2 to 6 carbon atoms. Unless otherwise indicated, an
alkynyl group is unsubstituted.
[0032] The term "alkylene," as used herein, refers to an alkyl
group, as defined above, wherein one of the alkyl group's hydrogen
atoms has been replaced with a bond. Non-limiting examples of
alkylene groups include --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH(CH.sub.3)CH.sub.2CH.sub.2--, --CH(CH.sub.3)-- and
--CH.sub.2CH(CH.sub.3)CH.sub.2--. In one embodiment, an alkylene
group has from 1 to about 6 carbon atoms. In another embodiment, an
alkylene group has from about 3 to about 5 carbon atoms. In another
embodiment, an alkylene group is branched. In another embodiment,
an alkylene group is linear. In one embodiment, an alkylene group
is --CH.sub.2--. The term "C.sub.1-C.sub.6 alkylene" refers to an
alkylene group having from 1 to 6 carbon atoms. The term
"C.sub.3-C.sub.5 alkylene" refers to an alkylene group having from
3 to 5 carbon atoms.
[0033] The term "alkenylene," as used herein, refers to an alkenyl
group, as defined above, wherein one of the alkenyl group's
hydrogen atoms has been replaced with a bond. Non-limiting examples
of alkenylene groups include --CH.dbd.CH--, --CH.dbd.CHCH.sub.2--,
--CH.sub.2CH.dbd.CH--, --CH.sub.2CH.dbd.CHCH.sub.2--,
--CH.dbd.CHCH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.dbd.CH-- and
--CH(CH.sub.3)CH.dbd.CH--. In one embodiment, an alkenylene group
has from 2 to about 6 carbon atoms. In another embodiment, an
alkenylene group has from about 3 to about 5 carbon atoms. In
another embodiment, an alkenylene group is branched. In another
embodiment, an alkenylene group is linear. The term
"C.sub.2-C.sub.6 alkylene" refers to an alkenylene group having
from 2 to 6 carbon atoms. The term "C.sub.3-C.sub.5 alkenylene"
refers to an alkenylene group having from 3 to 5 carbon atoms.
[0034] The term "aryl," as used herein, refers to an aromatic
monocyclic or multicyclic ring system comprising from about 6 to
about 14 carbon atoms. In one embodiment, an aryl group contains
from about 6 to about 10 carbon atoms. An aryl group can be
optionally substituted with one or more "ring system substituents"
which may be the same or different, and are as defined herein
below. In one embodiment, an aryl group can be optionally fused to
a cycloalkyl or cycloalkanoyl group. Non-limiting examples of aryl
groups include phenyl and naphthyl. In one embodiment, an aryl
group is phenyl. Unless otherwise indicated, an aryl group is
unsubstituted.
[0035] The term "arylene," as used herein, refers to a bivalent
group derived from an aryl group, as defined above, by removal of a
hydrogen atom from a ring carbon of an aryl group. An arylene group
can be derived from a monocyclic or multicyclic ring system
comprising from about 6 to about 14 carbon atoms. In one
embodiment, an arylene group contains from about 6 to about 10
carbon atoms. In another embodiment, an arylene group is a
naphthylene group. In another embodiment, an arylene group is a
phenylene group. An arylene group can be optionally substituted
with one or more "ring system substituents" which may be the same
or different, and are as defined herein below. An arylene group is
divalent and either available bond on an arylene group can connect
to either group flanking the arylene group. For example, the group
"A-arylene-B," wherein the arylene group is:
##STR00003##
is understood to represent both:
##STR00004##
[0036] In one embodiment, an arylene group can be optionally fused
to a cycloalkyl or cycloalkanoyl group. Non-limiting examples of
arylene groups include phenylene and naphthalene. In one
embodiment, an arylene group is unsubstituted. In another
embodiment, an arylene group is:
##STR00005##
Unless otherwise indicated, an arylene group is unsubstituted.
[0037] The term "cycloalkyl," as used herein, refers to a
non-aromatic mono- or multicyclic ring system comprising from about
3 to about 10 ring carbon atoms. In one embodiment, a cycloalkyl
contains from about 5 to about 10 ring carbon atoms. In another
embodiment, a cycloalkyl contains from about 3 to about 7 ring
atoms. In another embodiment, a cycloalkyl contains from about 5 to
about 6 ring atoms. The term "cycloalkyl" also encompasses a
cycloalkyl group, as defined above, which is fused to an aryl
(e.g., benzene) or heteroaryl ring. Non-limiting examples of
monocyclic cycloalkyls include cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Non-limiting
examples of multicyclic cycloalkyls include 1-decalinyl, norbornyl
and adamantyl. A cycloalkyl group can be optionally substituted
with one or more "ring system substituents" which may be the same
or different, and are as defined herein below. In one embodiment, a
cycloalkyl group is unsubstituted. The term "3 to 6-membered
cycloalkyl" refers to a cycloalkyl group having from 3 to 6 ring
carbon atoms. Unless otherwise indicated, a cycloalkyl group is
unsubstituted. A ring carbon atom of a cycloalkyl group may be
functionalized as a carbonyl group. An illustrative example of such
a cycloalkyl group (also referred to herein as a "cycloalkanoyl"
group) includes, but is not limited to, cyclobutanoyl:
##STR00006##
[0038] The term "CYP3A," as used herein, refers to the all the
known members of the 3A subfamily of the cytochrome P450
superfamily of genes. CYP3A includes, but is not limited to CYP3A4,
CYP3A5, CYP3A7 and CYP3A43. In one embodiment, the CYP3A gene is
CYP3A4.
[0039] The term "halo," as used herein, means --F, --Cl, --Br or
--I. In one embodiment, the halo group is F.
[0040] The term "haloalkyl," as used herein, refers to an alkyl
group as defined above, wherein one or more of the alkyl group's
hydrogen atoms has been replaced with a halogen. In one embodiment,
a haloalkyl group has from 1 to 6 carbon atoms. In another
embodiment, a haloalkyl group is substituted with from 1 to 3 F
atoms. Non-limiting examples of haloalkyl groups include --CHF,
--CHF.sub.2, --CF.sub.3, --CH.sub.2Cl and --CCl.sub.3. The term
"C.sub.1-C.sub.6 haloalkyl" refers to a haloalkyl group having from
1 to 6 carbon atoms.
[0041] The term "hydroxyalkyl," as used herein, refers to an alkyl
group as defined above, wherein one or more of the alkyl group's
hydrogen atoms have been replaced with an --OH group. In one
embodiment, a hydroxyalkyl group has from 1 to 6 carbon atoms.
Non-limiting examples of hydroxyalkyl groups include --CH.sub.2OH,
--CH.sub.2CH.sub.2OH, --CH.sub.2CH.sub.2CH.sub.2OH and
--CH.sub.2CH(OH)CH.sub.3. The term "C.sub.1-C.sub.6 hydroxyalkyl"
refers to a hydroxyalkyl group having from 1 to 6 carbon atoms.
[0042] The term "heteroaryl," as used herein, refers to an aromatic
monocyclic or multicyclic ring system comprising about 5 to about
14 ring atoms, wherein from 1 to 4 of the ring atoms is
independently O, N or S and the remaining ring atoms are carbon
atoms. In one embodiment, a heteroaryl group has 5 to 10 ring
atoms. In another embodiment, a heteroaryl group is monocyclic and
has 5 or 6 ring atoms. In another embodiment, a heteroaryl group is
bicyclic. A heteroaryl group can be optionally substituted by one
or more "ring system substituents" which may be the same or
different, and are as defined herein below. A heteroaryl group is
joined via a ring carbon atom, and any nitrogen atom of a
heteroaryl can be optionally oxidized to the corresponding N-oxide.
The term "heteroaryl" also encompasses a heteroaryl group, as
defined above, which is fused to a benzene ring. Non-limiting
examples of heteroaryls include pyridyl, pyrazinyl, furanyl,
thienyl, pyrimidinyl, pyridone (including N-substituted pyridones),
isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl,
pyrazolyl, furazanyl, pyrrolyl, triazolyl, 1,2,4-thiadiazolyl,
pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl,
imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl,
indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl,
imidazolyl, benzimidazolyl, thienopyridyl, quinazolinyl,
thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl,
benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like, and
all isomeric forms thereof. The term "heteroaryl" also refers to
partially saturated heteroaryl moieties such as, for example,
tetrahydroisoquinolyl, tetrahydroquinolyl and the like. In one
embodiment, a heteroaryl group is a 5-membered heteroaryl. In
another embodiment, a heteroaryl group is a 6-membered heteroaryl.
In another embodiment, a heteroaryl group comprises a 5- to
6-membered heteroaryl group fused to a benzene ring. Unless
otherwise indicated, a heteroaryl group is unsubstituted.
[0043] The term "heterocycloalkyl," as used herein, refers to a
non-aromatic saturated monocyclic or multicyclic ring system
comprising 3 to about 11 ring atoms, wherein from 1 to 4 of the
ring atoms are independently O, S, N or Si, and the remainder of
the ring atoms are carbon atoms. A heterocycloalkyl group can be
joined via a ring carbon, ring silicon atom or ring nitrogen atom.
In one embodiment, a heterocycloalkyl group is monocyclic and has
from about 3 to about 7 ring atoms. In another embodiment, a
heterocycloalkyl group is monocyclic has from about 4 to about 7
ring atoms. In another embodiment, the heterocycloalkyl group is
bicyclic and has 9 or 10 ring atoms. In still another embodiment, a
heterocycloalkyl group is monocyclic and has 5 or 6 ring atoms. In
one embodiment, a heterocycloalkyl group is monocyclic. In another
embodiment, a heterocycloalkyl group is bicyclic. There are no
adjacent oxygen and/or sulfur atoms present in the ring system. Any
--NH group in a heterocycloalkyl ring may exist protected such as,
for example, as an --N(BOC), --N(Cbz), --N(Tos) group and the like;
such protected heterocycloalkyl groups are considered part of this
invention. The term "heterocycloalkyl" also encompasses a
heterocycloalkyl group, as defined above, which is fused to an aryl
(e.g., benzene) or heteroaryl ring. A heterocycloalkyl group can be
optionally substituted by one or more "ring system substituents"
which may be the same or different, and are as defined herein
below. The nitrogen or sulfur atom of the heterocycloalkyl can be
optionally oxidized to the corresponding N-oxide, S-oxide or
S,S-dioxide. Non-limiting examples of monocyclic heterocycloalkyl
rings include oxetanyl, piperidyl, pyrrolidinyl, piperazinyl,
morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl,
tetrahydrofuranyl, tetrahydrothiophenyl, delta-lactam,
delta-lactone and the like, and all isomers thereof.
[0044] A ring carbon atom of a heterocycloalkyl group may be
functionalized as a carbonyl group. An illustrative example of such
a heterocycloalkyl group is:
##STR00007##
[0045] In one embodiment, a heterocycloalkyl group is a 5-membered
monocyclic heterocycloalkyl. In another embodiment, a
heterocycloalkyl group is a 6-membered monocyclic heterocycloalkyl.
The term "3 to 6-membered monocyclic cycloalkyl" refers to a
monocyclic heterocycloalkyl group having from 3 to 6 ring atoms.
The term "4 to 6-membered monocyclic cycloalkyl" refers to a
monocyclic heterocycloalkyl group having from 4 to 6 ring atoms.
The term "7 to 11-membered bicyclic heterocycloalkyl" refers to a
bicyclic heterocycloalkyl group having from 7 to 11 ring atoms.
Unless otherwise indicated, an heterocycloalkyl group is
unsubstituted.
[0046] The term "heteroarylene," as used herein, refers to a
bivalent group derived from a heteroaryl group, as defined above,
by removal of a hydrogen atom from a ring carbon of a heteroaryl
group. A heteroarylene group can be derived from a monocyclic or
multicyclic ring system comprising from about 6 to about 14 carbon
atoms. In one embodiment, a heteroarylene group contains from about
6 to about 10 carbon atoms. In another embodiment, a heteroarylene
group is a naphthylene group. In another embodiment, a
heteroarylene group is a phenylene group. A heteroarylene group can
be optionally substituted with one or more "ring system
substituents" which may be the same or different, and are as
defined herein below. A heteroarylene group is divalent and either
available bond on a heteroarylene group can connect to either group
flanking the heteroarylene group. For example, the group
"A-heteroarylene-B," wherein the arylene group is:
##STR00008##
is understood to represent both:
##STR00009##
[0047] Non-limiting examples of heteroarylene groups include
thiazolyl, pyridyl, pyranyl, tetrahydropyranyl, pyrmidinyl,
indolyl, benzoquinolinyl, oxazolyl, benzisoxazolyl and pyrazinyl.
In one embodiment, a heteroarylene group is unsubstituted. Unless
otherwise indicated, a heteroarylene group is unsubstituted.
[0048] The term "HIV," as used herein, refers generically to all
known species of the HIV virus, including, but not limited to,
HIV-1 and HIV-2.
[0049] The term "ring system substituent," as used herein, refers
to a substituent group attached to an aromatic or non-aromatic ring
system which, for example, replaces an available hydrogen on the
ring system. Ring system substituents may be the same or different,
each being independently selected from the group consisting of
alkyl, alkenyl, alkynyl, aryl, heteroaryl, -alkylene-aryl,
-arylene-alkyl, -alkylene-heteroaryl, -alkenylene-heteroaryl,
-alkynylene-heteroaryl, --OH, hydroxyalkyl, haloalkyl, --O-alkyl,
--O-haloalkyl, -alkylene-O-alkyl, --O-aryl, --O-alkylene-aryl,
acyl, --C(O)-aryl, halo, --NO.sub.2, --CN, --SF.sub.5, --C(O)OH,
--C(O)O-alkyl, --C(O)O-aryl, --C(O)O-alkylene-aryl, --S(O)-alkyl,
--S(O).sub.2-alkyl, --S(O)-aryl, --S(O).sub.2-aryl,
--S(O)-heteroaryl, --S(O).sub.2-heteroaryl, --S-alkyl, --S-aryl,
--S-heteroaryl, --S-alkylene-aryl, --S-alkylene-heteroaryl,
--S(O).sub.2-alkylene-aryl, --S(O).sub.2-alkylene-heteroaryl,
--Si(alkyl).sub.2, --Si(aryl).sub.2, --Si(heteroaryl).sub.2,
--Si(alkyl)(aryl), --Si(alkyl)(cycloalkyl),
--Si(alkyl)(heteroaryl), cycloalkyl, heterocycloalkyl,
--O--C(O)-alkyl, --O--C(O)-aryl, --O--C(O)-cycloalkyl,
--C(.dbd.N--CN)--NH.sub.2, --C(.dbd.NH)--NH.sub.2,
--C(.dbd.NH)--NH(alkyl), --N(Y.sub.1)(Y.sub.2),
-alkylene-N(Y.sub.1)(Y.sub.2), --C(O)N(Y.sub.1)(Y.sub.2) and
--S(O).sub.2N(Y.sub.1)(Y.sub.2), wherein Y.sub.1 and Y.sub.2 can be
the same or different and are independently selected from the group
consisting of hydrogen, alkyl, aryl, cycloalkyl, and
-alkylene-aryl. "Ring system substituent" may also mean a single
moiety which simultaneously replaces two available hydrogens on two
adjacent carbon atoms (one H on each carbon) on a ring system.
Examples of such moiety are methylenedioxy, ethylenedioxy,
--C(CH.sub.3).sub.2-- and the like which form moieties such as, for
example:
##STR00010##
[0050] The term "substituted" means that one or more hydrogens on
the designated atom is replaced with a selection from the indicated
group, provided that the designated atom's normal valency under the
existing circumstances is not exceeded, and that the substitution
results in a stable compound. Combinations of substituents and/or
variables are permissible only if such combinations result in
stable compounds. By "stable compound` or "stable structure" is
meant a compound that is sufficiently robust to survive isolation
to a useful degree of purity from a reaction mixture, and
formulation into an efficacious therapeutic agent.
[0051] The term "in substantially purified form," as used herein,
refers to the physical state of a compound after the compound is
isolated from a synthetic process (e.g., from a reaction mixture),
a natural source, or a combination thereof. The term "in
substantially purified form," also refers to the physical state of
a compound after the compound is obtained from a purification
process or processes described herein or well-known to the skilled
artisan (e.g., chromatography, recrystallization and the like), in
sufficient purity to be characterizable by standard analytical
techniques described herein or well-known to the skilled
artisan.
[0052] It should also be noted that any carbon as well as
heteroatom with unsatisfied valences in the text, schemes, examples
and tables herein is assumed to have the sufficient number of
hydrogen atom(s) to satisfy the valences.
[0053] When a functional group in a compound is termed "protected",
this means that the group is in modified form to preclude undesired
side reactions at the protected site when the compound is subjected
to a reaction. Suitable protecting groups will be recognized by
those with ordinary skill in the art as well as by reference to
standard textbooks such as, for example, T. W. Greene et al,
Protective Groups in Organic Synthesis (1991), Wiley, New York.
[0054] When any substituent or variable (e.g., C.sub.1-C.sub.6
alkyl, R.sup.2, R.sup.8, etc.) occurs more than one time in any
constituent or in Formula (I), its definition on each occurrence is
independent of its definition at every other occurrence, unless
otherwise indicated.
[0055] As used herein, the term "composition" is intended to
encompass a product comprising the specified ingredients in the
specified amounts, as well as any product which results, directly
or indirectly, from combination of the specified ingredients in the
specified amounts.
[0056] Prodrugs and solvates of the compounds of the invention are
also contemplated herein. A discussion of prodrugs is provided in
T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems
(1987) 14 of the A.C.S. Symposium Series, and in Bioreversible
Carriers in Drug Design, (1987) Edward B. Roche, ed., American
Pharmaceutical Association and Pergamon Press. The term "prodrug"
means a compound (e.g., a drug precursor) that is transformed in
vivo to provide a Sulfonamide Derivative or a pharmaceutically
acceptable salt of the compound. The transformation may occur by
various mechanisms (e.g., by metabolic or chemical processes), such
as, for example, through hydrolysis in blood.
[0057] For example, if a Sulfonamide Derivative or a
pharmaceutically acceptable salt, hydrate or solvate of the
compound contains a carboxylic acid functional group, a prodrug can
comprise an ester formed by the replacement of the hydrogen atom of
the acid group with a group such as, for example,
(C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.12)alkanoyloxymethyl,
1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms,
1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms,
alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms,
1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms,
1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon
atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon
atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon
atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl,
di-N,N--(C.sub.1-C.sub.2)alkylamino(C.sub.2-C.sub.3)alkyl (such as
.beta.-dimethylaminoethyl), carbamoyl-(C.sub.1-C.sub.2)alkyl,
N,N-di(C.sub.1-C.sub.2)alkylcarbamoyl-(C.sub.1-C.sub.2)alkyl and
piperidino-, pyrrolidino- or morpholino(C.sub.2-C.sub.3)alkyl, and
the like. Similarly, if a Sulfonamide Derivative contains an
alcohol functional group, a prodrug can be formed by the
replacement of one or more of the hydrogen atoms of the alcohol
groups with a group such as, for example,
(C.sub.1-C.sub.6)alkanoyloxymethyl,
1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
1-methyl-1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
(C.sub.1-C.sub.6)alkoxycarbonyloxymethyl,
N--(C.sub.1-C.sub.6)alkoxycarbonylaminomethyl, succinoyl,
(C.sub.1-C.sub.6)alkanoyl, .alpha.-amino(C.sub.1-C.sub.4)alkyl,
.alpha.-amino(C.sub.1-C.sub.4)alkylene-aryl, arylacyl and
.alpha.-aminoacyl, or .alpha.-aminoacyl-.alpha.-aminoacyl, where
each .alpha.-aminoacyl group is independently selected from the
naturally occurring L-amino acids, or glycosyl (the radical
resulting from the removal of a hydroxyl group of the hemiacetal
form of a carbohydrate) or a phosphate of structure PO.sub.3M.sub.2
where M is either sodium or potassium.
[0058] If a Sulfonamide Derivative incorporates an amine functional
group, a prodrug can be formed by the replacement of a hydrogen
atom in the amine group with a group such as, for example,
R-carbonyl-, RO-carbonyl-, NRR'-carbonyl- wherein R and R' are each
independently (C.sub.1-C.sub.10)alkyl, (C.sub.3-C.sub.7)cycloalkyl,
benzyl, a natural .alpha.-aminoacyl, --C(OH)C(O)OY.sup.1 wherein
Y.sup.1 is H, (C.sub.1-C.sub.6)alkyl or benzyl,
--C(OY.sup.2)Y.sup.3 wherein Y.sup.2 is (C.sub.1-C.sub.4)alkyl and
Y.sup.3 is (C.sub.1-C.sub.6)alkyl; carboxy(C.sub.1-C.sub.6)alkyl;
amino(C.sub.1-C.sub.4)alkyl or mono-N-- or
di-N,N--(C.sub.1-C.sub.6)alkylaminoalkyl; --C(Y.sup.4)Y.sup.5
wherein Y.sup.4 is H or methyl and Y.sup.5 is mono-N- or
di-N,N--(C.sub.1-C.sub.6)alkylamino morpholino; piperidin-1-yl or
pyrrolidin-1-yl, and the like.
[0059] Pharmaceutically acceptable esters of the present compounds
include the following groups: (1) carboxylic acid esters obtained
by esterification of the hydroxy group of a hydroxyl compound, in
which the non-carbonyl moiety of the carboxylic acid portion of the
ester grouping is selected from straight or branched chain alkyl
(e.g., methyl, ethyl, n-propyl, isopropyl, t-butyl, sec-butyl or
n-butyl), alkoxyalkyl (e.g., methoxymethyl), aralkyl (e.g.,
benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (e.g.,
phenyl optionally substituted with, for example, halogen,
C.sub.1-4alkyl, --O--(C.sub.1-4alkyl) or amino); (2) sulfonate
esters, such as alkyl- or aralkylsulfonyl (for example,
methanesulfonyl); (3) amino acid esters (e.g., L-valyl or
L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or
triphosphate esters. The phosphate esters may be further esterified
by, for example, a C.sub.1-20 alcohol or reactive derivative
thereof, or by a 2,3-di(C.sub.6-24)acyl glycerol.
[0060] One or more compounds of the invention may exist in
unsolvated as well as solvated forms with pharmaceutically
acceptable solvents such as water, ethanol, and the like, and it is
intended that the invention embrace both solvated and unsolvated
forms. "Solvate" means a physical association of a compound of this
invention with one or more solvent molecules. This physical
association involves varying degrees of ionic and covalent bonding,
including hydrogen bonding. In certain instances the solvate will
be capable of isolation, for example when one or more solvent
molecules are incorporated in the crystal lattice of the
crystalline solid. "Solvate" encompasses both solution-phase and
isolatable solvates. Non-limiting examples of solvates include
ethanolates, methanolates, and the like. A "hydrate" is a solvate
wherein the solvent molecule is water.
[0061] One or more compounds of the invention may optionally be
converted to a solvate. Preparation of solvates is generally known.
Thus, for example, M. Caira et al, J. Pharmaceutical Sci., 93(3),
601-611 (2004) describe the preparation of the solvates of the
antifungal fluconazole in ethyl acetate as well as from water.
Similar preparations of solvates, hemisolvate, hydrates and the
like are described by E. C. van Tonder et al, AAPS
PharmSciTechours., 5(1), article 12 (2004); and A. L. Bingham et
al, Chem. Commun., 603-604 (2001). A typical, non-limiting, process
involves dissolving the inventive compound in desired amounts of
the desired solvent (organic or water or mixtures thereof) at a
higher than room temperature, and cooling the solution at a rate
sufficient to form crystals which are then isolated by standard
methods. Analytical techniques such as, for example IR
spectroscopy, show the presence of the solvent (or water) in the
crystals as a solvate (or hydrate).
[0062] The Sulfonamide Derivatives can form salts which are also
within the scope of this invention. Reference to a Sulfonamide
Derivative herein is understood to include reference to salts
thereof, unless otherwise indicated. The term "salt(s)", as
employed herein, denotes acidic salts formed with inorganic and/or
organic acids, as well as basic salts formed with inorganic and/or
organic bases. In addition, when a Sulfonamide Derivative contains
both a basic moiety, such as, but not limited to a pyridine or
imidazole, and an acidic moiety, such as, but not limited to a
carboxylic acid, zwitterions ("inner salts") may be formed and are
included within the term "salt(s)" as used herein. In one
embodiment, the salt is a pharmaceutically acceptable (i.e.,
non-toxic, physiologically acceptable) salt. In another embodiment,
the salt is other than a pharmaceutically acceptable salt. Salts of
the Compounds of Formula (I) may be formed, for example, by
reacting a Sulfonamide Derivative with an amount of acid or base,
such as an equivalent amount, in a medium such as one in which the
salt precipitates or in an aqueous medium followed by
lyophilization.
[0063] Exemplary acid addition salts include acetates, ascorbates,
benzoates, benzenesulfonates, bisulfates, borates, butyrates,
citrates, camphorates, camphorsulfonates, fumarates,
hydrochlorides, hydrobromides, hydroiodides, lactates, maleates,
methanesulfonates, naphthalenesulfonates, nitrates, oxalates,
phosphates, propionates, salicylates, succinates, sulfates,
tartarates, thiocyanates, toluenesulfonates (also known as
tosylates) and the like. Additionally, acids which are generally
considered suitable for the formation of pharmaceutically useful
salts from basic pharmaceutical compounds are discussed, for
example, by P. Stahl et al, Camille G. (eds.) Handbook of
Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich:
Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences
(1977) 66(1) 1-19; P. Gould, International J of Pharmaceutics
(1986) 33 201-217; Anderson et al, The Practice of Medicinal
Chemistry (1996), Academic Press, New York; and in The Orange Book
(Food & Drug Administration, Washington, D.C. on their
website). These disclosures are incorporated herein by reference
thereto.
[0064] Exemplary basic salts include ammonium salts, alkali metal
salts such as sodium, lithium, and potassium salts, alkaline earth
metal salts such as calcium and magnesium salts, salts with organic
bases (for example, organic amines) such as dicyclohexylamine,
t-butyl amine, choline, and salts with amino acids such as
arginine, lysine and the like. Basic nitrogen-containing groups may
be quarternized with agents such as lower alkyl halides (e.g.,
methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl
sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long
chain halides (e.g., decyl, lauryl, and stearyl chlorides, bromides
and iodides), aralkyl halides (e.g., benzyl and phenethyl
bromides), and others.
[0065] All such acid salts and base salts are intended to be
pharmaceutically acceptable salts within the scope of the invention
and all acid and base salts are considered equivalent to the free
forms of the corresponding compounds for purposes of the
invention.
[0066] Diastereomeric mixtures can be separated into their
individual diastereomers on the basis of their physical chemical
differences by methods well-known to those skilled in the art, such
as, for example, by chromatography and/or fractional
crystallization. Enantiomers can be separated by converting the
enantiomeric mixture into a diastereomeric mixture by reaction with
an appropriate optically active compound (e.g., chiral auxiliary
such as a chiral alcohol or Mosher's acid chloride), separating the
diastereomers and converting (e.g., hydrolyzing) the individual
diastereomers to the corresponding pure enantiomers.
Sterochemically pure compounds may also be prepared by using chiral
starting materials or by employing salt resolution techniques.
Also, some of the Sulfonamide Derivatives may be atropisomers
(e.g., substituted biaryls) and are considered as part of this
invention. Enantiomers can also be directly separated using chiral
chromatographic techniques.
[0067] It is also possible that the Sulfonamide Derivatives may
exist in different tautomeric forms, and all such forms are
embraced within the scope of the invention. For example, all
keto-enol and imine-enamine forms of the compounds are included in
the invention.
[0068] All stereoisomers (for example, geometric isomers, optical
isomers and the like) of the present compounds (including those of
the salts, solvates, hydrates, esters and prodrugs of the compounds
as well as the salts, solvates and esters of the prodrugs), such as
those which may exist due to asymmetric carbons on various
substituents, including enantiomeric forms (which may exist even in
the absence of asymmetric carbons), rotameric forms, atropisomers,
and diastereomeric forms, are contemplated within the scope of this
invention. If a Sulfonamide Derivative incorporates a double bond
or a fused ring, both the cis- and trans-forms, as well as
mixtures, are embraced within the scope of the invention.
[0069] Individual stereoisomers of the compounds of the invention
may, for example, be substantially free of other isomers, or may be
admixed, for example, as racemates or with all other, or other
selected, stereoisomers. The chiral centers of the present
invention can have the S or R configuration as defined by the IUPAC
1974 Recommendations. The use of the terms "salt", "solvate",
"ester", "prodrug" and the like, is intended to apply equally to
the salt, solvate, ester and prodrug of enantiomers, stereoisomers,
rotamers, tautomers, positional isomers, racemates or prodrugs of
the inventive compounds.
[0070] In the Compounds of Formula (I), the atoms may exhibit their
natural isotopic abundances, or one or more of the atoms may be
artificially enriched in a particular isotope having the same
atomic number, but an atomic mass or mass number different from the
atomic mass or mass number predominantly found in nature. The
present invention is meant to include all suitable isotopic
variations of the compounds of generic Formula I. For example,
different isotopic forms of hydrogen (H) include protium (.sup.1H)
and deuterium (.sup.2H). Protium is the predominant hydrogen
isotope found in nature. Enriching for deuterium may afford certain
therapeutic advantages, such as increasing in vivo half-life or
reducing dosage requirements, or may provide a compound useful as a
standard for characterization of biological samples.
Isotopically-enriched Compounds of Formula (I) can be prepared
without undue experimentation by conventional techniques well known
to those skilled in the art or by processes analogous to those
described in the Schemes and Examples herein using appropriate
isotopically-enriched reagents and/or intermediates. In one
embodiment, a Compound of Formula (I) has one or more of its
hydrogen atoms replaced with deuterium.
[0071] Polymorphic forms of the Sulfonamide Derivatives, and of the
salts, solvates, hydrates, esters and prodrugs of the Sulfonamide
Derivatives, are intended to be included in the present
invention.
[0072] The following abbreviations are used below and have the
following meanings: AcOH is acetic acid; Boc is
tert-butyloxycarbonyl, (Boc).sub.2O or Boc.sub.2O is Boc anhydride;
n-BuLi is n-butyl lithium; t-BuNO.sub.2 or t-BuONO is tert-butyl
nitrite; Cbz is carboxybenzyl; DCM is dichloromethane; DIEA is
N,N-diisopropylethylamine; DMF is dimethylformamide; DMSO is
dimethylsulfoxide; EtOAc is ethyl acetate; EtOH is ethanol;
Et.sub.3 or TEA is triethylamine; HMPA is hexamethylphosphoramide;
HOAc is acetic acid; HPLC is high-pressure liquid chromatography;
KSCN is potassium thiocyanate; LCMS is liquid chromatography-mass
spectrometry; LDA is lithium diisopropylamide; MeCN is
acetonitrile; MeI is iodomethane; MeOH is methanol; MS is mass
spectroscopy; NaBH(OAc).sub.3 is sodium triacetoxy borohydride; NMR
is nuclear magnetic resonance spectroscopy; PCy.sub.3 is
tricyclohexylphosphine; Pd(OAc).sub.2 is palladium(II) acetate;
Pd.sub.2(dba).sub.3 is tris dibenzylideneacetone dipalladium; PE is
petroleum ether; PG is protecting group; Pd/C is palladium on
carbon; Prep is preparative; rt is room temperature; TBAF is
n-tetrabutylammonium fluoride; TFA is trifluoroacetic acid; TLC is
thin-layer chromatography; TMSCN is trimethylsilyl cyanide; Ts is
4-toluenesulfonyl; THF is tetrahydrofuran; wt % is percentage by
weight; and X-phos is
2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl.
The Compounds of Formula (I)
[0073] The present invention provides Sulfonamide Derivatives of
Formula (I):
##STR00011##
and pharmaceutically acceptable salts thereof, wherein A, W,
R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined above
for the Compounds of Formula (I).
[0074] In one embodiment, A is 5-membered heteroarylene.
[0075] In another embodiment, A is 6-membered heteroarylene.
[0076] In another embodiment, A is thiazolyl.
[0077] In another embodiment, A is pyridyl.
[0078] In another embodiment, A is pyrazinyl.
[0079] In one embodiment, W is N.
[0080] In another embodiment, W is CH.
[0081] In one embodiment, X is N.
[0082] In another embodiment, X is --C(R.sup.3)--.
[0083] In another embodiment, X is --CH--.
[0084] In still another embodiment, X is --C(R.sup.3)-- and R.sup.3
and an R.sup.2 group, together with the carbon atoms to which they
are attached, combine to form a cyclopropyl ring.
[0085] In one embodiment, R.sup.1 is --(C.sub.1-C.sub.6
alkylene)-aryl, wherein said aryl moiety can be optionally
substituted.
[0086] In another embodiment, R.sup.1 is --CH(CH.sub.3)-phenyl,
wherein said phenyl moiety can be optionally substituted with up to
four R.sup.7 groups, which can be the same or different.
[0087] In another embodiment, R.sup.1 is selected from:
##STR00012##
[0088] In another embodiment, R.sup.1 is:
##STR00013##
[0089] In still another embodiment, R.sup.1 is --(C.sub.1-C.sub.6
alkylene)-(5 or 6-membered heteroaryl), wherein said 5 or
6-membered heteroaryl moiety can be optionally substituted.
[0090] In another embodiment, R.sup.1 is --(C.sub.1-C.sub.6
alkylene)-O-aryl, wherein said aryl moiety can be optionally
substituted.
[0091] In yet another embodiment, R.sup.1 is --(C.sub.1-C.sub.6
alkylene)-O-(5 or 6-membered heteroaryl), wherein said 5 or
6-membered heteroaryl moiety can be optionally substituted
[0092] In a further embodiment, R.sup.1 is C.sub.3-C.sub.6
cycloalkyl, which can be optionally substituted.
[0093] In one embodiment, each occurrence of R.sup.2 is H.
[0094] In another embodiment, one occurrence of R.sup.2 is H and
the other occurrence of R.sup.2 is other than H.
[0095] In another embodiment, one occurrence of R.sup.2 is H and
the other occurrence of R.sup.2 is --OH.
[0096] In still another embodiment, one occurrence of R.sup.2 is H
and the other occurrence of R.sup.2 is --O--(C.sub.1-C.sub.6
alkyl).
[0097] In another embodiment, one occurrence of R.sup.2 is H and
the other occurrence of R.sup.2 is --(C.sub.1-C.sub.6
alkylene)-O--(C.sub.1-C.sub.6 alkyl).
[0098] In still another embodiment, one occurrence of R.sup.2 is H
and the other occurrence of R.sup.2 is --OCH.sub.3 or
--CH.sub.2CH.sub.2OCH.sub.3.
[0099] In one embodiment R.sup.3 is H.
[0100] In another embodiment, R.sup.3 is --CH.sub.2OH or --CN.
[0101] In one embodiment R.sup.4 is H.
[0102] In another embodiment, R.sup.4 and an R.sup.2 group, join to
form a group selected from --CH.sub.2--CH.sub.2--CH.sub.2--,
--C(O)--O--CH.sub.2--, --CH.sub.2--O--CH.sub.2-- and
--CH.sub.2--N(R.sup.8)--CH.sub.2--;
[0103] In one embodiment R.sup.5 is --NH(R.sup.6).
[0104] In another embodiment R.sup.5 is --NH(R.sup.6), wherein
R.sup.6 is pyridyl, which can be optionally substituted.
[0105] In another embodiment R.sup.5 is:
##STR00014##
[0106] In still another embodiment, R.sup.5 is 5 or 6-membered
monocyclic heterocycloalkyl, which is optionally substituted.
[0107] In another embodiment, R.sup.5 is 9 or 10 membered bicyclic
heterocycloalkyl, which is optionally substituted.
[0108] In another embodiment, R.sup.5 is 5 or 6-membered monocyclic
heterocycloalkyl, which forms a spirocycle with a C.sub.3-C.sub.6
cycloalkyl group or another 5 or 6-membered monocyclic
heterocycloalkyl group.
[0109] In yet another embodiment, R.sup.5 is selected from:
##STR00015##
[0110] In one embodiment, X is N and each of R.sup.2 is H.
[0111] In another embodiment, X is N, each of R.sup.2 is H, and
R.sup.4 is H.
[0112] In another embodiment, W is CH, X is N, each of R.sup.2 is
H, and R.sup.4 is H.
[0113] In one embodiment, R.sup.1 is selected from:
##STR00016##
and R.sup.5 is selected from:
##STR00017##
[0114] In one embodiment, the compounds of formula (I) have the
formula (Ia):
##STR00018##
or a pharmaceutically acceptable salt thereof, wherein:
[0115] R.sup.5 is 5 or 6-membered monocyclic heterocycloalkyl, 9 or
10-membered bicyclic heterocycloalkyl, wherein said 5 or 6-membered
monocyclic heterocycloalkyl group can optionally form a spirocycle
with a C.sub.3-C.sub.6 cycloalkyl group or another 5 or 6-membered
monocyclic heterocycloalkyl group, and wherein said 5 or 6-membered
monocyclic heterocycloalkyl group, said 9 or 10-membered bicyclic
heterocycloalkyl and said spirocycle can be optionally substituted
on one ring carbon atom with C.sub.1-C.sub.6 alkyl or halo; and
[0116] each occurrence of R.sup.7 is independently selected from H,
C.sub.1-C.sub.6 alkyl or halo.
[0117] In one embodiment, for the compounds of Formula (Ia),
R.sup.5 is 5 or 6-membered monocyclic heterocycloalkyl, which is
optionally as described above for the compounds of formula
(Ia).
[0118] In another embodiment, for the compounds of Formula (Ia),
R.sup.5 is 9 or 10 membered bicyclic heterocycloalkyl, which is
optionally substituted as described above for the compounds of
formula (Ia).
[0119] In another embodiment, for the compounds of Formula (Ia),
R.sup.5 is 5 or 6-membered monocyclic heterocycloalkyl, which forms
a spirocycle with a C.sub.3-C.sub.6 cycloalkyl group or another 5
or 6-membered monocyclic heterocycloalkyl group.
[0120] In yet another embodiment, for the compounds of Formula
(Ia), R.sup.5 is selected from:
##STR00019##
[0121] In one embodiment, for the compounds of Formula (Ia),
R.sup.7 is halo.
[0122] In another embodiment, for the compounds of Formula (Ia),
R.sup.7 is H.
[0123] In another embodiment, for the compounds of Formula (Ia),
R.sup.7 is C.sub.1-C.sub.6 alkyl.
[0124] In still another embodiment, for the compounds of Formula
(Ia), R.sup.7 is F.
[0125] In one embodiment, for the compounds of Formula (Ia),
R.sup.5 is selected from:
##STR00020##
and
[0126] R.sup.7 is F.
[0127] In one embodiment, variables A, W, R.sup.1, R.sup.2,
R.sup.3, R.sup.4 and R.sup.5 for the Compounds of Formula (I) are
selected independently of each other.
[0128] In another embodiment, the Compounds of Formula (I) are in
substantially purified form.
[0129] Other embodiments of the present invention include the
following:
[0130] (a) A pharmaceutical composition comprising an effective
amount of a Compound of Formula (I) or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable
carrier.
[0131] (b) The pharmaceutical composition of (a), further
comprising one or more therapeutic compounds that are metabolized
by CYP3A4.
[0132] (c) The pharmaceutical composition of (b), wherein the
therapeutic compound is an anti-HIV drug, preferably the anti-HIV
drug(s) are selected from the group consisting of HIV protease
inhibitors, HIV integrase inhibitors nucleoside reverse
transcriptase inhibitors and non-nucleoside reverse-transcriptase
inhibitors.
[0133] (d) A pharmaceutical combination that is (i) a Compound of
Formula (I) and ii) a therapeutic compound metabolized by CYP3A4;
wherein the Compound of Formula (I) and the therapeutic compound
metabolized by CYP3A4 are each employed in an amount that renders
the combination effective for inhibiting HIV replication, or for
treating HIV infection and/or reducing the likelihood or severity
of symptoms of HIV infection.
[0134] (e) The combination of (d), wherein the therapeutic compound
metabolized by CYP3A4 is selected from the group consisting of HIV
protease inhibitors, HIV integrase inhibitors, nucleoside reverse
transcriptase inhibitors and non-nucleoside reverse-transcriptase
inhibitors.
[0135] (f) A method of inhibiting HIV replication in a subject in
need thereof which comprises administering to the subject: (i) a
Compound of Formula (I) and (ii) one or more anti-HIV drugs,
wherein the amounts of the Compound of Formula (I) and the anti-HIV
drug(s) are together effective to inhibit HIV replication.
[0136] (g) A method of treating HIV infection and/or reducing the
likelihood or severity of symptoms of HIV infection in a subject in
need thereof which comprises administering to the subject (i) a
Compound of Formula (I) and (ii) one or more anti-HIV drugs,
wherein the amounts of the Compound of Formula (I) and the anti-HIV
drug(s) are together effective to treat HIV infection.
[0137] (h) The method of (h), wherein the anti-HIV drug(s) are an
selected from the group consisting of HIV protease inhibitors, HIV
integrase inhibitors, nucleoside reverse transcriptase inhibitors
and non-nucleoside reverse-transcriptase inhibitors.
[0138] (i) A method of inhibiting HIV replication in a subject in
need thereof which comprises administering to the subject the
pharmaceutical composition of (b) or (c) or the combination of (d)
or (e).
[0139] (j) A method of treating HIV infection and/or reducing the
likelihood or severity of symptoms of HIV infection in a subject in
need thereof which comprises administering to the subject the
pharmaceutical composition of (b) or (c) or the combination of (d)
or (e).
[0140] The present invention also includes a compound of the
present invention for use (i) in, (ii) as a medicament for, or
(iii) in the preparation of a medicament for: (a) medicine, (b)
inhibiting HIV replication or (c) treating HIV infection and/or
reducing the likelihood or severity of symptoms of HIV infection.
In these uses, the compounds of the present invention are employed
in combination with one or more anti-HIV drugs.
[0141] Additional embodiments of the invention include the
pharmaceutical compositions, combinations and methods set forth in
(a)-(j) above and the uses set forth in the preceding paragraph,
wherein the compound of the present invention employed therein is a
compound of one of the embodiments, aspects, classes, sub-classes,
or features of the compounds described above. In all of these
embodiments, the compound may optionally be used in the form of a
pharmaceutically acceptable salt or hydrate as appropriate. It is
understood that references to compounds would include the compound
in its present form as well as in different forms, such as
polymorphs, solvates and hydrates, as applicable.
[0142] It is further to be understood that the embodiments of
compositions and methods provided as (a) through (j) above are
understood to include all embodiments of the compounds, including
such embodiments as result from combinations of embodiments.
[0143] The Compounds of Formula (I) may be referred to herein by
chemical structure and/or by chemical name. In the instance that
both the structure and the name of a Compound of Formula (I) are
provided and a discrepancy is found to exist between the chemical
structure and the corresponding chemical name, it is understood
that the chemical structure will predominate.
[0144] Non-limiting examples of the Compounds of Formula (I)
include compounds 1-48 as set forth below, and pharmaceutically
acceptable salts thereof.
Uses of the Sulfonamide Derivatives
[0145] The Sulfonamide Derivatives are useful in human and
veterinary medicine for inhibiting CYP3A4. In addition, the
Sulfonamide Derivatives are useful for improving the
pharmacokinetics of a therapeutic compound that is metabolized by
CYP3A4.
[0146] The present invention provides novel Sulfonamide Derivatives
of Formula (I) that inhibit CYP3A. Uses of the compounds of Formula
(I) described herein include inhibiting CYP3A, which may be useful
for increasing the pharmacokinetics of compounds that are
metabolized by CYP3A.
Inhibition of CYP3A4
[0147] The present invention provides methods for inhibiting CYP3A4
in a subject, said method comprising administering to said subject
a Sulfonamide Derivative, or pharmaceutically acceptable salt
thereof, in an amount that is effective to inhibit CYP3A4 in said
subject.
[0148] The present invention also provides methods that may be, or
are believed to be, useful for inhibiting other members of CYP3A in
a subject, said method comprising administering to said subject a
Sulfonamide Derivative, or pharmaceutically acceptable salt
thereof, in an amount that is effective to inhibit CYP3A in said
subject. In one embodiment, the CYP3A being inhibited is CYP3A5. In
another embodiment, the CYP3A being inhibited is CYP3A7. In another
embodiment, the CYP3A being inhibited is CYP3A743.
Improving the Pharmacokinetics of a Therapeutic Compound that is
Metabolized by CYP3A4
[0149] The present invention provides methods for improving the
pharmacokinetics of a therapeutic compound that is metabolized by
CYP3A4, comprising administering to a subject in need of such
treatment an effective amount of a combination of said therapeutic
compound and a Sulfonamide Derivative or pharmaceutically
acceptable salt thereof.
[0150] The present invention also provides methods that may be, or
are believed to be, useful for improving the pharmacokinetics of a
therapeutic compound that is metabolized by other members of CYP3A,
comprising administering to a subject in need of such treatment an
effective amount of a combination of said therapeutic compound and
a Sulfonamide Derivative or pharmaceutically acceptable salt
thereof. In one embodiment, the therapeutic compound is metabolized
by CYP3A5. In another embodiment, the therapeutic compound is
metabolized by CYP3A7. In another embodiment, the therapeutic
compound is metabolized by CYP3A743.
[0151] In one embodiment, the therapeutic compound whose
pharmacokinetics are being improved is an anti-HIV drug.
[0152] In another embodiment, the therapeutic compound whose
pharmacokinetics are being improved is an HIV protease
inhibitor.
[0153] In still another embodiment, th the therapeutic compound
whose pharmacokinetics are being improved is an HIV integrase
inhibitor.
[0154] In another embodiment, the therapeutic compound whose
pharmacokinetics are being improved is a nucleoside reverse
transcriptase inhibitor (nRTI).
[0155] In yet another embodiment, the therapeutic compound whose
pharmacokinetics are being improved is a non-nucleoside reverse
transcriptase inhibitor (nnRTI).
Treatment or Prevention of HIV Infection
[0156] The present invention provides methods for treating or
preventing HIV infection in a subject comprising administering to
the subject: (i) a Sulfonamide Derivative or a pharmaceutically
acceptable salt thereof and (ii) one or more anti-HIV drugs,
wherein the amounts administered are together effective to treat or
prevent HIV infection in said subject. In one embodiment, the
present invention also provides methods for treating AIDS in a
subject comprising administering to the subject: (i) a Sulfonamide
Derivative or a pharmaceutically acceptable salt thereof and (ii)
one or more anti-HIV drugs, wherein the amounts administered are
together effective to treat AIDS in said subject.
[0157] The compositions and combinations of the present invention
can be useful for treating a subject suffering from infection
related to any HIV genotype.
[0158] In one embodiment, the HIV infection being treated is
HIV-1.
[0159] In another embodiment, the HIV infection being treated is
HIV-2.
[0160] In another embodiment, the HIV infection being treated has
transformed into AIDS.
Combination Therapy
[0161] When administering a combination of a Sulfonamide Derivative
and one or more anti-HIV drugs to a subject, the Sulfonamide
Derivative and anti-HIV drug may be administered in any order such
as, for example, sequentially, concurrently, together,
simultaneously and the like. The amounts of the various actives in
such combination therapy may be different amounts (different dosage
amounts) or same amounts (same dosage amounts). Thus, for
non-limiting illustration purposes, a Sulfonamide Derivative and
the anti-HIV drug(s) may be present in fixed amounts (dosage
amounts) in a single dosage unit (e.g., a capsule, a tablet, and
the like).
[0162] In one embodiment, the Sulfonamide Derivative is
administered during a time when the anti-HIV drug(s) exert their
prophylactic or therapeutic effect, or vice versa.
[0163] In another embodiment, the Sulfonamide Derivative and the
anti-HIV drug(s) are administered in doses commonly employed when
such agents are used as monotherapy for treating a viral
infection.
[0164] In another embodiment, when administered in combination with
a Sulfonamide Derivative, the anti-HIV drug(s) are administered in
doses lower than the doses commonly employed when such agents are
used as monotherapy for treating HIV infection. A lower dosage or
less frequent administration of the anti-HIV drug(s) may reduce the
toxicity of therapy without reducing the efficacy of therapy.
[0165] In one embodiment, the at least one Sulfonamide Derivative
and the anti-HIV drug(s) are present in the same composition. In
one embodiment, this composition is suitable for oral
administration. In another embodiment, this composition is suitable
for intravenous administration. In another embodiment, this
composition is suitable for subcutaneous administration. In still
another embodiment, this composition is suitable for parenteral
administration.
[0166] In one embodiment, the administration of a Sulfonamide
Derivative and the anti-HIV drug(s) may inhibit the resistance of
the HIV infection to one or more of the agents being
administered.
Anti-HIV Drugs
[0167] An "anti-HIV drug," as defined herein, is any agent which is
directly or indirectly effective in the inhibition of HIV reverse
transcriptase or another enzyme required for HIV replication or
infection, the treatment or prophylaxis of HIV infection, and/or
the treatment, prophylaxis or delay in the onset or progression of
AIDS. It is understood that an anti-HIV drug is effective in
treating, preventing, or delaying the onset or progression of HIV
infection or AIDS and/or diseases or conditions arising therefrom
or associated therewith. For example, the Sulfonamide Derivatives
of Formula (I) can be effectively administered, whether at periods
of pre-exposure and/or post-exposure, in combination with effective
amounts of one or more anti-HIV drugs selected from anti-HIV drugs,
immunomodulators, antiinfectives, useful for treating HIV infection
or AIDS. Suitable HIV antivirals for use in combination with the
compounds of the present invention include, for example, those
listed in Table A below.
TABLE-US-00001 TABLE A Name Type abacavir, ABC, Ziagen .RTM. nRTI
abacavir + lamivudine, Epzicom .RTM. nRTI abacavir + lamivudine +
zidovudine, Trizivir .RTM. nRTI amprenavir, Agenerase .RTM. PI
atazanavir, Reyataz .RTM. PI AZT, zidovudine, azidothymidine,
Retrovir .RTM. nRTI CMX-157 nRTI darunavir, Prezista .RTM. PI ddC,
zalcitabine, dideoxycytidine, Hivid .RTM. nRTI ddI, didanosine,
dideoxyinosine, Videx .RTM. nRTI ddI (enteric coated), Videx EC
.RTM. nRTI delavirdine, DLV, Rescriptor .RTM. nnRTI Dolutegravir PI
efavirenz, EFV, Sustiva .RTM., Stocrin .RTM. nnRTI efavirenz +
emtricitabine + tenofovir DF, Atripla .RTM. nnRTI + nRTI
Elvitegravir InI emtricitabine, FTC, Emtriva .RTM. nRTI
emtricitabine + tenofovir DF, Truvada .RTM. nRTI emvirine,
Coactinon .RTM. nnRTI enfuvirtide, Fuzeon .RTM. FI enteric coated
didanosine, Videx EC .RTM. nRTI etravirine, TMC-125 nnRTI
fosamprenavir calcium, Lexiva .RTM. PI indinavir, Crixivan .RTM. PI
lamivudine, 3TC, Epivir .RTM. nRTI lamivudine + zidovudine,
Combivir .RTM. nRTI lopinavir PI lopinavir + ritonavir, Kaletra
.RTM. PI maraviroc, Selzentry .RTM. EI nelfinavir, Viracept .RTM.
PI nevirapine, NVP, Viramune .RTM. nnRTI raltegravir, MK-0518,
Isentress .RTM. InI rilpivirine, TMC-278 nnRTI Rilpivirine +
emtricitabine + tenofovir, Complera nnRTI + nRTI ritonavir, Norvir
.RTM. PI saquinavir, Invirase .RTM., Fortovase .RTM. PI stavudine,
d4T, didehydrodeoxythymidine, Zerit .RTM. nRTI tenofovir DF (DF =
disoproxil fumarate), TDF, nRTI Viread .RTM. tipranavir, Aptivus
.RTM. PI EI = entry inhibitor; FI = fusion inhibitor; InI =
integrase inhibitor; PI = protease inhibitor; nRTI = nucleoside
reverse transcriptase inhibitor; nnRTI = non-nucleoside reverse
transcriptase inhibitor. Some of the drugs listed in the table are
used in a salt form; e.g., abacavir sulfate, indinavir sulfate,
atazanavir sulfate, nelfinavir mesylate.
[0168] In one embodiment, the one or more anti-HIV drugs are
selected from raltegravir, lamivudine, abacavir, ritonavir,
dolutegravir, atazanavir, elvitegravir and lopinavir.
[0169] In another embodiment, the compound of formula (I) is used
in combination with a single anti-HIV drug which is
raltegravir.
[0170] In another embodiment, the compound of formula (I) is used
in combination with a single anti-HIV drug which is lamivudine.
[0171] In still another embodiment, the compound of formula (I) is
used in combination with a single anti-HIV drug which is
atazanavir.
[0172] In another embodiment, the compound of formula (I) is used
in combination with a single anti-HIV drug which is darunavir.
[0173] In yet another embodiment, the compound of formula (I) is
used in combination with a single anti-HIV drug which is
dolutegravir.
[0174] In another embodiment, the compound of formula (I) is used
in combination with a single anti-HIV drug which is
elvitegravir.
[0175] In one embodiment, the compound of formula (I) is used in
combination with two anti-HIV drugs which are lamivudine and
abacavir.
[0176] In another embodiment, the compound of formula (I) is used
in combination with two anti-HIV drugs which are darunavir and
raltegravir.
[0177] In another embodiment, the compound of formula (I) is used
in combination with two anti-HIV drugs which are atazanavir and
raltegravir.
[0178] In still another embodiment, the compound of formula (I) is
used in combination with two anti-HIV drugs which are ritonavir and
lopinavir.
[0179] In another embodiment, the compound of formula (I) is used
in combination with two anti-HIV drugs which are lamivudine and
raltegravir.
[0180] In one embodiment, the compound of formula (I) is used in
combination with three anti-HIV drug which are abacavir, lamivudine
and raltegravir.
[0181] In another embodiment, the compound of formula (I) is used
in combination with three anti-HIV drug which are lopinavir,
ritonavir and raltegravir.
[0182] In one embodiment, the present invention provides
pharmaceutical compositions comprising (i) a compound of formula
(I) or a pharmaceutically acceptable salt thereof; (ii) a
pharmaceutically acceptable carrier; and (iii) one or more
additional anti-HIV drugs selected from lamivudine, abacavir,
ritonavir and lopinavir, or a pharmaceutically acceptable salt
thereof, wherein the amounts present of components (i) and (iii)
are together effective for the treatment or prophylaxis of
infection by HIV or for the treatment, prophylaxis, or delay in the
onset or progression of AIDS in the subject in need thereof.
[0183] In another embodiment, the present invention provides a
method for the treatment or prophylaxis of infection by HIV or for
the treatment, prophylaxis, or delay in the onset or progression of
AIDS in a subject in need thereof, which comprises administering to
the subject (i) a compound of formula (I) or a pharmaceutically
acceptable salt thereof and (ii) one or more additional anti-HIV
drugs selected from raltegravir, lamivudine, abacavir, atazanavir,
darunavir, ritonavir and lopinavir, or a pharmaceutically
acceptable salt thereof, wherein the amounts administered of
components (i) and (ii) are together effective for the treatment or
prophylaxis of infection by HIV or for the treatment, prophylaxis,
or delay in the onset or progression of AIDS in the subject in need
thereof.
[0184] It is understood that the scope of combinations of the
compounds of this invention with anti-HIV drugs is not limited to
the HIV antivirals listed in Table A, but includes in principle any
combination with any drug or pharmaceutical composition useful for
the treatment or prophylaxis of AIDS. The anti-HIV drugs and other
agents will typically be employed in these combinations in their
conventional dosage ranges and regimens as reported in the art,
including, for example, the dosages described in the Physicians'
Desk Reference, Thomson P D R, Thomson P D R, 57.sup.th edition
(2003), the 58.sup.th edition (2004), the 59.sup.th edition (2005),
and the like. The dosage ranges for a compound of the invention in
these combinations are the same as those set forth above.
[0185] The doses and dosage regimen of the other agents used in the
combination therapies of the present invention for the treatment or
prevention of HIV infection can be determined by the attending
clinician, taking into consideration the approved doses and dosage
regimen in the package insert; the age, sex and general health of
the subject; and the type and severity of the viral infection or
related disease or disorder. When administered in combination, the
Sulfonamide Derivative(s) and the other agent(s) can be
administered simultaneously (i.e., in the same composition or in
separate compositions one right after the other) or sequentially.
This particularly useful when the components of the combination are
given on different dosing schedules, e.g., one component is
administered once daily and another component is administered every
six hours, or when the preferred pharmaceutical compositions are
different, e.g., one is a tablet and one is a capsule. A kit
comprising the separate dosage forms is therefore advantageous.
Compositions and Administration
[0186] Due to their activity, the Sulfonamide Derivatives are
useful in veterinary and human medicine. As described above, the
Sulfonamide Derivatives are useful for: inhibiting CYP3A4;
improving the pharmacokinetics of a therapeutic compound that is
metabolized by CYP3A4; and in combination with one or more anti-HIV
agents for treating or preventing HIV infection in a subject in
need thereof.
[0187] When administered to a subject, the Sulfonamide Derivatives
can be administered as a component of a composition that comprises
a pharmaceutically acceptable carrier or vehicle. The present
invention provides pharmaceutical compositions comprising an
effective amount of at least one Sulfonamide Derivative and a
pharmaceutically acceptable carrier. In the pharmaceutical
compositions and methods of the present invention, the active
ingredients will typically be administered in admixture with
suitable carrier materials suitably selected with respect to the
intended form of administration, i.e., oral tablets, capsules
(either solid-filled, semi-solid filled or liquid filled), powders
for constitution, oral gels, elixirs, dispersible granules, syrups,
suspensions, and the like, and consistent with conventional
pharmaceutical practices. For example, for oral administration in
the form of tablets or capsules, the active drug component may be
combined with any oral non-toxic pharmaceutically acceptable inert
carrier, such as lactose, starch, sucrose, cellulose, magnesium
stearate, dicalcium phosphate, calcium sulfate, talc, mannitol,
ethyl alcohol (liquid forms) and the like. Solid form preparations
include powders, tablets, dispersible granules, capsules, cachets
and suppositories. Powders and tablets may be comprised of from
about 0.5 to about 95 percent inventive composition. Tablets,
powders, cachets and capsules can be used as solid dosage forms
suitable for oral administration.
[0188] Moreover, when desired or needed, suitable binders,
lubricants, disintegrating agents and coloring agents may also be
incorporated in the mixture. Suitable binders include starch,
gelatin, natural sugars, corn sweeteners, natural and synthetic
gums such as acacia, sodium alginate, carboxymethylcellulose,
polyethylene glycol and waxes. Among the lubricants there may be
mentioned for use in these dosage forms, boric acid, sodium
benzoate, sodium acetate, sodium chloride, and the like.
Disintegrants include starch, methylcellulose, guar gum, and the
like. Sweetening and flavoring agents and preservatives may also be
included where appropriate.
[0189] Liquid form preparations include solutions, suspensions and
emulsions and may include water or water-propylene glycol solutions
for parenteral injection.
[0190] Liquid form preparations may also include solutions for
intranasal administration.
[0191] Also included are solid form preparations which are intended
to be converted, shortly before use, to liquid form preparations
for either oral or parenteral administration. Such liquid forms
include solutions, suspensions and emulsions.
[0192] For preparing suppositories, a low melting wax such as a
mixture of fatty acid glycerides or cocoa butter is first melted,
and the active ingredient is dispersed homogeneously therein as by
stirring. The molten homogeneous mixture is then poured into
convenient sized molds, allowed to cool and thereby solidify.
[0193] Additionally, the compositions of the present invention may
be formulated in sustained release form to provide the rate
controlled release of any one or more of the components or active
ingredients to optimize therapeutic effects, i.e., antiviral
activity and the like. Suitable dosage forms for sustained release
include layered tablets containing layers of varying disintegration
rates or controlled release polymeric matrices impregnated with the
active components and shaped in tablet form or capsules containing
such impregnated or encapsulated porous polymeric matrices.
[0194] In one embodiment, the Sulfonamide Derivatives are
administered orally.
[0195] In another embodiment, the Sulfonamide Derivatives are
administered intravenously.
[0196] In one embodiment, the present invention provides
compositions comprising a Compound of Formula (I) or a
pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable carrier.
[0197] In one embodiment, a pharmaceutical preparation comprising
at least one Sulfonamide Derivative is in unit dosage form. In such
form, the preparation is subdivided into unit doses containing
effective amounts of the active components.
[0198] Compositions can be prepared according to conventional
mixing, granulating or coating methods, respectively, and the
present compositions can contain, in one embodiment, from about
0.1% to about 99% of the Sulfonamide Derivative(s) by weight or
volume. In various embodiments, the present compositions can
contain, in one embodiment, from about 1% to about 70% or from
about 5% to about 60% of the Sulfonamide Derivative(s) by weight or
volume.
[0199] The Sulfonamide Derivatives can be administered orally in a
dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body
weight per day in a single dose or in divided doses. One dosage
range is 0.01 to 500 mg/kg body weight per day orally in a single
dose or in divided doses. Another dosage range is 0.1 to 100 mg/kg
body weight per day orally in single or divided doses. For oral
administration, the compositions can be provided in the form of
tablets or capsules containing 1.0 to 500 milligrams of the active
ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150,
200, 250, 300, 400, and 500 milligrams of the active ingredient for
the symptomatic adjustment of the dosage to the subject to be
treated. The specific dose level and frequency of dosage for any
particular subject may be varied and will depend upon a variety of
factors including the activity of the specific compound employed,
the metabolic stability and length of action of that compound, the
age, body weight, general health, sex, diet, mode and time of
administration, rate of excretion, drug combination, the severity
of the particular condition, and the host undergoing therapy.
[0200] For convenience, the total daily dosage may be divided and
administered in portions during the day if desired. In one
embodiment, the daily dosage is administered in one portion. In
another embodiment, the total daily dosage is administered in two
divided doses over a 24 hour period. In another embodiment, the
total daily dosage is administered in three divided doses over a 24
hour period. In still another embodiment, the total daily dosage is
administered in four divided doses over a 24 hour period.
[0201] The amount and frequency of administration of the
Sulfonamide Derivatives will be regulated according to the judgment
of the attending clinician considering such factors as age,
condition and size of the subject as well as severity of the
symptoms being treated. The compositions of the invention can
further comprise one or more additional therapeutic agents,
selected from those listed above herein. Accordingly, in one
embodiment, the present invention provides compositions comprising:
(i) a Compound of Formula (I) or a pharmaceutically acceptable salt
thereof; (ii) a therapeutic compound that is metabolized by CYP3A4;
and (iii) a pharmaceutically acceptable carrier. In another
embodiment, the present invention provides compositions comprising:
(i) a Compound of Formula (I) or a pharmaceutically acceptable salt
thereof; (ii) one or more anti-HIV drugs; and (iii) a
pharmaceutically acceptable carrier, wherein the amounts in the
composition are together effective to treat HIV infection.
[0202] In another embodiment, the present invention provides
compositions comprising a Compound of Formula (I) or a
pharmaceutically acceptable salt thereof, a pharmaceutically
acceptable carrier, and one or more anti-HIV drugs, wherein said
anti-HIV drugs are selected from raltegravir, lamivudine, abacavir,
atazanavir, darunavir, lopinavir and ritonavir.
[0203] In still embodiment, the present invention provides
compositions comprising a Compound of Formula (I) or a
pharmaceutically acceptable salt thereof, a pharmaceutically
acceptable carrier, and raltegravir.
Kits
[0204] In one aspect, the present invention provides a kit
comprising a therapeutically effective amount of at least one
Sulfonamide Derivative, or a pharmaceutically acceptable salt,
solvate, ester or prodrug of said compound and a pharmaceutically
acceptable carrier, vehicle or diluent.
[0205] In another aspect the present invention provides a kit
comprising an amount of at least one Sulfonamide Derivative, or a
pharmaceutically acceptable salt, solvate, ester or prodrug of said
compound and a therapeutic compound that is metabolized by CYP3A4.
In one embodiment, the Sulfonamide Derivatives and the therapeutic
compound that is metabolized by CYP3A4 are provided in the same
container. In one embodiment, the Sulfonamide Derivatives and the
therapeutic compound that is metabolized by CYP3A4 are provided in
separate containers.
[0206] In another aspect the present invention provides a kit
comprising an amount of at least one Sulfonamide Derivative, or a
pharmaceutically acceptable salt, solvate, ester or prodrug of said
compound and an amount of at least one anti-HIV drug listed above,
wherein the amounts of the two or more active ingredients result in
a desired therapeutic effect. In one embodiment, the Sulfonamide
Derivatives and the one or more anti-HIV drugs are provided in the
same container. In one embodiment, the Sulfonamide Derivatives and
the one or more anti-HIV drugs are provided in separate
containers.
Methods for Making the Compounds of Formula (I)
[0207] The Compounds of Formula (I) may be prepared from known or
readily prepared starting materials, following methods known to one
skilled in the art of organic synthesis. Methods useful for making
the Compounds of Formula (I) are set forth in the Examples below
and generalized in Schemes A-L below. Alternative synthetic
pathways and analogous structures will be apparent to those skilled
in the art of organic synthesis.
[0208] Scheme A shows methods useful for making compounds of
formula A6, which are useful intermediates for the synthesis of
compounds of Formula (I), wherein Q is carbon.
##STR00021##
[0209] Amines of formula A1 can be condensed with an aldehyde to
provide intermediates of formula A2 which can undergo a cyclization
reaction with a reagent such as TosMIC to provide compounds f
formula A3. Intermediate A3 can subsequently be reduced with a
hydride reducing agent such as LiBH.sub.4 to provide carbinols of
formula A4. Compounds f formula A4 can alternatively be prepared in
a two-step procedure involving the condensation of amine A1 with
1,3-dihydroxyacetone dimer and KSCN to provide the thioimidazole
compounds of formula A5 which can then be oxidized with a reagent
such as hydrogen peroxide to provide intermediate A4. Primary
alcohols of formula A4 can then be oxidized with reagents such as
MnO.sub.2 to provide the key intermediates of formula A6.
[0210] Scheme B shows methods useful for making the compounds of
formula B3, which are useful intermediates for the synthesis of
compounds of Formula (I), wherein Q is nitrogen.
##STR00022##
[0211] Amines of formula A1 can be cyclocondensed with
1,2-diformylhydrazine to provide 1,2,4-triazoles of formula B2
which can subsequently be converted to the aldehydes of formula B3
using standard formylation reagents, such as DMF and
POCl.sub.3.
[0212] Scheme C shows methods useful for making the compounds of
formula C5, which correspond to the compounds of Formula (I),
wherein Q is carbon and X is a substituted carbon.
##STR00023##
[0213] Carbinols of formula A4 can be activated for alkylation of a
piperidine derivative by conversion to the chloride C1 which can
then be added to the anion of a 4-substituted piperidine in which
the G group is an anion stabilizing group such as nitrile or ester.
Deprotection of the piperidine nitrogen can afford compounds of
formula C3 which can be sulfonylated to provide compounds of
formula C4. The G group may undergo further modification using
standard functional group transforming reactions to provide analogs
of formula C5.
[0214] Scheme D shows methods useful for making compounds of
formulas D3, D6 and D9, which correspond to the compounds of
Formula (I), wherein Q is carbon; X is hydroxy or ether; and Y is
H, alkyl or trifluoromethyl.
##STR00024##
[0215] Aldehydes of formula A5 can be reacted with the anion of
2-chloro-4-methylpyridine to provide carbinol D1 which can be
reduced using hydrogenating conditions and a catalyst such as
PtO.sub.2 to provide piperidine compounds of formula D2. A compound
of formula D2 can then be sulfonylated with an appropriately
substituted arylsulfonyl chloride and a base such as triethylamine
to provide the compounds of formula D3. Additionally, carbinols of
formula D1 can be oxidized with a reagent such as MnO.sub.2 to the
ketones of formula D4 which can then be treated with methyl
(X.dbd.H) or trifluoromethyl (X.dbd.F) nucleophiles to provide D5
which can be hydrogenated and sulfonylated to provide compounds of
formula D6. Alternatively, carbinols of formula D1 can be alkylated
using a metal hydride base and electrophile, such as CH.sub.3I to
provide ethers D7 which can be converted to compounds of formula D9
using chemistry described for the synthesis of the compounds of
formulas D3 and D6.
[0216] Scheme E shows methods useful for making compounds of
formulas E3 and E6, which correspond to the compounds of Formula
(I), wherein Q is carbon and X is carbon which can be linked to Z
through a --CH.sub.2-- bridge.
##STR00025##
[0217] Aldehydes of formula A5 can undergo a McMurray coupling
reaction with an appropriately substituted 4-piperidinone
derivative using reagents such as zinc dust and
titanium(IV)chloride to provide olefins of formula E1 which can be
reduced and deprotected using hydrogenation conditions with a
catalyst such as Pd(OH).sub.2 to provide piperidines of formula E2.
Standard conditions for the sulfonylation of secondary amines
(ArSO.sub.2Cl, Et.sub.3N) can be used to provide targets of formula
E3. Alternatively, olefins of formula E1 can be cyclopropanated
using well-known chemistry (such as (CH.sub.3).sub.3S.sup.+I.sup.-
and NaH) to provide the spirocycles of formula E4 which can then be
converted to the desired compounds of formula E6 using conditions
similar to those described for the preparation of compounds of
formula E3.
[0218] Scheme F shows methods useful for making compounds of
formula F3 and F7, which correspond to the compounds of Formula
(I), wherein Q is carbon or nitrogen; X is nitrogen; and Z is H or
methyl.
##STR00026##
[0219] Aldehydes of formula A5 can be reductively aminated with a
piperazine derivative using standard conditions using a dehydrating
agent such as Ti(OiPr).sub.4 and a reducing agent such as
NaBH(OAc).sub.3 to provide intermediates of formula E1 which can
subsequently be deprotected and sulfonylated to provide targets of
formula E3 using conditions described in the schemes above.
Aldehyde A5 can also be converted to the secondary alcohols of
formula E4 by reaction with a methyl nucleophile such as
CH.sub.3MgBr. Ketone E5 can be formed from oxidizing E4 with an
oxidizing agent such as MnO.sub.2 which can then undergo reductive
amination, deprotection, and sulfonylation following chemistry
described above to provide analogs of formula E7.
[0220] Scheme G shows methods useful for making compounds of
formula G2, which correspond to the compounds of Formula (I),
wherein B is carbon and Z is CN.
##STR00027##
[0221] Aldehydes of formula A5 can be converted to the
alpha-aminonitriles of formula G1 using a suitably protected
piperazine and a cyanide source such as KCN. Compounds of formula
G2 can be obtained after deprotection of the Boc group and
sulfonylation of the resulting amine using standard conditions
(such as ArSO.sub.2Cl and Et.sub.3N) to provide targets of formula
G2.
[0222] Scheme H shows methods useful for making compounds of
formula H2 and H4, which correspond to the compounds of Formula
(I), wherein B is carbon; X is nitrogen; and Z is
(CH.sub.2).sub.nOR.sup.a wherein n is 1 or 2.
##STR00028##
[0223] Nitriles of formula G1 can be converted to its carboxylic
ester then reduced using standard conditions. The resulting alcohol
can be alkylated to intermediates of formula H2 (R.sup.a=alkyl)
using standard conditions or converted to the compounds of formula
H2 after deprotection of the Boc group and sulfonylation of the
resulting amine using standard conditions such as ArSO.sub.2Cl and
a tertiary amine base. Alternatively, aldehydes of formula A5 can
be olefinated using standard Horner-Emmons chemistry to provide the
unsaturated esters of formula H3 which can then undergo a Michael
addition with a suitably protected piperazine analog to provide a
.beta.-substituted ester which can subsequently be reduced using
known conditions for the reduction of esters to primary alcohols
such as LiBH.sub.4. The resulting alcohol can be further
functionalized to the compounds of formula H4 using methods
described above.
[0224] Scheme I shows methods useful for making compounds of
formula I5, which correspond to the compounds of Formula (I),
wherein Q is carbon; X is nitrogen; and R.sup.1 and Z are joined to
form a --CH.sub.2OCH.sub.2-- bridge.
##STR00029##
[0225] Aldehyde A5 can be converted to the nitrile ester I1 using
chemistry described for the preparation of G1. Nitrile I1 can be
transformed to the diester analog I2 under acidic conditions which
can then be converted to diol I3 using a hydride reducing agent
such as LiBH.sub.4. Ring closure to provide compounds of formula I4
can be affected by activating one of the alcohol functional groups
with a reagent such as toluene sulfonyl chloride followed by
deprotonating the second alcohol with a metal hydride base such as
NaH. Final targets of formula I5 can be obtained after deprotection
of the Boc group and sulfonylation of the resulting piperazine
amine using standard conditions such as ArSO.sub.2Cl and a tertiary
amine base.
[0226] Scheme J shows methods useful for making compounds of
formula J5, which correspond to the compounds of Formula (I),
wherein Q is carbon; X is nitrogen; and R.sup.1 and Z are joined to
form a --CH.sub.2CH.sub.2CH.sub.2-- bridge.
##STR00030##
[0227] Aldehydes of formula A5 can be converted to the
.alpha.,.beta.-unsaturated ketones of formula J2 by a standard
two-step procedure involving the addition of a vinyl Grignard
reagent and oxidation of the resulting carbinol with a reagent such
as MnO.sub.2. Intermediates of formula J2 can undergo a Michael
addition with the anion derived from metallating
2-methyl-1,4-pyrazine to form ketones of formula J3 which can then
undergo reductive cyclization after treatment with a metal catalyst
under a hydrogen atmosphere. Standard methodology for sulfonylating
secondary amines can give targets of formula J5.
[0228] Scheme K shows methods useful for making compounds of
formula K3, which correspond to the compounds of Formula (I),
wherein Q is carbon; X is nitrogen; and R.sup.1 and Z are joined to
form a --CH.sub.2OC(.dbd.O)-- bridge.
##STR00031##
[0229] Carboxylic esters of formula I1 can be reduced to the
corresponding primary alcohols of formula K2 with reagents such as
LiBH.sub.4 which can then undergo a lactonization reaction to
provide intermediates of formula K2 upon treatment with a strong
base such as KOH. Final targets K3 can be obtained after
deprotection of the Boc group and sulfonylation of the resulting
piperazine amino group using standard conditions (such as
ArSO.sub.2Cl and a tertiary amine base).
[0230] Scheme L shows methods useful for making the intermediates
of formula L2 and L4, which correspond to the compounds of Formula
(I), wherein Q is carbon; X is nitrogen; and R.sup.1 and Z are
joined to form a --C(.dbd.O)NR.sup.aCH.sub.2-- lactam bridge or a
--CH.sub.2N(CH.sub.3)CH.sub.2-- amine bridge.
##STR00032##
[0231] Nitriles of formula I1 can undergo reductive lactamization
using known conditions for the conversion of a nitrile to a primary
amine such as catalytic hydrogenation using a metal such as nickel
as the catalyst. The resulting lactam NH can be alkylated to
intermediates of formula L1 (R.sup.a=alkyl) using standard
conditions or converted to the final targets of formula L2
(R.sup.a=H) using methods described above. Alternatively,
intermediate lactams of formula L1 can be reduced to triamines of
formula L3 using a metal hydride reagent such as LiAlH.sub.4. Final
targets of formula L4 can be obtained after deprotection of the Boc
group and sulfonylation of the resulting amine using standard
conditions (such as ArSO.sub.2Cl and a tertiary amine base).
[0232] One skilled in the art of organic synthesis will recognize
that the synthesis of the Compounds of Formula (I) may require
protection of certain functional groups (i.e., derivatization for
the purpose of chemical compatibility with a particular reaction
condition). Suitable protecting groups for the various functional
groups of these compounds and methods for their installation and
removal are well known in the art of organic chemistry. A summary
of many of these methods can be found in Greene et al., Protective
Groups in Organic Synthesis, Wiley-Interscience, New York,
(1999).
[0233] One skilled in the art of organic synthesis will also
recognize that one route for the synthesis of the Compounds of
Formula (I) may be more desirable depending on the choice of
appendage substituents. Additionally, one skilled in the art will
recognize that in some cases the order of reactions may differ from
that presented herein to avoid functional group incompatibilities
and thus adjust the synthetic route accordingly.
[0234] The preparation of some intermediates useful for making the
Compounds of Formula (I) have been described in the literature and
in compendia such as "Comprehensive Heterocyclic Chemistry"
editions I, II and III, published by Elsevier and edited by A. R.
Katritzky & R. J K Taylor. Manipulation of the required
substitution patterns have also been described in the available
chemical literature as summarized in compendia such as
"Comprehensive Organic Chemistry" published by Elsevier and edited
by DH R. Barton and W. D. Ollis; "Comprehensive Organic Functional
Group Transformations" edited by edited by A. R. Katritzky & R.
J K Taylor and "Comprehensive Organic Transformation" published by
Wily-CVH and edited by R. C. Larock.
[0235] The Compounds Formula (I) may contain one or more silicon
atoms. The compounds contemplated in this invention in general can
be prepared using the carba-analog methodology unless otherwise
noted. A recent review of the synthesis of silicon containing
compounds can be found in "Silicon Chemistry: from Atom to Extended
Systems", Ed P. Jutzi & U. Schubet; ISBN 978-3-527-30647-3.
Preparation of silyl containing amino acids has been described. See
Bolm et al., Angew. Chem. Int Ed., 39:2289 (2000). Descriptions of
improved cellular update (Giralt, J. Am. Chem. Soc., 128:8479
(2006)) and reduced metabolic processing of silyl containing
compounds have been described (Johansson et al., Drug Metabolism
& Disposition, 38:73 (2009)).
[0236] The starting materials used and the intermediates prepared
using the methods set forth in Schemes A-L may be isolated and
purified if desired using conventional techniques, including but
not limited to filtration, distillation, crystallization,
chromatography and alike. Such materials can be characterized using
conventional means, including physical constants and spectral
data.
EXAMPLES
General Methods
[0237] Solvents, reagents, and intermediates that are commercially
available were used as received. Reagents and intermediates that
are not commercially available were prepared in the manner as
described below. .sup.1H NMR spectra were obtained on a Varian VNMR
System 400 (400 MHz) and are reported as ppm downfield from
Me.sub.4Si with number of protons, multiplicities, and coupling
constants in Hertz indicated parenthetically. Where LC/MS data are
presented, analyses was performed using an Agilent 6110A MSD or an
Applied Biosystems API-100 mass spectrometer and Shimadzu SCL-10A
LC column: Altech platinum C18, 3 micron, 33 mm.times.7 mm ID;
gradient flow: 0 minutes--10% CH.sub.3CN, 5 minutes--95%
CH.sub.3CN, 5-7 minutes--95% CH.sub.3CN, 7 minutes--stop. The
retention time and observed parent ion are given. Flash column
chromatography was performed using pre-packed normal phase silica
from Biotage, Inc. or bulk silica from Fisher Scientific. Unless
otherwise indicated, column chromatography was performed using a
gradient elution of hexanes/ethyl acetate, from 100% hexanes to
100% ethyl acetate.
Example 1
Preparation of Compound 1
##STR00033##
[0238] Step A--Preparation of Int 1-1
##STR00034##
[0240] To a solution of 1-(4-fluoro-phenyl)-ethanone (400 g, 2.9
mol) and 2-methylpropane-2-sulfinic acid amide (350 g, 2.9 mol) in
THF (4 L) was added Ti(OiPr).sub.4 (824 g, 2.9 mol). The reaction
mixture was allowed to stir at 90.degree. C. for 48 hours when TLC
(PE:EA=10:1) showed the reaction was complete. The mixture was
cooled to 0.degree. C. and NaBH.sub.4 (110 g, 209 mol) was added in
portions. The reaction was allowed to stir at 0.degree. C. until
TLC (petroleum ether/EtOAc=1:1) showed the reaction was complete
(.about.1 hour). The reaction mixture was poured into ice water and
the formed precipitate was filtered and washed with ethyl acetate.
The filtrate was concentrated in vacuo dissolved into water and the
aqueous layer was extracted with ethyl acetate (800 mL.times.3),
dried over anhydrous Na.sub.2SO.sub.4 and concentrated in vacuo to
provide the resulting residue Int 1-1, which was purified using
silica gel column. (350 g, 50 MS (ESI) m/z (M+1): 244.
Step B--Preparation of Int 1-2
##STR00035##
[0242] To a solution of compound Int 1-1 (350 g, 1.44 mol) in 500
mL of ethyl acetate was added HCl/EtOAc (700 mL, 4 M) in portions
at 0.degree. C. Within 30 minutes white solid was formed and TLC
(petroleum ether:EtOAc=1:1) showed the reaction to be complete. The
precipitate was filtered and washed with ethyl acetate. The filter
cake was dried to provide 200 g (79%) of compound Int 1-2 as white
powder. MS (ESI) m/z (M+1): 140.
Step C--Preparation of Int 1-4
##STR00036##
[0244] To a solution of compound Int 1-2 (200 g, 1.14 mol) in 2 L
of 50% aqueous acetonitrile was added K.sub.2CO.sub.3 to adjust the
solution to pH 8. Acetic acid (50 mL) was then added and the
reaction was allowed to stir for 20 min before 1,3-dihydroxyacetone
dimer (205 g, 1.14 mol) and KSCN (111 g, 1.14 mol) was added. The
reaction mixture was allowed to stir at 9.degree. C. for 5 hours
when TLC (petroleum ether:EtOAc=1:2) showed the reaction to be
complete. The reaction mixture was then cooled to 0.degree. C. and
H.sub.2O.sub.2 (388 mL, 30%, 3.42 mol) was added dropwise. The
mixture was allowed to stir at 0.degree. C. for 1 hour, then the
reaction mixture was quenched with saturated Na.sub.2SO.sub.3 at
0.degree. C. Solid Na.sub.2CO.sub.3 was added to the mixture to
adjust to pH 8.about.10 and the solid was filtered off. The
remained aqueous filtrate was extracted with ethyl acetate and the
combined organic extracts were dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo to provide compound Int 1-4 (90
g), which was used in next step without further purification. MS
(ESI) m/z (M-17): 203; (M+1): 221.
Step D--Preparation of Int 1-5
##STR00037##
[0246] To a solution of compound Int 1-4 (90 g, 0.41 mmol) in
dioxane (1 L) was added MnO.sub.2 (107 g, 1.23 mol) and the mixture
was allowed to stir at 80.degree. C. for 5 hours. The reaction
mixture was filtered through Celite and the filtrate was
concentrated in vacuo. The resulting residue was purified using
column chromatography (1:1 petroleum ether/EtOAc) to provide 70 g
(79%) of compound Int-1 as yellow oil. MS (ESI) m/z (M+1): 219.
Step E--Preparation of Int 1-6
##STR00038##
[0248] To a stirred solution of compound Int 1-5 (4.0 g, 18 mmol)
in THF (40 mL) was added N-Boc piperazine (3.58 g, 19 mmol). The
mixture was allowed to stir at room temperature for 1 hour.
NaBH(OAc).sub.3 (11.3 g, 54 mmol) was added in portions and the
reaction was allowed to stir at room temperature for about 15
hours. The reaction mixture was washed with water and extracted
with ethyl acetate (3.times.20 mL). The combined organic extracts
were washed with brine, dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The resulting yellow oily residue was
purified using column chromatography on silica gel with
CH.sub.2Cl.sub.2: MeOH=100:1 to provide 5.9 g of compound Int 1-6
as yellow solid. Yield: 85%. MS (ESI) m/z (M+1): 389.
Step F--Preparation of Int 1-7
##STR00039##
[0250] A mixture of compound Int 1-6 (5.9 g, 15 mmol) in HCl/EtOAc
(50 mL) was allowed to stir at room temperature for 2 hours then
concentrated in vacuo and used in the next step without further
purification. MS-ESI (m/z): 289 (M+1).sup.+
Step G--Preparation of Int 1-8
##STR00040##
[0252] To a stirred solution of compound Int 1-7 (5.0 g, 0.015 mol)
in 50 mL of CH.sub.2Cl.sub.2 was added triethylamine (6.25 mL,
0.045 mol) was added N-acetyl-2-aminothiazole-5-sulfonyl chloride
(4.8 g, 0.02 mol) at room temperature. The reaction was allowed to
stir for 2 hours then the reaction mixture was concentrated in
vacuo. The resulting residue was purified using column
chromatography on silica gel with CH.sub.2Cl.sub.2: MeOH=50:1 to
provide 3.9 g of compound Int 1-8 as yellow solid. Yield: 45%. MS
(ESI) m/z (M+1): 492.
Step H--Preparation of Int 1-9
##STR00041##
[0254] To a stirred solution of compound Int 1-8 (3.9 g, 7.9 mmol)
in 40 mL of ethanol was added 6M HCl (40 mL). The mixture was
heated to 80.degree. C. and allowed to stir at this temperature for
12 hours. The reaction mixture was concentrated in vacuo and the
resulting residue was covered with saturated aqueous NaHCO.sub.3,
extracted with EtOAc, dried over sodium sulfate, filtered and in
vacuo. The resulting residue was used in the next step without
further purification. .sup.1H NMR .delta. 9.22 (s, 1H), 7.55 (s,
1H), 7.40 (s, 1H), 7.23.about.7.20 (m, 2H), 7.06.about.7.01 (m,
2H), 5.91 (t, J=6.8 Hz, 1H), 3.62 (d, J=14.4 Hz, 1H), 3.40 (d,
J=14.4 Hz, 1H), 2.92 (m, 2H), 2.82 (m, 2H), 2.50 (m, 2H), 2.42 (m,
2H), 1.86 (d, J=6.8 Hz, 3H). MS-ESI (ESI) m/z (M+1): 451
Step I--Preparation of Int 1-10
##STR00042##
[0256] To a stirred mixture of CuBr (1.2 g, 8.35 mmol) and
t-BuNO.sub.2 (0.89 mL, 6.68 mmol) in 4 mL of CH.sub.3CN was added
compound Int 1-9 (1.5 g, 3.34 mmol) in 50 mL of CH.sub.3CN in
portions. The mixture was heated to 60.degree. C. and allowed to
stir at this temperature for 17 hours then cooled to room
temperature and concentrated in vacuo. The resulting residue was
purified using column chromatography with 1:2 EtOAc/hexanes to
provide 0.6 g (35%) of compound Int 1-10 as a brown solid. MS (ESI)
m/z (M+1): 513
Step J--Preparation of Compound 1
##STR00043##
[0258] To a stirred solution of compound Int 1-10 (200 mg, 0.39
mmol) in 4 mL of DMA was added K.sub.2CO.sub.3 (161 mg, 1.17 mmol)
followed by piperazine (40 mg, 0.47 mmol). The mixture was allowed
to stir at 120.degree. C. for 3 hours. The reaction mixture was
then concentrated in vacuo and the resulting residue was purified
using HPLC to provide 10 mg (26%) of Compound 1 as a white solid.
.sup.1H NMR (CD.sub.3OD) .delta. 9.26 (s, 1H), 7.59 (s, 1H), 7.55
(s, 1H), 7.18.about.7.16 (m, 2H), 7.01.about.6.97 (m, 2H), 5.87 (t,
J=6.8 Hz, 1H), 3.87.about.3.85 (m, 4H), 3.67 (d, J=14.4 Hz, 1H),
3.40.about.3.37 (m, 4H), 3.35 (d, J=14.4 Hz, 1H), 2.85 (m, 2H),
2.70 (m, 2H), 2.47 (m, 2H), 2.37 (m, 2H), 1.86 (d, J=6.8 Hz, 3H).
MS-ESI (ESI) m/z (M+1): 520
[0259] The following compounds were prepared as described in step J
above starting from Int 1-10.
TABLE-US-00002 No. Structure M + 1 .sup.1H NMR 2 ##STR00044## 534
(CD.sub.3OD) .delta. 7.92 (s, 1H), 7.51 (s, 1H), 7.11~7.05 (m, 1H),
6.93~6.87 (m, 3H), 5.61 (q, J = 6.8 Hz, 1H), 3.61 (m, 4H),
3.53~3.50 (m, 1H), 3.25~3.22 (m, 1H), 2.82 (s, 1H), 2.68 (s, 2H),
2.58~2.57 (m, 4H), 2.39~2.34 (m, 7H), 1.78 (d, J = 6.8 Hz, 3H). 3
##STR00045## 590 (CD.sub.3OD) .delta.: 9.25 (s, 1H), 7.56-7.54 (m,
2H), 7.20-7.17 (m, 2H), 7.02-6.98 (m, 2H), 5.88 (q, J = 6.8 Hz,
1H), 4.68 (d, J = 6.8 Hz, 2H), 4.01 (d, J = 5.2 Hz, 2H), 3.74 (d, J
= 3.6 Hz, 2H), 3.67 (d, J = 14.4 Hz, 1H), 3.38 (d, J = 14.4 Hz,
1H), 2.88 (bs, 2H), 2.75 (bs, 2H), 2.49 (bs, 2H), 2.40 (bs, 2H),
2.21 (bs, 2H), 2.06 (bs, 2H), 1.86 (d, J = 6.8 Hz, 3H) 4
##STR00046## 603 (CD.sub.3OD) .delta. 9.26 (s, 1H), 8.69 (s, 1H),
8.00 (d, J = 6.4 Hz, 1H), 7.80 (s, 1H), 7.56 (d, J = 8.4 Hz, 3H),
7.30 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 1H), 5.96 (q, J =
6.8 Hz, 1H), 3.65 (d, J = 14.4 Hz, 1H), 3.34 (d, J = 14.4 Hz, 1H),
2.94 (m, 2H), 2.81 (m, 2H), 2.53 (m, 2H), 2.44~2.42 (m, 2H), 1.84
(d, J = 6.8 Hz, 3H). 6 ##STR00047## 576 (CD.sub.3OD) .delta. 7.98
(s, 1H), 7.52 (s, 1H), 7.10-7.07 (m, 2H), 6.95-6.90 (m, 3H),
5.66-5.60 (q, J = 7.2, 1H), 4.38-4.34 (m, 1H), 4.14-4.10 (d, J =
13.6, 1H), 3.99-3.95 (d, J = 13.6, 1H), 3.55-3.52 (m, 1H),
3.39-3.35 (m, 1H), 3.27-3.24 (m, 1H), 3.13-3.11 (m, 1H), 3.09-3.01
(m, 2H), 2.84-2.83 (m, 2H), 2.70-2.69 (m, 2H), 2.43-2.27 (m, 7H),
2.19-2.15 (m, 1H), 1.80-1.78 (d, J = 7.6, 3H), 1.50-1.40 (m, 1H). 7
##STR00048## 583 (CDCl3) .delta. 7.94-7.80 (m, 1H), 7.60 (s, 1H),
6.96-6.91 (m, 5H), 5.54-5.53 (q, J = 7.2, 1H), 4.09-4.06 (m, 1H),
4.05-3.96 (m, 1H), 3.94-3.87 (m, 1H), 3.85-3.76 (m, 1H), 3.65-3.59
(m, 1H), 3.34-3.31 (m, 1H), 3.23-3.20 (m, 1H), 2.99-2.88 (m, 7H),
2.75-2.68 (m, 1H), 2.58-2.53 (m, 1H), 2.43-2.37 (m, 4H), 1.81-1.80
(m, 3H). 8 ##STR00049## 583 (CDCl3) .delta. 7.95-7.86 (m, 1H), 7.54
(s, 1H), 7.19 (s, 1H), 6.96-6.88 (m, 5H), 5.51-5.47 (q, J = 7.2,
1H), 4.07-4.03 (m, 1H), 3.93-3.88 (m, 1H), 3.82-3.79 (m, 1H),
3.73-3.67 (m, 1H), 3.57-3.53 (m, 1H), 3.26-3.12 (m, 2H), 2.93-2.83
(m, 7H), 2.69-2.64 (m, 1H), 2.55-2.48 (m, 1H), 2.37-2.30 (m, 4H),
1.76-1.74 (d, J = 7.2, 3H). 9 ##STR00050## 617 (CD3OD .delta. 7.92
(s, 1H), 7.51 (s, 1H), 7.06-7.10 (m, 2H), 6.88-6.94 (m, 2H), 5.61
(q, J = 6.5 Hz, 1H), 3.58-3.61 (m, 4H), 3.53 (d, J = 14 Hz, 1H),
3.24 (d, J = 14 Hz, 1H), 2.83- 2.95 (M, 4H), 2.72-2.74 (m, 6H),
2.34-2.39 (m, 5H). 2.33 (s, 3H), 2.05 (t, J = 14.4 Hz, 2H),
1.63-1.90 (m, 2H). 1.78 (d, J = 7.2 Hz, 3H). 1.54-1.59 (m, 2H) 10
##STR00051## 589 CD3OD .delta. 7.92 (s, 1H), 7.51 (s, 1H),
7.10~7.06 (m, 2H), 6.92 (t, J = 8.4 Hz, 2H), 6.87 (s, 1H), 5.62 (q,
J = 7.2 Hz, 1H), 4.16~4.13 (m, 1H), 3.98~3.94 (m, 1H), 3.55~3.51
(m, 1H), 3.33 (s, 1H), 3.26~2.23 (m, 1H), 3.26~3.23 (m, 1H),
3.12~3.09 (m, 1H), 2.97~2.92 (m, 2H), 2.83 (m, 2H), 2.69~2.63 (m,
4H), 2.41~2.21 (m, 8H), 2.16~2.09 (m, 1H), 1.78 (d, J = 7.2 Hz,
3H), 1.19~1.12 (m, 1H). 11 ##STR00052## 552 (CDCl3) .delta. 7.68
(s, 1H), 7.53 (s, 1H), 6.96~6.87 (m, 5H), 5.50 (q, J = 7.2 Hz, 1H),
5.07 (br, 1.5H), 4.36~4.21 (m, 2H), 3.87~3.84 (m, 1H), 3.46~3.12
(m, 5H), 2.91 (br, 2H), 2.83 (br, 2H), 2.41~2.35 (m, 4H), 2.10~2.05
(m, 1H), 1.78 (d, J = 7.2 Hz, 3H), 1.61~1.51 (m, 1H). 12
##STR00053## 552 (CDCl3) .delta. 7.68 (s, 1H), 7.54 (s, 1H),
6.97~6.88 (m, 5H), 5.50 (q, J = 7.2 Hz, 1H), 4.76 (br, 1.5H),
4.36~4.22 (m, 2H), 3.89~3.86 (m, 1H), 3.34~3.12 (m, 5H), 2.92 (br,
2H), 2.85 (br, 2H), 2.43~2.36 (m, 4H), 2.10~2.05 (m, 1H), 1.78 (d,
J = 7.2 Hz, 3H), 1.62~1.53 (m, 1H). 13 ##STR00054## 576 (CDCl3)
.delta. 7.65 (s, 1H), 7.51 (s, 1H), 6.92-6.88 (m, 5H), 5.48 (q, J =
6.8 Hz, 1H), 4.02~3.99 (m, 2H), 3.90~3.86 (m, 1H), 3.72~3.66 (m,
1H), 3.31~3.17 (m, 4H), 3.07~3.00 (m, 1H), 2.93~2.84 (m, 6H),
2.67~2.61 (s, 1H), 2.40~2.33 (m, 4H), 2.01~1.91 (m, 1H), 1.79~1.72
(m, 4H). 14 ##STR00055## 576 (CDCl3) .delta. 7.68 (s, 1H), 7.52 (s,
1H), 6.96~6.88 (m, 5H), 5.49 (q, J = 6.58 Hz, 1H), 4.07~3.98 (m,
2H), 3.92~3.88 (m, 1H), 3.75~3.69 (m, 1H), 3.34~3.18 (m, 4H),
3.09~3.03 (m, 1H), 2.96~2.84 (m, 6H), 2.71~2.65 (s, 1H), 2.41~2.35
(m, 4H), 1.99 (s, 1H), 1.79~1.67 (m, 4H). 15 ##STR00056## 576
(CDCl3) .delta. 7.68 (s, 1H), 7.54 (s, 1H), 6.97~6.88 (m, 5H), 5.50
(q, J = 6.8 Hz, 1H), 4.12~4.02 (m, 2H), 3.92~3.88 (m, 1H),
3.70~3.64 (m, 1H), 3.33~3.30 (m, 1H), 3.24~3.00 (m, 5H), 2.97~2.85
(m, 5H), 2.67~2.63 (m, 1H), 2.43~2.35 (m, 4H), 1.82 (m, 1H), 1.79
(d, J = 6.8 Hz, 3H), 1.63~1.58 (m, 1H). 16 ##STR00057## 590
(DMSO-d6) .delta.: 7.9 (s, 1H), 7.6 (s, 1H), 7.10~7.07 (m, 2H),
6.96 (t, J = 8.0 Hz, 2H), 6.77 (s, 1H), 5.49 (q, J = 8.0 Hz, 1H),
5.12 (d, J = 2 Hz, 1H), 4.38~4.20 (m, 3H), 4.07~3.97 (m, 1H), 3.87
(d, J = 16.0 Hz, 1H), 3.59 (dd, J.sub.1 = 12.0 Hz, J.sub.2 = 4 Hz,
1H), 3.48 (d, J = 14.0 Hz, 1H), 3.25~3.18 (m, 3H), 2.74~2.48 (m,
4H), 2.25~2.24 (m, 4H), 2.05~2.01 (m, 1H), 1.77~1.66 (m, 4H). 17
##STR00058## 526 (CD.sub.3OD) .delta. 7.90 (s, 1H), 7.42 (s, 1H),
7.10-7.06 (m, 2H), 6.93 (t, J = 8.6 Hz, 2H), 6.86 (s, 1H), 5.62 (q,
J = 7.0 Hz, 1H), 4.72 (d, J = 47.12 Hz, 1H), 3.75-3.57 (m, 2H),
3.48 (d, J = 13.92 Hz, 1H), 3.24 (d, J = 13.92 Hz, 1H), 2.92-2.72
(m, 6H), 2.41-2.32 (m, 4H), 1.77 (d, J = 7.16 Hz, 3H) 18
##STR00059## 590 (DMSO-d6) .delta.: 7.98 (s, 1H), 7.88 (s, 1H),
7.06-7.02 (m, 2H), 6.85-6.81 (m, 2H), 6.73 (s, 1H), 5.46 (q, J =
6.8 Hz, 1H), 4.91 (d, J = 4.4 Hz, 1H), 4.22-4.13 (m, 3H), 3.76-3.72
(m, 1H), 3.47 (d, J = 12.8 Hz, 1H), 3.14-3.11 (m, 4H), 3.05-2.98
(m, 1H), 2.73-2.70 (m, 2H), 2.62-2.58 (m, 1H), 2.46-2.22 (m, 5H),
2.17-2.15 (m, 1H), 2.13-1.97 (m, 1H), 1.65 (d, J = 6.8 Hz, 3H). 19
##STR00060## 590 (CDCl3) .delta. 7.67 (s, 1H), 7.49 (s, 1H),
6.91-6.83 (m, 5H), 5.44 (q, J = 7.2 Hz, 1H), 3.82-3.73 (m, 3H),
3.28-3.21 (m, 2H), 3.15 (d, J = 14.0 Hz, 1H), 3.01 (dd, J1 = 10.4
Hz, J2 = 3.2 Hz, 1H), 2.87-2.77 (m, 6H), 2.36-2.30 (m, 5H),
2.05-2.03 (m, 1H), 1.97-1.87 (m, 2H), 1.73 (d, J = 7.2 Hz, 3H),
1.67-1.57 (m, 2H), 1.31-1.19 (m, 2H) 20 ##STR00061## 622 (CD3OD)
.delta. 7.69 (s, 1H), 7.48 (s, 1H), 6.95-6.80 (m, 5H), 5.47 (q, J =
6.8 Hz, 1H), 5.05 (d, J = 48.4 Hz, 1H), 4.38 (t, J = 12.4 Hz, 1H),
4.05 (d, J = 12.8 Hz, 1H), 3.81-3.60 (m, 4H), 3.30-3.09 (m, 4H),
2.99-2.70 (m, 4H), 2.69-2.53 (m, 4H), 2.52-2.21 (m, 5H), 2.11~2.01
(m, 1H), 1.85-1.78 (m, 1H), 1.73 (d, J = 6.8 Hz, 3H) 21
##STR00062## 590 (CDCl3) .delta. 7.67 (s, 1H), 7.56 (s, 1H),
6.96~6.86 (m, 5H), 5.50 (q, J = 6.8 Hz, 1H), 4.45 (m, 1H),
4.11~4.08 (m, 1H), 3.75~3.65 (m, 2H), 3.47~3.45 (m, 1H), 3.35~3.30
(m, 1H), 3.29~3.23 (m, 1H), 3.04~3.03 (m, 2H), 2.98~2.95 (m, 3H),
2.94~2.88 (m, 3H), 2.42~2.36 (m, 4H), 2.09~2.06 (m, 1H), 1.82 (d, J
= 6.8 Hz, 3H), 1.48 (m, 3H). 22 ##STR00063## 590 (CDCl3) .delta.
7.67 (s, 1H), 7.56 (s, 1H), 6.96~6.86 (m, 5H), 5.50 (q, J = 6.8 Hz,
1H), 4.45 (m, 1H), 4.11~4.08 (m, 1H), 3.75~3.65 (m, 2H), 3.47~3.45
(m, 1H), 3.35~3.30 (m, 1H), 3.29~3.23 (m, 1H), 3.04~3.03 (m, 2H),
2.98~2.95 (m, 3H), 2.94~2.88 (m, 3H), 2.42~2.36 (m, 4H), 2.09~2.06
(m, 1H), 1.82 (d, J = 6.8 Hz, 3H), 1.48 (m, 3H). 23 ##STR00064##
590 (CD3OD) .delta.: 7.93 (s, 1H), 7.51 (s, 1H), 7.09-7.05 (m, 2H),
6.94-6.87 (m, 3H), 5.61 (q, J = 7.2 Hz, 1H), 4.39-4.35 (m, 1H),
4.13 (d, J = 11.2 Hz, 1H), 3.89 (d, J = 11.2 Hz, 1H), 3.64-6.61 (m,
1H), 3.51 (d, J = 14.0 Hz, 1H), 3.26-3.22 (m, 1H), 2.91-2.81 (m,
4H), 2.71-2.55 (m, 3H), 2.53- 2.49 (m, 1H), 2.47-2.29 (m, 4H),
2.01-2.11 (m, 1H), 1.71-1.88 (m, 5H), 1.14 (d, J = 6.8 Hz, 3H) 24
##STR00065## 590 (CDCl3) .delta. 7.61 (s, 1H), 7.48 (s, 1H),
6.89-6.85 (m, 5H), 5.43 (q, J = 6.8 Hz, 1H), 4.73 (m, 2H),
4.44~4.34 (m, 1H), 3.61~3.54 (m, 1H), 3.35~3.31 (m, 3H), 3.23~3.21
(m, 2H), 3.07~3.01 (m, 1H), 2.91~2.82 (m, 6H), 2.32~2.31 (m, 4H),
2.01~1.98 (m, 2H), 1.95 (d, J = 6.8 Hz, 3H), 1.71 (s, 3H). 25
##STR00066## (CD3OD) .delta. 7.93 (s, 1H), 7.52 (s, 1H), 7.12-7.03
(m, 2H), 6.94 (t, J = 8.8, 2H), 6.88 (s, 1H), 5.62 (q, J = 7.2,
1H), 3.98-3.64 (m, 4H), 3.65 (s, 2H), 3.25 (d, J = 14.0, 2H),
2.92-2.62 (m, 4H), 2.48-2.26 (m, 4H), 1.92-1.82 (m, 2H), 1.82 (d, J
= 6.8, 3H), 1.68- 1.60 (m, 2H) 26 ##STR00067## 576 (CD3OD) .delta.:
7.92 (s, 1H), 7.53 (s, 1H), 7.09-7.05 (m, 2H), 6.95-6.86 (m, 3H)
5.61- 5.57 (q, J = 7.2 Hz, 1H), 4.52- 4.48 (t, J = 8.8, 1H), 4.34
(d, J = 8.8 Hz, 1H), 4.12-4.05 (m, 3H), 3.85-3.82 (m, 1H), 3.51 (d,
J = 14 Hz, 1H), 3.23- 3.11 (m, 4H), 2.83 (bs, 2H), 2.69 (bs, 2H),
2.39 (bs, 2H), 2.32 (bs, 2H), 1.77 (d, J = 6.8 Hz, 3H) 27
##STR00068## 576 (CD3OD) .delta. 7.93 (s, 1H), 7.52 (s, 1H),
7.09~7.05 (m, 2H), 6.94~6.90 (m, 2H), 6.89~6.87 (m, 1H), 5.60 (q, J
= 6.8 Hz, 1H), 4.24~4.23 (m, 1H), 3.97~3.93 (m, 2H), 3.54~3.51 (m,
1H), 3.26~3.21 (m, 2H), 3.06~3.01 (m, 3H), 2.86~2.83 (m, 2H),
2.46~2.23 (m, 7H), 2.07~2.06 (m, 1H), 1.79 (d, J = 6.8 Hz, 3H),
1.62~1.60 (m, 1H)
Example 2
Preparation of Compound 28
##STR00069##
[0260] Step A Preparation of Int 2-1
##STR00070##
[0262] Potassium tert-butoxide (2.8 g, 24.84 mmol) was dissolved in
DMF (10 mL) and benzylthiol (2.6 g, 20.70 mmol) was added dropwise
at 0.degree. C. The mixture was allowed to stir at room temperature
for 15 minutes and then cooled to 0.degree. C., a solution of
5-bromo-2-chloropyridine (4.0 g, 20.70 mmol) in DMF (4 mL) was
added dropwise at 0.degree. C. and the mixture was heated at
80.degree. C. for 1.5 hours. The mixture was poured into water (100
mL) and extracted with ethyl estate (3.times.100 mL). The combined
organic phases were washed with brine (100 mL), water (100 mL) and
dried (Na.sub.2SO.sub.4). Concentrated in vacuo to provide the
residue, which was purified with column chromatography (petroleum
ether:EtOAc=10:1) to provide Int 2-1 (4.0 g, 69%). MS (ESI): m/z
(M+H).sup.+ 280.
Step B Preparation of Int 2-2
##STR00071##
[0264] To a solution of Int 2-1 (1.5 g, 5.40 mmol) in DCM (100 mL)
was added water (100 mL) and HCOOH (100 mL). The heterogeneous
mixture was cooled to 0.degree. C. and Cl.sub.2 gas was bubbled for
30 minutes until the mixture turned to deep yellow. The organic
phase was separated, extracted with DCM (3.times.100 mL) and the
combined organic phase was washed with 1M NaOH (100 mL) followed by
brine (100 mL), concentration to provide a residue (1.1 g) of Int
2-2 which was used for the next step without purification.
Step C Preparation of Int 2-3
##STR00072##
[0266] To the suspension of Int 1-7 (474 mg, 1.85 mmol) in DCM (15
mL) was added Et.sub.3N (476 mg, 4.62 mmol) and compound Int 2-2
(500 mg, 1.54 mmol) at 0.degree. C. The mixture was allowed to stir
at 0.degree. C. for 1 hour. The mixture was poured into water (20
mL) and extracted with DCM (3.times.15 mL). The combined organic
phases were washed with brine (20 mL), water (20 mL) and dried
(Na.sub.2SO.sub.4). Concentrated in vacuo to provide the residue,
which was purified with column chromatography
(CH.sub.2Cl.sub.2:MeOH=20:1) to provide Int 2-3 (350 mg, 45%). MS
(ESI): m/z (M+H).sup.+ 508.
Step C Preparation of Compound 28
##STR00073##
[0268] A mixture of compound Int 2-3 (80 mg, 0.16 mmol), Boc
piperazine (32 mg, 0.24 mmol), Pd.sub.2(dba).sub.3 (15 mg, 0.016
mmol), X-phos (11 mg, 0.032 mmol) and Cs.sub.2CO.sub.3 (104 mg,
0.32 mmol) in DMF (3 mL) was heated to 80.degree. C. for about 15
hours under nitrogen. The mixture was filtered and the filtrate was
concentrated in vacuo, the resulting residue was purified using
HPLC to provide (100 mg, 0.16 mmol) of the Boc piperazine adduct
which was dissolved in HCl/EtOAc (15 mL) and stirred at room
temperature for 1 hour before the solvent was concentrated in
vacuo. The resulting residue was purified using HPLC to provide
compound 28 (59 mg, 70%). .sup.1H NMR (CD.sub.3OD): .delta. 8.36
(d, J=2.8 Hz, 1H), 7.91 (s, 1H), 7.70 (d, J=8.8 Hz, 1H), 7.43-7.46
(m, 1H), 7.02-7.06 (m, 2H), 6.85-6.89 (m, 3H), 5.57-5.62 (m, 1H),
3.47-3.50 (m, 5H), 3.21-3.25 (m, 1H), 3.09 (s, 4H), 2.94-2.96 (m,
2H), 2.79-2.81 (m, 2H), 2.28-2.36 (m, 4H), 1.76 (d, J=7.2 Hz, 3H).
MS (ESI): m/z (M+H).sup.+ 514.
[0269] The following compounds were prepared as described in
Example 2 using from Int 2-2 and the appropriately substituted
sulfonylchloride.
TABLE-US-00003 Cmpd Structure M + 1 .sup.1H NMR 29 ##STR00074## 514
(CD3OD) .delta. 8.50 (s, 1H), 8.17 (s, 1H), 7.87 (s, 1H), 7.44 (s,
1H), 6.99-7.03 (m, 2H), 6.82 (t, J = 8.0 Hz, 3H), 5.52-5.58 (m,
1H), 3.43-3.47 (m, 1H), 3.29-3.31 (m, 4H), 3.19-3.22 (m, 1H), 2.98
(t, J = 5.0 Hz, 4H), 2.70-2.82 (m, 4H), 2.30- 2.73 (m, 4H), 1.72
(d, J = 7.2 Hz, 3H). 30 ##STR00075## 515 (CDCl3): .delta. 8.52 (s,
1H), 8.01 (s, 1H), 7.66 (s, 1H), 6.87-6.96 (m, 5H), 5.46~5.51 (m,
1H), 3.73~7.75 (t, 4H), 3.33 (d, J = 14.0 Hz, 1H) 3.20 (d, J = 14.0
Hz, 1H), 2.99~3.06 (m, 8H), 2.33~2.39 (m, 4H), 1.77 (d, J = 4.8 Hz,
3H).
Example 3
Preparation of Compound 31
##STR00076##
[0270] Step A Preparation of Int 3-1
##STR00077##
[0272] To a stirred solution of 5-bromo-2-cyanopyridine (30.0 g,
0.165 mol) and Ti(O-iPr).sub.4 (51.5 g, 0.181 mol) in 900 mL THF
was added EtMgBr (330 mL, 0.045 mmol) under nitrogen at 0.degree.
C. The reaction mixture was allowed to stir at room temperature for
5 hours. The reaction was quenched by water and extracted by EtOAc,
filtrated and the organic layers were dried over Na.sub.2SO.sub.4,
filtrated and concentrated in vacuo. The resulting residue was
purified using flash column chromatography on silica gel eluted
with petroleum ether:EtAOc=30:1 to provide product (7.2 g, 21%).
MS-ESI (m/z): 213, 215 (M+H).sup.+
Step B Preparation of Int 3-3
##STR00078##
[0274] To a solution of compound Int 3-1 (7.1 g, 0.033 mol) in the
80 mL of mixed solvent (MeCN/H.sub.2O=1:1) was added
2,5-bis(hydroxymethyl)-1,4-dioxane-2,5-diol (7.81 g, 0.043 mol),
KSCN (4.18 g, 0.043 mol) and acetic acid (4 mL). The mixture was
allowed to stir at 90.degree. C. for 6 hrs. then cooled to
0.degree. C. and treated dropwise with H.sub.2O.sub.2 (2.7 g). The
ice bath was removed and the mixture was allowed to stir at room
temperature for 1 hr. The mixture was quenched by adding
NaHSO.sub.3 and basified by adding ammonium hydroxide until
pH>8. The mixture was extracted with EtOAc and the organic layer
was washed with brine, dried over Na.sub.2SO.sub.4 and concentrated
in vacuo. The resulting residue of compound Int 3-3 was used
without purification (9.67 g, 100%) MS-ESI (m/z): 294, 296
(M+H).sup.+.
Step C Preparation of Int 3-4
##STR00079##
[0276] To a solution of compound Int 3-3 (9.67 g, 0.033 mol) in
dioxane (100 mL) was added MnO.sub.2 (14.2 g, 0.165 mol) in one
portion. The mixture was refluxed for about 15 hours, cooled and
the mixture was filtered through Celite and concentrated in vacuo.
The resulting residue was purified using flash column
chromatography on silica gel eluting with
dichloromethane:methanol=50:1 to provide compound Int 3-4 (0.45 g,
Yield: 12%) as brown oil. MS-ESI (m/z): 292, 294 (M+H).sup.+.
Step D Preparation of Int 3-5
##STR00080##
[0278] To a solution of compound Int 3-4 (0.5 g, 1.72 mmol) in
1,2-dichloroethane (15 mL) was added N-Boc-piperazine (320 mg, 1.72
mmol). The reaction mixture was allowed to stir at room temperature
for 1 hour and followed by the addition of NaBH(OAc).sub.3 (1.1 g,
5.15 mmol). Then the mixture was allowed to stir at room
temperature for about 15 hours. The reaction mixture was quenched
with ice cooled water and extracted with dichloromethane
(3.times.30 mL). The combined organic extracts were washed with
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo to
provide crude desired product as yellow oil. The resulting residue
of compound Int 3-5 (0.74 g, 97%) was used without purification.
MS-ESI (m/z): 462, 464 (M+H).sup.+.
Step E Preparation of Int 3-6
##STR00081##
[0280] A mixture of compound Int 3-5 (774 mg, 1.68 mmol) in
HCl/EtOAc (20 mL) was allowed to stir at room temperature for 1
hours, then concentrated in vacuo and used in the next step without
further purification. MS-ESI (m/z): 362, 364 (M+H).sup.+
Step F Preparation of Int 3-7
##STR00082##
[0282] A solution of 2-bromothiazole (36.46 g, 0.22 mol) in
N-methylpiperazine (109.75 g, 1.10 mol) was added NaI (0.33 g, 2.2
mmol) with stirring under N.sub.2. The reaction mixture was allowed
to stir at 120.degree. C. for 16 hrs. The reaction mixture was
cooled to 25.degree. C. and diluted with 1000 mL of EtOAc. The
mixture was washed with a solution of 5% citric acid (100
mL.times.3) and saturated solution of Na.sub.2CO.sub.3 (100
mL.times.2). The organic layer was dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo to provide compound Int 3-7 as
red oil (25.7 g, 64%). .sup.1H NMR (CDCl.sub.3) .delta.: 7.14 (d,
J=3.6 Hz, 1H), 6.52 (d, J=3.6 Hz, 1H), 3.46 (t, J=5.2 Hz, 4H), 2.47
(t, J=5.2 Hz, 4H), 2.31 (s, 3H). MS-ESI (m/z): 184 (M+1).sup.+
R.sub.f: 0.2 (petroleum ether:EtOAc=1:2)
Step G Preparation of Int 3-8
##STR00083##
[0284] A solution of Int 3-7 (10 g, 54 mmol) in CHCl.sub.3 (100 mL)
was treated drop wise with 20 mL of HSO.sub.3C1 with stirring at
0.degree. C. The reaction mixture was allowed to stir at
100.degree. C. for 2 hrs, cooled and concentrated in vacuo to
remove the CHCl.sub.3. 20 mL of SOCl.sub.2 was added and the
reaction mixture was allowed to stir at 100.degree. C. for another
16 hrs. Then the reaction mixture was cooled and concentrated in
vacuo to remove the excess SOCl.sub.2. The resulting residue was
carefully poured onto water-ice and filtered. The filter cake was
dried under vacuum to provide compound Int 3-8 as yellow solid
(6.75 g, 44%). .sup.1H NMR (CDCl.sub.3) .delta.: 7.94 (s, 1H), 4.23
(d, J=14.8 Hz, 2H), 3.65.about.3.54 (m, 5H), 3.22.about.3.16 (m,
1H), 2.89 (s, 3H). MS-ESI (m/z): 282 (M+1).sup.+
Step H Preparation of Int 3-9
##STR00084##
[0286] To a stirred solution of compound Int 3-6 (610 mg HCl salt,
1.415 mmol) in DCM (10 mL) was added Et.sub.3N (0.3 mL). The
mixture was allowed to stir at room temperature for 0.5 hours
before 437 mg (1.4 mmol) of Int 3-8 was added in portions at
0.degree. C. The mixture was allowed to stir at room temperature
for 2 hours, the reaction mixture was filtered, and the filtrate
was added to water (30 mL) and EtOAc (60 mL). The separated organic
layer was washed with water (3.times.20 mL) again. The combined
organic layer was dried with MgSO.sub.4, concentrated in vacuo to
provide resulting residue. The resulting residue was purified using
pre-TLC to provide 350 mg of compound Int 3-7 as a brown solid.
MS-ESI (m/z): 607, 609 (M+H).sup.+
Step I Preparation of Compound 31
##STR00085##
[0288] To a stirred solution of compound Int 3-7 (200 mg, 0.33
mmol) and MeB(OH).sub.2 (50 mg, 0.066 mmol) in 8 mL dioxane was
added Pd(OAc).sub.2 (10 mg, 0.045 mmol), PCy.sub.3(25 mg, 0.09
mmol) and K.sub.3PO.sub.4 (210 mg, 0.99 mmol). The mixture was
degassed with nitrogen and stirred at 120.degree. C. for about 15
hours. The reaction was concentrated in vacuo and the resulting
residue was purified using preparatory HPLC to provide 30 mg of
Compound 31 as a white solid. .sup.1H NMR (CD.sub.3OD) .delta. 8.12
(s, 1H), 7.85 (s, 1H), 7.46 (s, 1H), 7.34.about.7.32 (d, J=8.0 Hz,
1H), 6.93 (s, 1H), 6.27.about.6.25 (d, J=8.0 Hz, 1H),
3.62.about.3.59 (m, 4H), 3.43 (s, 2H), 2.63.about.2.56 (m, 8H),
2.59.about.2.57 (m, 7H), 2.17 (s, 3H), 1.75 (m, 2H), 1.65 (m, 2H).
MS-ESI-ESI (m/z): 543 (M+H).sup.+
[0289] The following compounds were prepared as described in
Example 3 above using the appropriately substituted amine as Int
3-1.
TABLE-US-00004 MS No. Structure (M + 1) .sup.1H NMR 32 ##STR00086##
566 (CD3OD) .delta. 7.71 (s, 1H), 7.56 (s, 1H), 7.19 (t, J = 8.8,
2H), 6.85 (s, 1H), 6.79 (t, J = 9.2, 2H), 4.42 (t, J = 10.0, 2H),
4.24 (t, J = 10.0, 2H), 3.62-3.58 (m, 6H), 3.02 (br, 4H), 2.58-2.48
(m, 8H), 2.33 (s, 3H). 33 ##STR00087## 551 (CDCl3) .delta. 7.87 (s,
1H), 7.56 (s, 1H), 7.52 (s, 1H), 7.36-7.30 (m, 1H), 6.88 (s, 1H),
6.67 (dd, J1 = 9.2, J2 = 3.6, 1H), 4.49 (t, J = 10.4, 2H), 4.32 (t,
J = 10.8, 2H), 3.55 (t, J = 10.0, 4H), 3.50 (s, 2H), 3.08 (br, 4H),
2.54-2.48 (m, 8H), 2.33 (s, 3H). 34 ##STR00088## 581 (CD3OD)
.delta. 7.60 (d, J = 8.0 Hz, 1H), 7.54 (s, 1H), 7.49 (t, J = 8 Hz,
2H), 7.31 (s, 1H), 6.93 (s, 1H), 5.98 (t, J = 7.6 Hz, 1H),
3.64-3.52 (m, 6H), 3.29-3.18 (m, 1H), 3.09- 3.00 (m, 5H), 2.82-2.57
(m, 1H), 2.57-2.52 (m, 8H), 2.35 (s, 3H), 2.31-2.26 (m, 1H).
Example 4
Preparation of Compound 35
##STR00089##
[0290] Step A Preparation of Int 4-1
##STR00090##
[0292] To a solution of Int 1-5 from Example 1, Step D above (2.0
g, 9.17 mmol) in Et.sub.2O (50 mL) was added TMSCN (1.12 g, 10.09
mmol) and ZnI.sub.2 (0.86 g, 2.76 mmol). The mixture was allowed to
stir at 0.degree. C. for 10 minutes, piperazine-1-carboxylic acid
tert-butyl ester (1.9 g, 10.09 mmol) in MeOH (50 mL) was added at
0.degree. C. Then Et.sub.3N (1.4 g, 13.73 mmol) was added and the
mixture was heated at 60.degree. C. for 24 hours. The mixture was
poured into H.sub.2O (20 mL) and extracted with EtOAc (20
mL.times.3), the combined organic layer was washed with brine (20
mL), dried over sodium sulfate and concentrated in vacuo. The crude
mixture was and purified with column chromatography (PE:EtOAc=3:1)
to provide Int 4-1 (3.0 g, 79%). MS (ESI): m/z (M+H).sup.+ 414.
Step B Preparation of Int 4-2
##STR00091##
[0294] The solution of Int 4-1 (3.0 g, 7.26 mmol) in HCl/MeOH (100
mL) was allowed to stir at 70.degree. C. for about 15 hours. The
reaction mixture was cooled and concentrated in vacuo to provide
crude Int 4-2 (2.5 g) as the HCl salt. MS (ESI): m/z (M+H).sup.+
347.
Step C Preparation of Int 4-3
##STR00092##
[0296] To a solution of Int 4-2 (2.5 g, 7.26 mmol) in DCM (50 mL)
and H.sub.2O (30 mL) was added NaOH (1.5 g, 36.30 mmol) at
0.degree. C., then (Boc).sub.2O (2.4 g, 10.89 mmol) was added at
0.degree. C. The reaction mixture was allowed to warm to room
temperature and stirred for 5 hours. The reaction mixture was
poured into H.sub.2O (20 mL), extracted with DCM (20 mL.times.3),
the combined organic layer was washed with brine (20 mL), dried
over sodium sulfate and concentrated in vacuo. The crude mixture
was and purified with column chromatography (petroleum
ether/EtOAc=3:1) to provide Int 4-3 (2.5 g, 78%). MS (ESI): m/z
(M+H).sup.+ 447.
Step D Preparation of Int 4-4
##STR00093##
[0298] To a solution of Int 4-3 (1.0 g, 2.24 mmol) in THF (20 mL)
was added LiAlH.sub.4 (255 mg, 6.73 mmol) at 0.degree. C. and the
whole mixture was allowed to stir at 0.degree. C. for 4 hours. The
mixture was poured into H.sub.2O (20 mL) and extracted with EtOAc
(20 mL.times.3), the combined organic layer was washed with brine
(20 mL), dried over sodium sulfate and concentrated in vacuo to
provide Int 4-4 (650 mg, 69%). MS (ESI): m/z (M+H).sup.+ 419.
Step E Preparation of Int 4-5
##STR00094##
[0300] To a solution of Int 4-4 (200 mg, 0.48 mmol) in THF (10 mL)
was added NaH (58 mg, 1.44 mmol) at 0.degree. C. The mixture was
allowed to stir at 0.degree. C. for 10 minutes before MeI (68 mg,
0.48 mmol) was added and the mixture was allowed to warm to room
temperature and stirred for about 15 hours. The mixture was poured
into H.sub.2O (10 mL) and extracted with EtOAc (10 mL.times.3), the
combined organic layer was washed with brine (10 mL), dried over
sodium sulfate and concentrated in vacuo to provide Int 4-5 (200
mg, 97%) MS (ESI): m/z (M+H).sup.+ 433.
Step F Preparation of Int 4-6
##STR00095##
[0302] The solution of Int 4-5 (200 mg, 0.46 mmol) in HCl/EtOAc (10
mL) was allowed to stir at 0.degree. C. for 1 hour. The reaction
mixture was concentrated in vacuo to provide crude Int 4-6 (150 mg)
which was used into the next step without further purification. MS
(ESI): m/z (M+H).sup.+ 333.
Step G Preparation of Compound 35
##STR00096##
[0304] To a solution of Int 4-6 (150 mg, 0.45 mmol) in DMF (10 mL)
was added Et.sub.3N (227 mg, 2.25 mmol) at 0.degree. C. for 10
minutes then 4-(4-methyl-piperazin-1-yl)-thiazole-2-sulfonyl
chloride (252 mg, 0.90 mmol) was added, the mixture was allowed to
stir at 0.degree. C. for 30 minutes, filtered and the filtrate was
purified using preparative HPLC to provide Compound 35
[0305] Diastereomer A: (8 mg, 3%). .sup.1H NMR (CD.sub.3OD):
.delta. 7.80 (s, 1H), 7.45 (s, 1H), 7.03-7.07 (m, 2H), 6.85-6.91
(m, 3H), 5.56 (q, J=7.2 Hz, 1H), 4.04 (t, J=6.0 Hz, 1H), 3.87-3.91
(m, 1H), 3.70-3.74 (m, 1H), 3.60 (s, 4H), 3.34 (s, 3H), 2.49-2.68
(m, 10H), 2.47-2.48 (m, 2H), 2.34 (s, 3H), 1.76 (d, J=6.8 Hz, 3H).
MS (ESI): m/z (M+H).sup.+ 578.
[0306] Diastereomer B: (25 mg, 10%). .sup.1H NMR (CD.sub.3OD):
.delta. 7.97 (s, 1H), 7.55 (s, 1H), 6.99-7.01 (m, 4H), 6.93 (s,
1H), 5.77 (q, J=7.2 Hz, 1H), 3.52-3.73 (m, 7H), 3.30 (s, 1H), 2.95
(s, 4H), 2.72-2.75 (m, 2H), 2.56-2.60 (m, 6H), 2.36 (s, 3H), 1.79
(d, J=7.2 Hz, 3H). MS (ESI): m/z (M+H).sup.+ 578.
Example 5
Preparation of Compound 36
##STR00097##
[0307] Step A Preparation of Int 5-1
##STR00098##
[0309] To a solution of methyl
2-(hydroxy(methoxy)phosphoryl)acetate (3.34 g, 18.3 mmol) in THF
(40 mL) was added NaH (1.1 g, 27.5 mmol) at 0.degree. C. After
stirring at 0.degree. C. for 1 hour, a solution of Int 1-5 (4 g,
18.3 mmol) in THF (4 mL) was added dropwise. The mixture was
allowed to stir at room temperature for about 15 hours. The
reaction mixture was quenched with aqueous NH.sub.4Cl (10 mL) then
extracted with EtOAc (30 mL.times.4). The combined organic layer
was dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The
resulting residue was purified using column chromatography
(petroleum ether/EtOAc=5:1) to provide Int 5-1 (4 g, 80%). .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.03 (s, 1H), 7.55 (s, 1H),
7.40-7.45 (m, 1H), 7.16-7.19 (m, 2H), 7.04-7.08 (m, 2H), 6.25-6.31
(m, 1H), 5.63-5.69 (m, 1H), 3.69 (s, 3H). MS (ESI): m/z (M+H).sup.+
275.
Step B Preparation of Int 5-2
##STR00099##
[0311] To a mixture of compound Int 5-1 (1 g, 3.65 mmol) and
piperazine-1-carboxylic acid tert-butyl ester (6.7 g, 36.5 mmol)
was added ZrCl.sub.4 (500 mg) and the mixture was allowed to stir
at 130.degree. C. for 8 hours. The mixture was filtered and the
filtrated was concentrated in vacuo. The resulting residue was
purified using preparative HPLC to provide Int 5-2 (0.5 g, 30%).
.sup.1H NMR (CD.sub.3OD): .delta. 9.11 (s, 1H), 7.64 (s, 1H),
7.33-7.36 (m, 2H), 7.16-7.19 (m, 2H), 5.99-6.05 (m, 1H), 4.53-4.56
(m, 1H), 3.64 (s, 3H), 2.99-3.10 (m, 6H), 2.35-2.38 (m, 4H), 1.93
(d, J=7.2 Hz, 3H), 1.40 (s, 9H). MS (ESI): m/z (M+H).sup.+ 331.
Step C Preparation of Int 5-3
##STR00100##
[0313] To a solution of compound Int 5-2 (300 mg, 0.652 mmol) in
THF (30 mL) was added LiAlH.sub.4 (49 mg, 1.3 mmol) at 0.degree.
C., and the reaction mixture was allowed to stir at room
temperature for 2 hours before water (0.3 mL) was added to quench
the reaction. The mixture was extracted with EtOAc (3.times.10 mL)
and the combined organic layer was dried over Na.sub.2SO.sub.4 and
concentrated in vacuo to provide Int 5-3 (240 mg, 85%). .sup.1H NMR
(CD.sub.3OD): .delta. 7.81 (s, 1H), 7.19-7.23 (m, 2H), 7.05-7.10
(m, 2H), 6.91 (s, 1H), 5.65-5.71 (m, 1H), 3.98-3.99 (m, 1H),
3.61-3.64 (m, 1H), 3.35-3.41 (m, 1H), 2.94-3.06 (m, 4H), 2.30-2.33
(m, 4H), 1.81 (d, J=7.2 Hz, 3H), 1.40 (s, 9H). MS (ESI): m/z
(M+H).sup.+ 433.
Step D Preparation of Int 5-4
##STR00101##
[0315] To a solution of Int 5-3 (130 mg, 0.3 mmol) in THF (5 mL)
was added NaH (12 mg, 0.3 mmol) at -10.degree. C. Stirring was
continued for 30 min before CH.sub.3I (42.7 mg, 0.3 mmol) was
added. The mixture was allowed to stir at -10.degree. C. for 2 h,
quenched with water (4 mL) and extracted with EtOAc (4.times.5 mL).
The organic layer was dried over Na.sub.2SO.sub.4 and concentrated
in vacuo to provide the resulting residue Int 5-4 (130 mg, 97%)
which was used in next step without further purification. MS (ESI):
m/z (M+H).sup.+ 447.
Step E Preparation of Int 5-5
##STR00102##
[0317] The solution of Int 5-4 (200 mg, 0.4 mmol) in HCl/EtOAc (10
mL) was allowed to stir at 0.degree. C. for 1 hour. The reaction
mixture was concentrated in vacuo to provide crude Int 5-5 which
was used in the next step without further purification. MS (ESI):
m/z (M+H).sup.+ 347.
Step F Preparation of Compound 36
##STR00103##
[0319] To a solution of Int 5-5 (150 mg, 0.43 mmol) in DMF (10 mL)
was added Et.sub.3N (227 mg, 2.25 mmol) at 0.degree. C. After
stirring for 10 minutes,
4-(4-methyl-piperazin-1-yl)-thiazole-2-sulfonyl chloride (252 mg,
0.90 mmol) was added and the mixture was allowed to stir at
0.degree. C. for 30 minutes. The reaction mixture was filtered and
the filtrate was purified using preparative HPLC to provide
Compound 36.
[0320] Diastereomer A (22 mg, 17%). .sup.1H NMR (CD.sub.3OD):
.delta. 7.81 (s, 1H), 7.46 (s, 1H), 7.06-7.09 (m, 2H), 6.86-6.91
(m, 3H), 5.51-5.57 (m, 1H), 3.98-4.01 (m, 1H), 3.41-3.60 (m, 5H),
3.21-3.25 (m, 4H), 2.49-2.68 (m, 12H), 2.34 (s, 3H), 2.12-2.18 (m,
1H), 1.86-1.98 (m, 1H), 1.76 (d, J=7.2 Hz, 3H). MS (ESI): m/z
(M+H).sup.+ 592.
[0321] Diastereomer B (30 mg, 22%). .sup.1H NMR (CD.sub.3OD):
.delta. 7.96 (s, 1H), 7.54 (s, 1H), 7.01-7.04 (m, 4H), 6.92 (s,
1H), 5.59-5.65 (m, 1H), 3.56-3.76 (m, 5H), 3.19-3.23 (m, 1H),
2.87-2.97 (m, 8H), 2.46-2.63 (m, 8H), 2.34 (s, 3H), 1.98-2.01 (m,
1H), 1.86-1.92 (m, 1H), 1.79 (d, J=7.2 Hz, 3H). MS (ESI): m/z
(M+H).sup.+ 592.
Example 6
Preparation of Compound 37
##STR00104##
[0322] Step A Preparation of Int 6-1
##STR00105##
[0324] CH.sub.3MgBr (5 mL, 15 mmol) was added drop wise to a
mixture of compound Int 1-5 (1.09 g, 5 mmol) in anhydrous THF (70
mL) at 0.degree. C. The mixture was allowed to stir at 0.degree. C.
for 1 hour, quenched with sat.NH.sub.4Cl and extracted with ethyl
acetate (3.times.50 mL). The organic washings were washed with
brine, dried, concentrated in vacuo to provide 1.05 g (90%) of
compound Int 6-1 as a yellow oil. MS-ESI (m/z): 235
(M+H).sup.+.
Step B--Synthesis of Int 6-2
##STR00106##
[0326] To a solution of compound Int 6-1 (1.05 g, 4.5 mmol) in
dioxane (10 mL) was added MnO.sub.2 (1.95 g, 22.5 mmol) and the
mixture was allowed to stir at 80.degree. C. for 4 hours. The
reaction mixture was filtered through Celite and concentrated in
vacuo. The resulting residue was purified using column
chromatography to provide 1.02 g (98%) of compound Int 6-2 as
yellow oil (yield: 98%). MS-ESI (m/z): 233 (M+H).sup.+.
Step C--Synthesis of Int 6-3
##STR00107##
[0328] A mixture of compound Int 6-2 (1.02 g, 4.37 mmol),
Boc-piperazine (0.82 g, 4.4 mmol) and Ti(OiPr).sub.4 (1 mL) in
anhydrous THF (1 mL) was allowed to stir at 90.degree. C. for about
15 hours under N.sub.2. The reaction mixture was cooled and THF (10
mL) and NaBH(OAc).sub.3 (4.6 g, 21.8 mmol) were added and the
mixture was allowed to stir at 80.degree. C. for 1 hour. The
mixture was cooled then quenched with water and extracted with
ethyl acetate (3.times.50 mL). The organic washings were washed
with brine, dried over sodium sulfate, filtered and concentrated in
vacuo to provide the resulting residue which was purified using
column chromatography to provide 0.76 g (43%) of compound Int 6-3
as yellow oil. MS-ESI (m/z): 403 (M+H).sup.+.
Step D--Synthesis of Int 6-4
##STR00108##
[0330] A mixture of compound Int 6-4 (0.76 g, 1.89 mmol) in
HCl/EtOAc (10 mL) was allowed to stir at room temperature for 30
minutes then concentrated in vacuo and used in the next step
without further purification. MS-ESI (m/z): 303 (M+H).sup.+.
Step E--Synthesis of Int 6-5
##STR00109##
[0332] To a mixture of compound Int 6-4 (570 mg, 1.89 mmol) and
triethylamine (606 mg, 6 mmol) in DMF (3 mL) was added in portions
N-acetyl-2-aminothiazole-5-sulfonyl chloride (480 mg, 2 mmol). The
mixture was allowed to stir at room temperature for 30 min, and
then extracted with ethyl acetate (3.times.50 mL). The organic
layer was washed with brine, dried over sodium sulfate, filtered
and concentrated in vacuo to provide the resulting residue which
was purified using column chromatography to provide 0.77 g (82%) of
compound Int 6-5 as yellow solid. MS-ESI (m/z): 507
(M+H).sup.+.
Step F--Synthesis of Int 6-6
##STR00110##
[0334] A mixture of compound Int 6-5 (770 mg, 1.52 mmol) in EtOH/6N
HCl (10/10 mL) was allowed to stir at 80.degree. C. for 1 hour,
cooled and concentrated in vacuo. The resulting residue was diluted
with EtOAc (20 mL), basified with saturated NaHCO.sub.3 solution
then extracted with ethyl acetate (3.times.30 mL). The organic
layer was washed with brine, dried over sodium sulfate, filtered
and in vacuo to provide the resulting residue which was purified
using column chromatography to provide 0.58 g (82%) of compound Int
6-6 as yellow solid. MS-ESI (m/z): 465 (M+H).sup.+.
Step G--Synthesis of Int 6-7
##STR00111##
[0336] To a mixture of tert-butylnitrite (466 mg, 4.52 mmol) in DMF
(5 mL) was added compound Int 6-6 (0.52 g, 1.15 mmol). The mixture
was allowed to stir at 60.degree. C. for 2 hours then diluted with
EtOAc (20 mL) and washed with concentrated in vacuo NH.sub.4OH. The
organic washings were dried over sodium sulfate, filtered and in
vacuo to provide the resulting residue which was purified using
column chromatography to provide 0.32 g (52%) of compound Int 6-7
as yellow solid. MS-ESI (m/z): 528, 530 (M+H).sup.+.
Step H--Synthesis of Compounds 37a and 37b
##STR00112##
[0338] A mixture of compound Int 6-7 (300 mg, 0.56 mmol),
(7R,8aS)-octahydropyrrolo[1,2-a]piperazin-7-ol (0.62 mmol) and
K.sub.2CO.sub.3 (207 mg, 1.5 mmol) in CH.sub.3CN (5 mL) was allowed
to stir at 80.degree. C. for about 15 hours. The mixture was cooled
and extracted with EtOAc/H.sub.2O. The organic extracts were washed
with brine, dried, concentrated in vacuo and purified using HPLC to
provide 80 mg (.about.25%) of each diastereomer 37a and 37b.
[0339] Compound 37a: .sup.1H NMR (CD.sub.3OD) .delta.: 7.83 (s,
1H), 7.44 (s, 1H), 7.05-7.01 (m, 2H), 6.88-6.82 (m, 3H), 5.60 (q,
J=6.8 Hz, 1H), 4.43-4.38 (m, 1H), 4.16 (d, J=12.8 Hz, 1H),
4.08-4.03 (m, 1H), 3.95 (d, J=12.8 Hz, 1H), 3.50-3.46 (m, 1H),
3.11-3.09 (m, 1H), 2.92-2.86 (m, 1H), 2.68 (br, 2H), 2.55-2.42 (m,
8H), 2.40-2.39 (m, 1H), 2.18-2.14 (m, 5H), 1.81-1.73 (m, 4H).
MS-ESI (m/z): 590 (M+H).sup.+.
[0340] Compound 37b .sup.1H NMR (CD.sub.3OD) .delta.: 7.91 (s, 1H),
7.55 (s, 1H), 7.07-7.01 (m, 4H), 6.88 (s, 1H), 5.81 (q, J=6.8 Hz,
1H), 4.41-4.38 (m, 1H), 4.12 (d, J=12.8 Hz, 1H), 3.95 (d, J=12.8
Hz, 1H), 3.62-3.58 (m, 1H), 3.49-3.45 (m, 1H), 3.32-3.28 (m, 1H),
3.24-3.00 (m, 5H), 2.90-2.84 (m, 1H), 2.59-2.36 (m, 6H), 2.16-2.12
(m, 1H), 1.79-1.75 (m, 5H), 1.21 (d, J=6.8 Hz, 3H). MS-ESI (m/z):
590 (M+H).sup.+.
Example 7
Preparation of Compound 38
##STR00113##
[0341] Step A Preparation of Int 7-1
##STR00114##
[0343] To a solution of Int 1-4 (5.0 g, 22.9 mmol) in THF (80 mL)
was added ethyl magnesium bromide (25 mL, 25 mmol) at 0.degree. C.
The mixture was allowed to stir at room temperature for about 15
hours then quenched with saturated NH.sub.4Cl solution (20 mL) and
extracted with EtOAc (3.times.30 mL). The combined organic layer
was dried over sodium sulfate, filtered and in vacuo and the
resulting residue was purified using column chromatography
(EtOAc/petroleum ether=1/3) to provide Int 7-1 (4.5 g, 80%). MS
(ESI): m/z (M+H).sup.+ 247.
Step B--Synthesis of Int 7-2
##STR00115##
[0345] A mixture of Int 7-1 (700 mg, 2.8 mmol) and MnO.sub.2 (3.7
g, 42.7 mmol) in dioxane (20 mL) was heated to 60.degree. C. for 17
hours. The reaction mixture was cooled and filtered through Celite
and the filtrate was concentrated in vacuo to provide Int 7-2 which
was used into the next step without further purification (500 mg,
78%). .sup.1H NMR (CDCl.sub.3) .delta. 7.87 (s, 1H), 7.78 (s, 1H),
7.17-7.25 (m, 2H), 6.90-7.03 (m, 3H), 6.50 (d, J=3.2 Hz, 1H), 6.39
(q, J=1.2 Hz, 1H), 5.80 (d, J=1.2 Hz, 1H), 3.78 (s, 1H), 3.69 (s,
1H), 1.83 (d, J=7.2 Hz, 3H). MS (ESI): m/z (M+H).sup.+ 245.
Step C--Synthesis of Int 7-3
##STR00116##
[0347] To a solution of 2-methylpyrazine (272 mg, 2.9 mmol) and
HMPA (520 mg, 2.9 mmol) in THF (2.5 mL) was added LDA (1.6 mL, 3
mmol) at -78.degree. C. dropwise. The mixture was allowed to stir
at -78.degree. C. for 30 minutes before a solution of Int 7-2 (600
mg, 2.45 mmol) in 2 mL of THF was added. The mixture was allowed to
warm to room temperature for 3 hours before it was quenched with 10
mL of saturated NH.sub.4Cl solution. The resulting mixture was
extracted with EtOAc (3.times.10 mL) and the combined organic
washings were dried over sodium sulfate, filtered and in vacuo. The
resulting residue was purified using column chromatography (25%
EtOAc/petroleum ether) to provide Int 7-3 (100 mg, 12%). MS (ESI):
m/z (M+H).sup.+ 339.
Step D--Synthesis of Int 7-4
##STR00117##
[0349] A mixture of Int 7-3 (400 mg, 1.03 mmol) and PtO.sub.2 (50
mg) in AcOH (10 mL) was hydrogenated under 1 atmosphere of H.sub.2
pressure for about 15 hours. The reaction was filtered and the
filtrate was concentrated in vacuo to leave a residue that was
purified using HPLC to provide Int 7-4 (200 mg, 59%). MS (ESI): m/z
(M+H).sup.+ 329.
Step E--Synthesis of Compound 38
##STR00118##
[0351] To a solution of Int 7-4 (100 mg, 0.3 mmol) and TEA (101 mg,
1.0 mmol) in DMF (4 mL) was added the sulfonyl chloride (65 mg, 0.3
mmol) at 0.degree. C. and the reaction mixture was allowed to stir
at room temperature for 2 hours. The reaction mixture was purified
using HPLC to provide Compound 38 (80 mg) as three
diastereomers.
[0352] Diastereomer A: .sup.1H NMR (CD.sub.3OD) .delta. 8.39 (d,
J=6.0 Hz, 1H), 7.87 (s, 1H), 7.71-7.77 (m, 2H), 7.00-7.07 (m, 5H),
6.94 (s, 2H), 5.46 (t, J=9.2 Hz, 1H), 4.02 (s, 1H), 3.05-3.09 (m,
1H), 2.80 (d, J=10.4 Hz, 2H), 2.40 (s, 2H), 1.90-1.95 (m, 2H), 1.77
(d, J=6.8 Hz, 4H), 1.63 (d, J=8.0 Hz, 3H), 1.38-1.53 (m, 2H). MS
(ESI): m/z (M+H).sup.+ 568.
[0353] Diastereomer B: .sup.1H NMR (CD.sub.3OD) .delta. 8.38 (d,
J=4.4 Hz, 1H), 7.91 (s, 1H), 7.72-7.78 (m, 2H), 7.12 (s, 2H),
7.00-7.06 (m, 4H), 6.89 (s, 1H), 5.72-5.88 (m, 1H), 3.48 (d, J=8.0
Hz, 1H), 2.61 (d, J=12.0 Hz, 1H), 2.50 (s, 1H), 2.32 (t, J=10.4 Hz,
1H), 2.21 (d, J=10.8 Hz, 1H), 1.59-1.77 (m, 7H), 1.44 (d, J=9.2 Hz,
3H), 1.25 (d, J=14.4 Hz, 2H). MS (ESI): m/z (M+H).sup.+ 568.
[0354] Diastereomer C: .sup.1H NMR (CD.sub.3OD) .delta. 8.41 (d,
J=4.8 Hz, 1H), 7.94 (d, J=5.6 Hz, 1H), 7.71-7.78 (m, 2H), 7.01-7.08
(m, 4H), 6.86 (s, 3H), 3.47 (d, J=6.8 Hz, 1H), 3.24 (t, J=2.0 Hz,
1H), 2.68-2.74 (m, 1H), 2.20 (s, 2H), 1.92-2.01 (m, 2H), 1.77-1.78
(m, 5H), 1.61-1.64 (m, 2H), 1.33 (s, 3H). MS (ESI): m/z (M+H).sup.+
568.
Example 8
Preparation of Compound 39
##STR00119##
[0355] Step A Preparation of Int 8-1
##STR00120##
[0357] To a solution of Int 1-5 (300 mg, 1.37 mmol) in 10 mL of
diethyl ether was added trimethylsilyl cyanide (151 mg, 1.52 mmol)
and zinc iodide (122 mg, 0.38 mmol) at room temperature under
nitrogen. The mixture was cooled to 0.degree. C. and stirred for 5
minutes. A solution of tert-butyl
3-(hydroxymethyl)piperazine-1-carboxylate (300 mg, 1.22 mmol) was
added followed by triethylamine (281 mg, 2.68 mmol) and the mixture
was allowed to stir at 50.degree. C. for about 15 hours. The
mixture was cooled to room temperature and 10 mL of saturated
aqueous solution of K.sub.2CO.sub.3 was added. The resulting
aqueous solution was extracted with EtOAc (3.times.5 mL). The
organic layer was dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The resulting residue was purified using
flash chromatography (50% EtOAc/petroleum ether) to provide the
desired product Int 8-1 (200 mg, 32%). .sup.1H NMR (CDCl.sub.3):
.delta. 8.67 (s, 1H), 7.54 (s, 1H), 7.14-7.17 (m, 2H), 7.05-7.09
(m, 2H), 6.04-6.09 (m, 1H), 5.61 (s, 1H), 3.89-4.02 (m, 2H),
3.67-3.73 (m, 1H), 2.82-2.88 (m, 1H), 2.61-2.64 (m, 1H), 2.49-2.56
(m, 1H), 2.40-2.42 (m, 1H), 2.25-2.27 (m, 1H), 1.83-1.90 (m, 3H),
1.49 (s, 9H). MS (ESI): m/z (M+H).sup.+ 444.23.
Step B--Synthesis of Int 8-2
##STR00121##
[0359] To a solution of Int 8-1 (2 g, 4.5 mmol) in MeOH/H.sub.2O
(30 mL/10 mL) was added KOH (3.02 g, 54 mmol). The mixture was
allowed to stir at 85.degree. C. for about 15 hours before the
mixture was cooled to room temperature, adjusted to pH=6 and
stirred at 60.degree. C. for 1 hour. The reaction mixture was
cooled and concentrated in vacuo to remove MeOH and the resulting
aqueous mixture was extracted with EtOAc (3.times.20 mL). The
combined organic phase was dried, filtered and concentrated in
vacuo. The resulting residue was purified using flash
chromatography (33% EtOAc/petroleum ether) to provide the desired
product Int 8-2 (1.3 g, 65%). MS (ESI): m/z (M+H).sup.+ 445
Step C--Synthesis of Int 8-3
##STR00122##
[0361] Compound Int 8-2 (2 g, 4.5 mmol) was dissolved in HCl/EtOAc
(20 mL) and the mixture was allowed to stir at room temperature for
1 hour. The formed precipitate was filtered and dried to provide
the desired product Int 8-3 (622 mg, 41%). MS (ESI): m/z
(M+H).sup.+ 345
Step D--Synthesis of Compound 39
##STR00123##
[0363] To a solution of Int 8-3 (200 mg, 0.6 mmol) in DMF (3 mL)
was added TEA (0.4 mL) and the mixture was allowed to stir at room
temperature for 5 minutes. A solution of
2-(5-(trifluoromethyl)pyridin-2-ylamino)thiazole-5-sulfonyl
chloride (246 mg, 0.72 mmol) in DMF (2 mL) was added and the
mixture was allowed to stir at room temperature for 20 minutes. The
mixture was concentrated in vacuo and purified using HPLC to
provide Compound 39A and Compound 39B (90 mg, 25%).
[0364] Diastereomer A: .sup.1H NMR (CD.sub.3OD): .delta. 9.07 (s,
1H), 8.72 (s, 1H), 8.03 (dd, J.sub.1=8.8 Hz, J.sub.2=2.0 Hz, 1H),
7.84 (s, 1H), 7.68 (s, 1H), 7.21-7.28 (m, 3H), 6.87 (t, J=8.4 Hz,
2H), 5.63 (q, J=7.2 Hz, 1H), 4.71 (s, 1H), 4.53 (dd, J.sub.1=3.6
Hz, J.sub.2=11.6 Hz, 1H), 4.33 (t, J=11.2 Hz, 1H), 3.75 (d, J=11.2
Hz, 1H), 3.41 (d, J=11.6 Hz, 1H), 3.03-3.11 (m, 1H), 2.46 (d,
J=12.0 Hz, 1H), 2.22-2.28 (m, 1H), 2.04 (t, J=10.8 Hz, 1H), 1.78
(d, J=5.2 Hz, 3H), 1.71-1.72 (m, 1H). MS (ESI): m/z (M+H).sup.+
652.13.
[0365] Diastereomer B: .sup.1H NMR (CD.sub.3OD): .delta. 9.14 (s,
1H), 8.69 (s, 1H), 8.02 (d, J=8.8 Hz, 1H), 7.87 (s, 1H), 7.64 (s,
1H), 7.18-7.25 (m, 3H), 7.09-7.13 (m, 2H), 6.00 (q, J=5.2 Hz, 1H),
4.51 (s, 1H), 4.41 (dd, J.sub.1=10.8 Hz, J.sub.2=2.0 Hz, 1H), 4.19
(t, J=10.8 Hz, 1H), 3.78 (d, J=10.4 Hz, 1H), 3.56-3.59 (m, 1H),
2.98-3.05 (m, 1H), 2.53-2.61 (m, 1H), 2.30 (t, J=10.8 Hz, 1H),
1.96-1.99 (m, 1H), 1.90 (d, J=6.8 Hz, 3H). MS (ESI): m/z
(M+H).sup.+ 652.13.
Example 9
Preparation of Compound 40
##STR00124##
[0366] Step A Preparation of Int 9-1
##STR00125##
[0368] TMSCN (1.5 g, 15 mmol) and K.sub.2PdCl.sub.4 (326 mg, 1
mmol) was added to the solution of Int 1-5 (2.3 g, 10 mmol) and
1-tert-butyl 3-methyl piperazine-1,3-dicarboxylate (2.44 g, 10
mmol) in H.sub.2O (20 mL), the resultant mixture was allowed to
stir at r.t. for 48 h, then extracted with EtOAc (3.times.30 mL),
the combined organic layer was concentrated in vacuo and purified
using column chromatography (25% EtOAc/petroleum ether) to stir Int
9-1 (1.5 g, 30%). .sup.1H NMR (CDCl.sub.3): .delta. 7.98 (s, 1H),
7.32 (s, 1H), 6.99.about.7.18 (m, 4H), 6.02.about.6.04 (m, 1H),
5.02 (s, 1H), 3.71 (s, 3H), 3.27.about.3.30 (m, 1H),
2.64.about.2.80 (m, 2H), 2.33.about.2.36 (m, 2H), 2.17.about.2.25
(m, 2H), 1.82 (s, 3H), 1.38 (s, 9H). MS (ESI): m/z (M+H).sup.+
472.1.
Step B--Synthesis of Int 9-2
##STR00126##
[0370] The mixture of Int 9-1 (5 g, 10.6 mmol) in HCl/MeOH (50 mL)
was allowed to stir at 70.degree. C. for about 15 hours. The
mixture was cooled and concentrated in vacuo to provide the crude
Int 9-2 which was used into the next step without further
purification. MS (ESI): m/z (M+H).sup.+ 405.
Step C--Synthesis of Int 9-3
##STR00127##
[0372] To a solution of Int 9-2 (5 g, 11.4 mmol) in MeOH (50 mL)
was added TEA (3 mL) and (Boc).sub.2O under nitrogen atmosphere.
The mixture was allowed to stir at room temperature for 3 hours
then concentrated in vacuo and purified using column chromatography
(petroleum ether:EtOAc:DCM=3:2:1) to provide the product Int 9-3
(1.7 g, 30%). MS (ESI): m/z (M+H).sup.+ 505.
Step D--Synthesis of Int 9-4
##STR00128##
[0374] To a solution of compound Int 9-3 (1.78 g, 3.5 mmol) in THF
(20 mL) was added LiAlH.sub.4 (402 mg, 10.6 mmol) at 0.degree. C.
and the reaction mixture was allowed to stir at room temperature
for 3 hours. Water (1 mL) was added to quench the reaction and the
mixture was extracted with CH.sub.2Cl.sub.2 (3.times.10 mL). The
combined organic washings were dried over Na.sub.2SO.sub.4 and
concentrated in vacuo to provide the crude mixture (800 mg) which
was purification by HPLC to provide two isomers Int 9-4-a (200 mg,
13%) and Int 9-4-b (200 mg, 13%). MS (ESI): m/z (M+H).sup.+
449.
Step E--Synthesis of Int 9-5a
##STR00129##
[0376] To a solution of Int 9-4-a (80 mg, 0.18 mmol) in THF (2 mL)
was added NaH (22 mg, 0.54 mmol) at 0.degree. C. After stirred for
30 minutes, a solution of p-TsCl (24 mg, 0.13 mmol) in THF (1 mL)
was added dropwise. The mixture was allowed to stir for about 15
hours at for 16 hours. Water (3 mL) was added to the solution and
extracted with EtOAc (3.times.5 mL). The organic layer was dried
over Na.sub.2SO.sub.4 and concentrated in vacuo to provide the
product Int 9-4-a (65 mg, 83%). MS (ESI): m/z (M+H).sup.+
431.2.
Step F--Synthesis of Int 9-6a
##STR00130##
[0378] Compound Int 9-5a (65 mg, 0.15 mmol) was dissolved in
HCl/EtOAc (6 mL) and the mixture was allowed to stir at room
temperature for 40 minutes. The mixture was concentrated in vacuo
to provide the crude compound Int 9-6a (40 mg, 80%). MS (ESI): m/z
(M+H).sup.+ 331.2.
Step G--Synthesis of Compound 40
##STR00131##
[0380] To a solution of Int 9-6a (40 mg, 0.11 mmol) in DMF (3 mL)
was added TEA (0.5 mL) at 0.degree. C. The mixture was allowed to
stir for 5 minutes then 2-(pyridin-2-ylamino)thiazole-5-sulfonyl
chloride (30 mg, 0.11 mmol) was added. The mixture was allowed to
stir at room temperature for 20 minutes. The reaction mixture was
directly purified using HPLC to provide Compound 40 (14 mg, 22%).
.sup.1H NMR (CD.sub.3OD): .delta. 9.29 (s, 1H), 8.37 (d, J=4.4 Hz,
1H), 7.73-7.80 (m, 3H), 7.00-7.17 (m, 6H), 5.80-5.85 (q, J=6.4 Hz,
1H), 3.80-3.87 (m, 2H), 3.60 (d, J=9.2 Hz, 1H), 3.48 (d, J=12.0 Hz,
1H), 3.41 (d, J=6.0 Hz, 1H), 3.32-3.35 (m, 1H), 3.18-3.24 (m, 1H),
3.01 (d, J=11.6 Hz, 1H), 2.87 (t, J=10 Hz, 1H), 2.79 (t, J=10.4 Hz,
1H), 2.32 (q, J=11.6 Hz, 2H), 1.93 (d, J=6.8 Hz, 3H). MS (ESI): m/z
(M+H).sup.+ 570.
Example 10
Preparation of Compound 41
##STR00132##
[0381] Step A Preparation of Int 10-1
##STR00133##
[0383] To a solution of Int 9-1 (1.1 g, 2.3 mmol) in MeOH (5 mL)
was added Ni (700 mg, 12 mmol) and the resulting mixture was
allowed to stir at 50.degree. C. under H.sub.2 (50 psi) for 4
hours. The mixture was cooled and filtered through Celite and
purified using preparative HPLC to provide compound Int 10-1 (700
mg, 68%). .sup.1H NMR (CDCl.sub.3): .delta. 8.64 (s, 1H), 7.81 (s,
1H), 7.28.about.7.32 (m, 4H), 5.67.about.5.70 (m, 2H),
3.72.about.3.78 (m, 3H), 2.67.about.2.98 (m, 7H), 1.30.about.1.33
(m, 3H). MS (ESI): m/z (M+H).sup.+ 444.1.
Step B Preparation of Int 10-2
##STR00134##
[0385] NaH (40 mg, 1 mmol) was added to the solution of Int 10-1
(110 mg, 0.25 mmol) in THF (5 mL) and the resulting mixture was
allowed to stir at room temperature for 0.5 hours before Met (37
mg, 0.26 mg) was added. The reaction was allowed to stir for about
15 hours then quenched with water (5 mL), extracted with EtOAc
(3.times.5 mL). The combined organic washings were concentrated in
vacuo and purified using prepreparative TLC to provide compound Int
10-2 (100 mg, 90%). .sup.1H NMR (CDCl.sub.3) .delta. 7.58 (s, 1H),
7.50 (s, 1H), 6.96.about.6.99 (m, 4H), 5.27.about.5.32 (m, 1H),
3.08.about.3.27 (m, 4H), 2.69 (s, 3H), 2.16.about.2.33 (m, 6H),
1.67.about.1.69 (m, 3H), 1.29 (s, 9H). MS (ESI): m/z (M+H).sup.+
458.1.
Step C Preparation of Int 10-3
##STR00135##
[0387] LiAlH.sub.4 (150 mg, 4 mmol) was added to the solution of
Int 10-2 (360 mg, 1 mmol) in THF (5 mL) at 0.degree. C. The
reaction mixture was allowed to stir at room temperature for about
15 hours. The reaction was quenched with MeOH and filtered through
Celite and the mixture was purified using prepreparative TLC to
provide compound Int 10-3 (300 mg, 88%). .sup.1H NMR (CD.sub.3OD):
.delta. 7.92 (s, 1H), 7.81 (s, 1H), 7.01.about.7.22 (m, 5H),
3.33.about.3.56 (m, 5H), 3.33 (s, 3H), 2.17.about.2.25 (m, 7H),
1.79.about.1.80 (m, 3H). MS (ESI): m/z (M+H).sup.+ 344.1.
Step D Preparation of Int 10-4
##STR00136##
[0389] TFA (2 mL) was added to the solution of Int 10-3 (500 mg) in
DCM (10 mL) and the resulting mixture was allowed to stir at room
temperature for 2 h, then concentrated in vacuo to provide the
crude Int 10-4 (360 mg, 92%) which was used without further
purification. MS (ESI): m/z (M+H).sup.+ 444
Step E Preparation of Compound 41
##STR00137##
[0391] 2-(pyridin-2-ylamino)thiazole-5-sulfonyl chloride (55 mg,
0.2 mmol) was added to a solution of Int 10-4 (60 mg, 0.18 mmol)
and TEA (0.1 g, 1 mmol) in DCM (5 mL). The resulting mixture was
allowed to stir for 12 h, then concentrated in vacuo and purified
using preparative HPLC to provide compound 41 (20.6 mg, 19.8%).
.sup.1H NMR (CD.sub.3OD): .delta. 9.33.about.9.36 (m, 1H),
8.33.about.8.39 (m, 1H), 7.63.about.7.79 (m, 3H), 7.31.about.7.34
(m, 1H), 6.75.about.7.13 (m, 5H), 5.75.about.5.78 (m, 1H),
3.38.about.3.82 (m, 5H), 2.76.about.3.11 (m, 7H), 2.43.about.2.64
(m, 2H), 1.81.about.1.93 (m, 3H), 1.08.about.1.25 (m, 1H). MS
(ESI): m/z (M+H).sup.+ 583.1.
Example 11
Preparation of Compound 42
##STR00138##
[0392] Step A Preparation of Int 11-1
##STR00139##
[0394] To a solution of compound
(R)-4-fluoro-.beta.-methylbenzylamine HCl (1.32 g, 7.57 mmol) and
Int 11-a (2 g, 22.7 mmol) in pyridine (40 mL) was added TMSC1 (12.7
g, 113 mmol) and TEA (5.3 g, 53 mmol). The mixture was allowed to
stir at 80.degree. C. for about 15 hours, cooled then treated with
200 mL of EtOAc. The mixture was filtered and the filtrate was
concentrated in vacuo and chromatographed to provide 0.61 g (42%)
of compound Int 11-1 as yellow oil. .sup.1H NMR (CD.sub.3OD)
.delta. 8.66 (s, 2H), 7.43-7.39 (m, 2H), 7.18-7.14 (m, 2H), 5.69
(q, J=6.8 Hz, 1H), 1.88 (d, J=6.8 Hz, 3H). MS-ESI (m/z): 192
(M+H).sup.+.
Step B--Synthesis of Int 11-2
##STR00140##
[0396] A mixture of POCl.sub.3 (1.2 g, 7.85 mmol) in DMF (2 mL) was
allowed to stir at 0.degree. C. for 2 hours before compound Int
11-1 (300 mg, 1.57 mmol) in DMF (0.5 mL) was added. The reaction
mixture was allowed to stir at 0.degree. C. for another 2 hours,
then allowed warmed to room temperature for about 15 hours. The
reaction mixture was quenched with cold water, basified with
saturated NaHCO.sub.3 then extracted with EtOAc (3.times.10 mL).
The organic layer was washed with brine, dried over sodium sulfate,
filtered and in vacuo, then chromatographed on silica gel to
provide 160 mg (50%) of compound Int 11-2 as a yellow oil. .sup.1H
NMR (CDCl.sub.3) .delta. 10.07 (s, 1H), 8.32 (s, 1H), 7.24-7.19 (m,
2H), 7.05-7.01 (m, 2H), 6.25 (q, J=6.8 Hz, 1H), 1.85 (d, J=6.8 Hz,
3H). MS-ESI (m/z): 220 (M+H).sup.+.
Step C--Synthesis of Int 11-3
##STR00141##
[0398] To a stirred solution of Compound 3-acetamido-5-thiazole
sulfonyl chloride (21.0 g, 0.08 mol) in 200 mL of CH.sub.2Cl.sub.2
was added triethylamine (36.4 mL, 0.25 mol) followed by N-Boc
piperazine (16.3 g, 0.08 mol) at room temperature. The mixture was
allowed to stir for 2 hours until the reaction completed. The
solvent was concentrated in vacuo and the resulting residue was
purified using column chromatography on silica gel with petroleum
ether/ethyl acetate=5:1 to provide 25 g (81%) of compound Int 11-3
as a white solid. MS (ESI) m/z (M+1): 391
Step D--Synthesis of Int 11-4
##STR00142##
[0400] To a stirred solution of compound Int 11-3 (25 g, 0.064 mol)
in 250 mL of ethanol was added 6M HCl (60 mL). The mixture was
heated to 80.degree. C. for 12 hours until the reaction completed.
The reaction was cooled and concentrated in vacuo. The resulting
residue was basified with sat.NaHCO.sub.3 and treated with
Boc.sub.2O (13.9 g, 0.064 mol). The mixture was allowed to stir at
room temperature for 2 hours before a white solid was formed. The
mixture was filtered and the filter cake was washed with water and
dried to provide 20 g of compound Int 11-4 as a white solid.
.sup.1H-NMR (DMSO-d6) .delta. 7.85 (s, 2H), 3.40 (s, 4H), 2.89 (s,
4H), 2.25 (s, 3H), 1.33 (s, 9H). MS (ESI) m/z (M+1): 349
Step E--Synthesis of Int 11-5
##STR00143##
[0402] To a solution of CuBr.sub.2 (55 g, 248 mmol) in CH.sub.3CN
(150 mL) was added t-BuONO (26 g, 248 mmol), and the mixture was
then stirred at room temperature for 5 min. Compound Int 11-4 (45
g, 124 mmol) in CH.sub.3CN (150 mL) was added dropwise to the
reaction mixture in an ice bath. The mixture was then stirred at
50.degree. C. for 0.5 hr, and then cooled to room temperature. The
solution was poured into H.sub.2O, then concentrated in vacuo
ammonium hydroxide was added until the solution was clear. The
aqueous layer was extracted with ethyl acetate (3.times.100 mL),
the combined organic extracts were washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to provide resulting
residue as green solid. The resulting residue was purified using
chromatography on silical gel (petroleum ether:EtOAc=7:1) to
provide 47 g (89%) of Int 11-5 as yellow solid.
Step F--Synthesis of Int 11-6
##STR00144##
[0404] To a solution of compound Int 11-5 (2.0 g, 4.35 mmol) in
MeCN (40 mL) was added K.sub.2CO.sub.3 (1.20 g, 8.70 mmol) and
(7R,8aS)-octahydropyrrolo[1,2-a]piperazin-7-ol TBS ether. The
mixture was refluxed for about 15 hours, then filtered and
concentrated in vacuo. The resulting residue was purified using
column chromatography on silica gel (EtOAc) to provide 2.88 g of
the addition product which was dissolved 30 mL of in DCM and
treated with 6 mL of TFA. The mixture was allowed to stir for 1
hour then basified with Na.sub.2CO.sub.3 and extracted with
DCM.times.3. The combined organic washings were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to provide desired
compound Int 11-6 (2.2 g, 92%). MS-ESI (m/z): 488 (M+H).sup.+
Step G Preparation of Compound 42
##STR00145##
[0406] To a solution of compound Int 11-2 (180 mg, 0.821 mmol) in
DCM (5 mL) was added compound Int 11-6 (400 mg, 0.821 mmol). The
mixture was allowed to stir at room temperature for 2 hours then
NaBH(OAc).sub.3 (348 mg, 1.642 mmol) was added. The mixture was
allowed to stir at room temperature for another 1 hour. The
reaction mixture was quenched with water and extracted with DCM
(3.times.10 mL). The organic layer was dried over Na2SO4 and
concentrated in vacuo then treated with HCl/EtOAc (5 mL) was
allowed to stir at room temperature for 30 minutes and concentrated
in vacuo. The crude was purified using HPLC to provide Compound 42
(31 mg, 23%). .sup.1H NMR (CD.sub.3OD) .delta.: 8.84 (s, 1H), 7.53
(s, 1H), 7.20-7.16 (m, 2H), 6.97-6.93 (m, 2H), 5.72-5.67 (q, J=6.4,
1H), 4.44-4.42 (m, 1H), 4.20-4.16 (m, 1H), 3.98-3.94 (m, 1H),
3.86-3.82 (m, 1H), 3.54-3.47 (m, 3H), 3.39-3.36 (m, 1H), 3.18-3.12
(m, 1H), 3.09-2.93 (m, 1H), 2.84 (m, 2H), 2.69-2.65 (m, 3H),
2.49-2.34 (m, 2H), 1.82-1.81 (d, J=7.2, 5H). MS-ESI (m/z): 577
(M+H).sup.+
Example 12
Preparation of Compound 43
##STR00146##
[0407] Step A Preparation of Int 12-1
##STR00147##
[0409] To a suspension of Zn dust (8.22 mmol) in THF (60 mL) under
N.sub.2 was added TiCl.sub.4 (13.74 mmol) in portions via syringe
slowly. The result suspension was heated to reflux for 1.5 hours. A
solution of N-Cbz-piperidin-4-one (1.37 mmol) in THF (10 mL) was
added to the mixture in one portion via syringe and the whole was
refluxed for 15 minutes. A solution of compound Int 1-5 (1.37 mmol)
in THF (10 mL) was drop wise in over 15 minutes after which the
mixture was refluxed for 2 hours. The whole was cooled to and
concentrated in vacuo under reduced pressure. The resulting residue
was treated with water (50 mL) and aqueous ammonia (150 mL); the
result suspension was then stirred at room temperature for 3 hours.
The resulting mixture was filtered, and the filter cake was washed
with EtOAc (3.times.20 mL). The filtrate was extracted with EtOAc
(2.times.40 mL). The organics were washed with water and brine then
dried over Na.sub.2SO.sub.4. The solvent was removed to provide
resulting residue which was purified using column chromatography on
silica gel [CH.sub.2Cl.sub.2/MeOH (60:1)] to provide desired
compound Int 12-1 as a yellow oil. MS-ESI (m/z): 421
(M+H).sup.+
Step B--Synthesis of Int 12-2
##STR00148##
[0411] A mixture of compound Int 12-1 (420 mg, 1 mmol) in HCl/MeOH
(10 mL) was allowed to stir at reflux for 2 hours then concentrated
in vacuo and used in the next step without further purification.
MS-ESI (m/z): 286 (M+1).sup.+
Step C--Synthesis of Int 12-3
##STR00149##
[0413] To a solution of compound Int 12-2 (285 mg, 1 mmol) and
Et.sub.3N (300 mg, 3 mmol) in DMF (5 mL) was added Int 3-8 (300 mg,
1.06 mmol) in portions. The reaction mixture was allowed to stir at
room temperature for 30 min, and then extracted with
EtOAc/H.sub.2O. The organic layer was dried over MgSO.sub.4 and
concentrated in vacuo to provide the resulting residue which was
chromatographed on silica gel to provide 350 mg (61%) of compound
Int 12-3 as a yellow solid. R.sub.f=0.5 (EtOAc:MeOH=20:1). MS-ESI
(m/z): 531 (M+1).sup.+.
Step D--Synthesis of Compounds 43a and 43b
##STR00150##
[0415] A mixture of trimethylsulfonium iodide (670 mg, 3.28 mmol)
and NaH (130 mg, 3.28 mmol) in DMSO (3 mL) was allowed to stir at
60.degree. C. for 2 hours. Compound Int 12-3 (350 mg, 0.66 mmol) in
DMSO (1 mL) was added dropwise and the reaction mixture was allowed
to stir at 60.degree. C. for 10 h, cooled to room temperature,
quenched with water, and extracted with EtOAc. The organic washings
were washed with brine, dried over sodium sulfate, filtered and in
vacuo. The resulting residue was purified using preparative HPLC to
provide Compound 43 as a mixture of 2 diastereomers (55 g of each
diasteromer, 30%).
[0416] Compound 43a: .sup.1H NMR (CD.sub.3OD) .delta.: 9.20 (s,
1H), 7.61 (s, 1H), 7.47 (s, 1H), 7.23-7.18 (m, 2H), 7.04-7.00 (m,
2H), 5.97 (d, J=7.6 Hz, 1H), 5.66 (q, J=6.8 Hz, 1H), 3.96-3.92 (m,
5H), 3.64-3.61 (m, 4H), 3.35-3.27 (m, 5H), 3.18-3.15 (m, 1H),
2.66-2.60 (m, 1H), 2.47-2.24 (m, 5H), 1.89 (d, J=6.8 Hz, 3H).
MS-ESI (m/z): 545 (M+1).sup.+.
[0417] Compound 43b: .sup.1H NMR (CD.sub.3OD) .delta.: 9.19 (s,
1H), 7.58 (s, 1H), 7.46 (s, 1H), 7.20-7.17 (m, 2H), 7.02-6.98 (m,
2H), 5.97 (d, J=7.6 Hz, 1H), 5.66 (q, J=6.8 Hz, 1H), 3.96-3.78 (m,
4H), 3.64-3.61 (m, 1H), 3.36-3.27 (m, 7H), 3.18-3.16 (m, 1H), 2.95
(s, 2H), 2.66-2.19 (m, 6H), 1.89 (d, J=6.8 Hz, 3H). MS-ESI (m/z):
545 (M+1).sup.+.
Example 13
Preparation of Compound 44
##STR00151##
[0418] Step A--Synthesis of Int 12-1
##STR00152##
[0420] To a solution of compound Int 12-1 (0.58 mmol) in methanol
(30 mL) was added Pd(OH).sub.2 (100 mg). The result suspension was
allowed to stir at room temperature under 1 atm pressure of H.sub.2
for 3 hours. The whole was filtered through Celite and the filtrate
was concentrated in vacuo to provide compound Int 13-1 as yellow
oil which was used directly in the next step without further
purification. MS-ESI (m/z): 288 (M+1).sup.+
Step B--Synthesis of Compound 44
##STR00153##
[0422] To a stirred solution of compound Int 13-1 (103 mg, 0.36
mmol) and Et.sub.3N (0.72 mmol) in DMF (5 mL) was added Int 3-8
(108 mg, 0.36 mmol). The reaction mixture was allowed to stir at
room temperature for 17 hours then extracted with EtOAc/H.sub.2O.
The organic layer was separated and dried over MgSO.sub.4, filtered
and concentrated in vacuo to provide the resulting residue which
was chromatographed on silica gel to provide 350 mg (61%) of
compound 44 as a yellow solid. .sup.1H NMR (CD.sub.3OD) .delta.:
9.16 (s, 1H), 7.57 (s, 1H), 7.43 (d, J=12.4 Hz, 1H), 7.29-7.22 (m,
2H), 7.14 (q, J=9.6 Hz, 2H), 5.71 (q, J=6.8 Hz, 1H), 4.41-3.44 (m,
10H), 2.96 (s, 3H), 2.51 (d, J=5.6 Hz, 2H), 2.25-2.14 (m, 2H), 1.90
(d, J=7.2 Hz, 3H), 1.62 (t, J=7.6 Hz, 2H), 3.20 (d, J=12.0 Hz, 3H).
MS-ESI (m/z): 533 (M+1).sup.+.
Example 14
Preparation of Compound 45
##STR00154##
[0423] Step A Preparation of Int 14-1
##STR00155##
[0425] To a solution of 2-chloro-4-iodopyridine (4 g, 16.5 mmol) in
anhydrous THF (40 mL) was added .sup.iPrMgCl solution (2M, 10 mL)
during 30 minutes at -50.degree. C. under a N.sub.2 atmosphere. The
mixture was allowed to stir at -50.degree. C. for 1 hour before
adding Int 1-5 (3 g, 13.8 mmol) solution drop wise. Then the
mixture was allowed to stir at -50.degree. C. for 0.5 hours and at
room temperature for 1 hour. The reaction mixture was quenched by
saturated NH.sub.4Cl solution (aqueous, 50 mL) and extracted with
EtOAc (3.times.30 mL). The combined organic washings were washed
with brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
The crude compound Int 14-1 was used directly for the next step
without further purification (4 g, 88%).
Step B Preparation of Int 14-2
##STR00156##
[0427] To a solution of compound Int 14-1 (2.4 g, 7.25 mmol) in
anhydrous THF (30 mL) was added NaH (435 mg, 10.88 mmol) in one
portion at 0.degree. C. under a N.sub.2 atmosphere. The mixture was
allowed to stir at 0.degree. C. for 1 hour and then the CH.sub.3I
was added dropwise at 0.degree. C. The reaction mixture was
quenched by saturated NH.sub.4Cl solution (aqueous, 30 mL) and
extracted with EtOAc (3.times.20 mL). The combined organic layers
were washed with brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The resulting residue of compound Int 14-2
was used directly for the next step without further purification (2
g, 80%).
Step C Preparation of Int 14-3
##STR00157##
[0429] To a solution of compound Int 14-2 (1.6 g, 4.64 mmol) in a
mixed solvent (HOAc/water=3:1, 40 mL) was added PtO.sub.2 (0.6 g).
The mixture was allowed to stir at room temperature for 8 hrs under
H.sub.2 atmosphere (50 psi). The mixture was filtered through
Celite and concentrated in vacuo. Resulting residue Int 14-3 (1.4
g, 100%) was used directly in the next step without
purification.
Step D--Synthesis of Compound 45
##STR00158##
[0431] To a solution of compound Int 14-3 (200 mg, 0.63 mmol) in
DMF (3 mL) was added Et.sub.3N (0.5 mL) and
2-(5-trifluoromethylpyridin-2-ylamino)-thiazole-5-sulfonyl chloride
(175 mg, 0.63 mmol). The mixture was allowed to stir for 1 hour at
room temperature. The resulting residue solution of DMF was
filtered and purified using preparative HPLC to provide Compound 45
(30 mg, 10%) as white solid. The two diastereomers were
subsequently separated by chiral HPLC eluting with
CO.sub.2/MeOH.
[0432] Compound 45A: .sup.1H NMR (CD.sub.3OD) .delta.: 9.34 (s,
1H), 8.71 (s, 1H), 8.00 (d, J=8.8 Hz, 1H), 7.76 (s, 1H), 7.60 (s,
1H), 7.18-7.22 (m, 3H), 6.95-7.05 (m, 2H), 5.86 (q, J=6.6 Hz, 1H),
4.10 (d, J=6 Hz, 1H), 3.73 (d, J=11.6 Hz, 1H), 3.54 (d, J=10.4 Hz,
1H), 3.06 (s, 3H), 2.13 (t, J=11.2 Hz, 1H), 2.03 (d, J=10.8 Hz,
1H), 1.88 (d, J=7.2 Hz, 3H), 1.78 (t, J=6.4 Hz, 1H), 1.20-1.50 (m,
3H), 1.00-1.10 (m, 1H). MS-ESI (m/z): 625 (M+1).sup.+.
[0433] Compound 45B: .sup.1H NMR (CD.sub.3OD) .delta.: 9.27 (s,
1H), 8.69 (s, 1H), 8.01 (d, J=8.8 Hz, 1H), 7.78 (s, 1H), 7.57 (s,
1H), 7.25-7.30 (m, 2H), 7.15-7.20 (m, 1H), 7.00-7.10 (m, 2H), 5.85
(q, J=6.6 Hz, 1H), 4.24 (d, J=6 Hz, 1H), 3.73 (d, J=11.6 Hz, 1H),
3.64 (d, J=10.4 Hz, 1H), 3.09 (s, 3H), 2.18-2.25 (m, 2H), 1.91 (br,
1H), 1.87 (d, J=7.2 Hz, 3H), 1.20-1.50 (m, 4H). MS-ESI (m/z): 625
(M+1).sup.+.
Example 15
Preparation of Compound 46
##STR00159##
[0434] Step A Preparation of Int 15-1
##STR00160##
[0436] To a solution of compound Int 14-1 (3.01 mmol) in dioxane
(30 mL) was added MnO.sub.2 (30.1 mmol). The whole was heated to
reflux for 3 hours. The reaction mixture was cooled, and filtered
through Celite and the filtrate was concentrated in vacuo to
provide compound Int 15-1 as yellow solid which was used in the
next step without purification.
Step B--Synthesis of Int 15-2
##STR00161##
[0438] To a solution of compound Int 15-1 (3.03 mmol) in THF (30
mL) was cooled to 0.degree. C. and methylmagnesium bromide (9.10
mmol, 3.0M in THF) was added drop wise. The ice bath was removed
and the solution was allowed to stirto room temperature for 1 hour.
The reaction mixture was cooled to 0.degree. C., quenched with
saturated NH.sub.4Cl, extracted with EtOAc, then washed with brine.
The organic layer was dried over Na.sub.2SO.sub.4 and concentrated
in vacuo to provide compound Int 15-2.
Step C--Synthesis of Int 15-3
##STR00162##
[0440] To a solution of compound Int 15-2 (1.44 mmol) in 1:1 acetic
acid/MeOH (10 mL) was added concentrated in vacuo HCl (imp then
PtO.sub.2 (200 mg). The mixture was charged with H.sub.2 (50 psi)
and stirred at 50.degree. C. for 8 hours. The reaction mixture was
cooled, filtered and concentrated in vacuo to provide desired
compound Int 15-3 which was used directly in the next step without
purification.
Step D Preparation of Compound 46
##STR00163##
[0442] To a stirred solution of compound Int 15-3 (0.32 mmol) and
Et.sub.3N (0.64 mmol) in DMF (5 mL) was added the sulfonyl chloride
(0.32 mmol). The mixture was allowed to stir at room temperature
for 2 hrs. The mixture was filtered and the filtrate was purified
using preparative HPLC to provide two diastereomers of Compound
46.
[0443] Compound 46A: .sup.1H NMR (CD.sub.3OD) .delta.: 8.71 (s,
1H), 8.49 (s, 1H), 8.03.about.8.01 (m, 1H), 7.78 (s, 1H),
7.30.about.7.19 (m, 4H), 7.01.about.6.94 (m, 2H), 6.44.about.6.42
(m, 1H), 3.71 (d, J=12 Hz, 1H), 3.67 (d, J=10.4 Hz, 1H), 2.20 (t,
J=10.8 Hz, 1H), 2.18.about.1.75 (m, 6H), 1.67.about.1.44 (m, 3H).
MS-ESI (m/z): 679 (M+1).sup.+.
[0444] Compound 46B: .sup.1H NMR (CD.sub.3OD) .delta.: 9.25 (s,
0.3H), 8.89 (s, 0.6H), 8.70 (d, J=0.8 Hz, 1H), 8.02 (dd,
J.sub.1=8.8 Hz, J.sub.2=2.0 Hz, 1H), 7.84 (s, 1H), 7.80.about.7.72
(m, 1H), 7.40.about.7.30 (m, 2H), 7.19 (d, J=8.8 Hz, 1H),
7.18.about.7.02 (m, 2H), 6.62.about.6.57 (m, 1H), 3.89 (d, J=7.6
Hz, 0.7H), 3.80.about.3.73 (m, 1.3H), 2.50.about.2.05 (m, 3H),
1.99.about.1.63 (m, 7H). MS-ESI (m/z): 679 (M+1).sup.+.
Example 16
Preparation of Compound 47
##STR00164##
[0445] Step A--Synthesis of Int 16-1
##STR00165##
[0447] A mixture of compound Int 1-5 (5 g, 22.9 mmol) and
NaBH.sub.4 (2.6 g, 68.8 mmol) in EtOH (50 mL) was allowed to stir
at room temperature for 4 hours then poured into saturated
NH.sub.4Cl. The mixture was concentrated in vacuo and extracted
with EtOAc (3.times.20 mL). The organic layer was washed with
brine, dried over MgSO.sub.4 and concentrated in vacuo. The
resulting residue was purified using flash column chromatography on
silica gel eluting with 10% MeOH/EtOAc to provide compound Int 16-1
(5 g, 99%) as yellow oil. R.sub.f=0.3 (EtOAc: MeOH=10:1). MS-ESI
(m/z): 203 (M-17), 221 (M+1).sup.+.
Step B Preparation of Int 16-2
##STR00166##
[0449] To a solution of compound Int 16-1 (5 g, 22.7 mmol) in
toluene (50 mL) was added thionyl chloride (300 mg, 1.06 mmol) drop
wise at room temperature. The reaction mixture was allowed to stir
at 90.degree. C. for about 15 hours. The reaction mixture was
cooled and concentrated in vacuo. The resulting residue of compound
Int 16-2 (5 g, 80%) was used directly without further purification.
MS-ESI (m/z): 275 (M+1).sup.+.
Step C Preparation of Int 16-3
##STR00167##
[0451] To a solution of compound Int 16-2 (2.5 g, 9.12 mmol) and
N-Boc-piperidine-4-carboxylic acid methyl ester (2.4 g, 9.12 mmol)
in anhydrous THF (50 mL) was added the LDA solution at -78.degree.
C. under N.sub.2. The mixture was allowed to stir at -78.degree. C.
for 2 hours then quenched by the addition of saturated NH.sub.4Cl.
The resulting mixture was extracted with EtOAc (3.times.20 mL). The
organic washings were washed with brine, dried over MgSO.sub.4 and
concentrated in vacuo. The resulting residue was purified using
flash column chromatography on silica gel eluting with 50%
petroleum ether/EtOAc to provide compound Int 16-3 as a yellow oil
(1.0 g, 25%). MS-ESI (m/z): 446 (M+1).sup.+.
Step D Preparation of Int 16-4
##STR00168##
[0453] The mixture of compound Int 16-3 (1 g, 2.25 mmol) and TFA
(20 mL) was allowed to stir at room temperature for 1 hour. The
reaction mixture was concentrated in vacuo. The resulting residue
of compound Int 16-4 (0.8 g, 100%) was used directly without
further purification. MS-ESI (m/z): 346 (M+1).sup.+.
Step E Preparation of Int 16-5
##STR00169##
[0455] To a solution of compound Int 16-4 (0.8 g, 2.32 mmol) in DMF
(10 mL) was added Et.sub.3N (1 mL) and Int 3-8 (0.65 g, 2.32 mmol).
The mixture was allowed to stir for 1 hour at room temperature. The
mixture was filtered and concentrated in vacuo. The resulting
residue was purified using flash column chromatography on silica
gel eluting with DCM:MeOH (10:1) to provide Int 16-5 (0.65 g, 48%)
as white solid. .sup.1H NMR (CD.sub.3OD) .delta. 9.17 (s, 1H), 7.58
(s, 1H), 7.32 (s, 1H), 7.20-7.25 (m, 2H), 7.10-7.15 (m, 2H), 5.66
(q, J=7.6 Hz, 1H), 4.00-4.40 (br, 2H), 3.62 (s, 3H), 3.40-3.55 (m,
5H), 3.29 (s, 3H), 2.95 (s, 3H), 2.91 (s, 1H), 2.80 (d, J=8.0 Hz,
1H), 2.50-2.65 (m, 2H), 2.10-2.30 (m, 2H), 1.90 (d, J=6.8 Hz, 3H),
1.60-1.70 (m, 1H), 1.50-1.60 (m, 1H).
Step F Preparation of Compound 47
##STR00170##
[0457] To a solution of Int 16-5 (650 mg, 1.10 mmol) in anhydrous
THF (20 mL) was added LAH (126 mg, 3.30 mmol) in portions at
0.degree. C. The mixture was allowed to stir at 0.degree. C. for 2
hours, then quenched by the drop wise addition of water. The
mixture was filtered and the filtrate was extracted with EtOAc
(3.times.10 mL). The resulting residue was purified using
preparative HPLC to provide Compound 47 (300 mg, 48%). .sup.1H NMR
(CD.sub.3OD) .delta.: 9.10 (s, 1H), 7.60 (s, 1H), 7.43 (s, 1H),
7.20-7.30 (m, 2H), 7.10-7.15 (m, 2H), 6.06 (q, J=7.6 Hz, 1H),
4.00-4.50 (br, 2H), 3.40-3.80 (br, 4H), 3.35 (d, J=7.2 Hz, 2H),
3.26 (s, 1H), 3.19 (d, J=7.2 Hz, 2H), 2.95 (s, 3H), 2.80-2.95 (m,
2H), 2.70 (d, J=15.6 Hz, 1H), 2.55 (d, J=15.6 Hz, 1H), 1.89 (d,
J=6.8 Hz, 3H), 1.70-1.80 (br, 1H), 1.50-1.65 (br, 3H). MS-ESI
(m/z): 563 (M+1).sup.+.
Example 17
Preparation of Compound 48
##STR00171##
[0458] Step A Preparation of Int 17-1
##STR00172##
[0460] A solution of Boc-4-cyanopiperidine (4.00 g, 19.0 mmol) in
20 mL of HCl/EtOAc (4M) was allowed to stir at room temperature for
30 min. The mixture was concentrated in vacuo to provide 2.10 g of
compound Int 17-1 as a white solid. Yield: 100%. .sup.1H-NMR
(DMSO-d6) .delta. 9.32 (br, 1H), 3.18.about.3.08 (m, 3H),
2.97.about.2.92 (m, 2H), 2.08.about.2.04 (m, 2H), 1.95.about.1.85
(m, 2H).
Step B Preparation of Int 17-2
##STR00173##
[0462] To a stirred solution of compound Int 17-1 (2.10 g, 19.0
mmol) and DIEA (4.91 g, 38.0 mmol) in 20 mL of CH.sub.2Cl.sub.2 was
added compound Int 3-8 (8.04 g, 28.5 mmol). The mixture was allowed
to stir at room temperature for 3 hours then concentrated in vacuo.
The mixture was redissloved in ethyl acetate and the organic layer
was washed with 2N NaOH, water, brine, dried over sodium sulfate,
filtered and in vacuo. The resulting residue was recrystallized
from petroleum ether/ethyl acetate=100:1 to provide 3.78 g (56%) of
compound Int 17-2 as a yellow solid. .sup.1H-NMR (DMSO-d6) .delta.
7.64 (s, 1H), 3.48.about.3.46 (m, 4H), 3.18.about.3.15 (m, 2H),
2.97.about.2.94 (m, 1H), 2.81.about.2.76 (m, 2H), 2.39.about.2.36
(m, 4H), 2.19 (s, 3H), 1.97.about.1.94 (m, 2H), 1.80.about.1.73 (m,
2H). MS (ESI) m/z (M+1): 356.
Step C Preparation of Compound 48
##STR00174##
[0464] To a stirred solution of compound Int 17-2 (1.0 g, 2.81
mmol) and compound Int 16-2 (670 mg, 2.81 mmol) in THF (10 mL) was
added LDA (5.6 mL, 5.60 mmol) at -78.degree. C. The reaction was
allowed to stir at -78.degree. C. for 2 hours then quenched with
saturated NH.sub.4Cl. The aqueous layer was extracted with 3 times
with ethyl acetate. The combined organic washings were washed with
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo to
provide resulting residue as yellow oil which was purified using
flash column chromatography on silica gel using ethyl acetate as
the eluent to provide 235 mg of compound 48 as yellow oil.
.sup.1H-NMR (CD.sub.3OD) .delta. 7.60 (s, 1H), 7.43 (s, 1H),
7.28.about.7.24 (m, 2H), 7.16.about.7.11 (m, 2H), 5.68 (q, J=6.8
Hz, 1H), 3.88.about.3.77 (m, 4H), 3.54.about.3.35 (m, 2H),
3.42.about.3.38 (m, 4H), 2.89 (s, 3H), 2.89.about.2.77 (m, 2H),
2.57.about.2.48 (m, 2H), 2.30.about.2.18 (m, 2H), 1.84 (d, J=7.2
Hz, 3H), 1.69.about.1.58 (m, 2H). MS (ESI) m/z (M+1): 558
Example 18
Preparation of Compound 5
##STR00175##
[0466] To a stirred solution of compound Int 1-10 (1800 mg, 3.5
mmol) in 10 mL of acetonitrile was added K.sub.2CO.sub.3 (1.5 g,
10.6 mmol) followed by (7R,8aS)-octahydropyrrolo[1,2-a]pyrazin-7-ol
(500 mg, 3.5 mmol). The resulting reaction was heated to reflux and
allowed to stir at this temperature for 2 hours. The reaction
mixture was then cooled, filtered, and concentrated in vacuo. The
resulting residue was purified using HPLC to provide Compound 5
(900 mg, 45%) as a white solid. .sup.1H NMR (CDCl.sub.3) .delta.
7.71 (s, 1H), 7.57 (s, 1H), 7.26-6.90 (m, 5H), 5.52 (q, J=6.8 Hz,
1H), 4.57-4.54 (m, 1H), 4.13-4.10 (m, 1H), 3.94-3.91 (m, 1H),
3.59-3.55 (m, 1H), 3.35-3.30 (m, 2H), 3.24-3.20 (m, 1H), 3.11-3.08
(m, 1H), 2.95-2.89 (m, 5H), 2.58-2.34 (m, 5H), 2.26-2.23 (m, 1H),
1.86-1.72 (m, 2H), 1.70 (d, J=6.8 Hz, 3H). MS-ESI (ESI) m/z (M+1):
576
Example 19
Determination of IC.sub.50 vs CYP3A by Measurement of Inhibition of
Lopinavir Metabolism
[0467] This assay was performed in a standard 96-well plate design.
IC.sub.50 values were calculated from the percent inhibition
observed for each test compound at 6 concentrations (for example,
0.098, 0.391, 1.56, 6.25, 25 and 100 nM). The incubation substrate
mix contains 1.5 .mu.M lopinavir, 0.01 mg/mL protein human liver
microsomes (BD Gentest), 1 mM NAPDH, 3.3 mM MgCl.sub.2 and 100 mM
potassium phosphate buffer (pH 7.4). The production of the sum of
three hydroxylated metabolites (M2: 6-hydroxy lopinavir, M3:
4-hydroxy lopinavir, M4: 4-hydroxy lopinavir (epimer of M3), Kumar
et al., 1999) was determined after incubation for 8 min at
37.degree. C. Quantitation of the metabolite peak area ratio
against an internal standard (tolbutamide) was determined by
LC/MS/MS analysis following acetonitrile treatment of the
incubations.
[0468] Samples were analyzed in the MRM mode with a SCIEX API-4000
mass spectrometer (Applied Biosystems, Foster City, Calif.), with a
Shimadzu LC-20 AD pump (Shimadzu corporation, Kyoto, JP) and a CTC
PAL autosampler (Agilent Technologies, Switzerland). A Phenomenex,
Luna, 5 .mu.m, 100 A, 2.00.times.30 mm HPLC column was used for the
separation. The mobile phases were: (A) 0.1% formic acid in water
and (B) 0.1% formic acid in acetonitrile. The binary gradient was
as follows.
TABLE-US-00005 AutoSampler: CTC PAL Loop Volume 1 (user entered)
100 .mu.L Loop Volume 2 (user entered) 100 .mu.L Actual Injection
Volume 10.0 .mu.L
TABLE-US-00006 Binary Gradient Total Flow: 700 .mu.L/min Time (min)
A (%) B (%) 0.01 95 5 0.50 2 98 0.70 2 98 0.71 95 5 1.00 System
Controller Stop
The mass spectrum parameters were as follows:
TABLE-US-00007 MS Parameters: CUR Curtain gas (psi): 20 GS1 Ion
source gas1(psi): 55 GS2 Ion source gas2(psi): 60 IS IonSpray
voltage (V): 5500 TEM Temperature (.degree. C.): 600 ihe Interface
heater (on/off): ON CAD Collision Activated Dissociation (psi): 10
EP Entrance Potential (V): 10 CXP Collision Cell Exit Potential (V)
12
The LC/MS/MS parameters for the analytes were as follows.
TABLE-US-00008 LC/MS/MS Analysis Ion Transition DP De- CE Col- RT
Re- Q1 Q3 clustering lission tention Mass Mass Poten- Energy Time
Compound (m/z) (m/z) tial (V) (V) (min) M2-4 645.2 447.2 30 25 0.51
Lopinavir 629.2 183.1 80 63 0.56 IS 271.1 155.3 52 25 0.49
(Tolbutamide)
[0469] The peak area ratio of the analyte to the internal standard
was used to quantify the metabolite. The values of peak area ratios
in the presence of test compound were compared to those of maximum
or minimum controls and were expressed as % inhibition by
interpolating between the maximum and minimum peak area ratios.
Incubations with no inhibitor were defined as the maxima and with 5
.mu.M ketoconazole were defined as the minima
The following equation was used to calculate the % inhibition:
[1-[(X-Low control)/(High control-Low control)]]*100
[0470] For the IC.sub.50 calculation, SigmaPlot was used to plot
the mean % inhibition versus the test compound concentrations and
for non-linear regression analysis of the data. Depending on the
range of data points defining the inhibition curve, the data may
have been fit to the 4-parameter logistic equation.
Example 20
Determination of IC.sub.50 in a Cocktail Assay for CYPs 1A2, 2C9,
2C19, 2D6 and 3A4
[0471] This assay was performed in a standard 96-well plate design.
IC.sub.50 values were calculated from the percent inhibition
observed for each test compound at 6 concentrations (for example,
0.0032, 0.016, 0.08, 0.4, 2 and 10 .mu.M). The incubation substrate
mix contains 10 .mu.M phenacetin (1A2), 5 .mu.M diclofenac (2C9),
30 .mu.M mephenyloin (2C19), 5 .mu.M dextromethorphan (2D6) and 2
.mu.M midazolam (3A4), 0.1 mg/mL protein human liver microsomes (BD
Gentest), 1 mM NAPDH, 3.3 mM MgCl.sub.2 and 100 mM potassium
phosphate buffer (pH 7.4). The production of the metabolite of each
probe substrate was determined after incubation for 10 min at
37.degree. C. Quantitation of the metabolite peak area ratio
against an internal standard (tolbutamide) was determined by
LC/MS/MS analysis following acetonitrile treatment of the
incubations.
TABLE-US-00009 Probe Substrate Reaction (isoform) Metabolite
Detected Phenacetin O-deethylation (CYP1A2) Acetaminophen
Diclofenac 4'-hydroxylation (CYP2C9) 4'-Hydroxydiclofenac
Mephenytoin 4'-hydroxylation (CYP2C19) 4'-Hydroxymephenytoin
Dextro- O-demethylation (CYP2D6) Dextrorphan methorphan Midazolam
1'-hydroxylation (CYP3A4) 1'-Hydroxymidazolam
[0472] Samples were analyzed in the MRM mode with a SCIEX API-4000
mass spectrometer (Applied Biosystems, Foster City, Calif.), with a
Shimadzu LC-20 AD pump (Shimadzu corporation, Kyoto, JP) and a CTC
PAL autosampler (Agilent Technologies, Switzerland). A Phenomenex,
Luna, 5 nm, 100 A, 2.00.times.30 mm HPLC column was used for the
separation. The mobile phases were: (A) 0.1% formic acid in water
and (B) 0.1% formic acid in acetonitrile. The binary gradient was
as follows.
TABLE-US-00010 AutoSampler: CTC PAL Loop Volume 1 (user entered)
100 .mu.L Loop Volume 2 (user entered) 100 .mu.L Actual Injection
Volume 10.0 .mu.L
TABLE-US-00011 Binary Gradient Total Flow: 700 .mu.L/min Time (min)
A (%) B (%) 0.01 98 2 0.40 30 70 0.80 2 98 1.00 System Controller
Stop
The mass spectrum parameters were as follows:
TABLE-US-00012 MS Parameters: CUR Curtain gas (psi): 20 GS1 Ion
source gas1(psi): 50 GS2 Ion source gas2(psi): 60 IS IonSpray
voltage (V): 5500 TEM Temperature (.degree. C.): 600 ihe Interface
heater (on/off): ON CAD Collision Activated Dissociation (psi): 10
EP Entrance Potential (V): 10 CXP Collision Cell Exit Potential (V)
12
The LC/MS/MS parameters for the analytes were as follows.
TABLE-US-00013 LC/MS/MS Analysis Ion Transition DP De- CE Col- RT
Re- Q1 Q3 clustering lission tention Mass Mass Poten- Energy Time
Compound (m/z) (m/z) tial (V) (V) (min) Acetominophen 152.2 110 40
23 0.36 4'-Hydroxy- 312 231 32 29 0.72 diclofenac 4'-Hydroxy- 235.3
150.3 45 25 0.49 mephenytoin Dextrorphan 258.2 157.2 40 55 0.42
1'-hydroxy- 342.2 203.2 40 30 0.53 midazolam IS 271.1 155.3 69 25
0.71
[0473] The peak area ratio of the analyte to the internal standard
was used to quantify the metabolite. The values of peak area ratios
in the presence of test compound were compared to those of maximum
or minimum controls and were expressed as % inhibition by
interpolating between the maximum and minimum peak area ratios.
Incubations with no inhibitor were defined as the maxima.
The following equation was used to calculate the % inhibition:
[1-[(X-Low control)/(High control-Low control)]]*100
[0474] For the IC.sub.50 calculation, SigmaPlot was used to plot
the mean % inhibition versus the test compound concentrations and
for non-linear regression analysis of the data. Depending on the
range of data points defining the inhibition curve, the data may
have been fit to the 4-parameter logistic equation.
Example 21
[0475] Determination of IC.sub.50 vs CYP11B1/CYP11B2 by Measurement
of Cortisol/Aldosterone Synthesis
[0476] This assay was performed in a standard 384-well plate design
using cultured V79 cells stably expressing human CYP11B1 or human
CYP11B2. Test compounds at 10 concentrations (for example, 10000,
3333.3, 1111.1, 370.4, 123.5, 41.2, 13.7, 4.6, 1.5 and 0.5 nM) were
added in 384-well plate after the cell-seeding procedure. The
incubation substrate contains 1500 nM RSS for CYP11B1 assay/750 nM
DOC for CYP11B2 assay. The
[0477] Cortisol/Aldosterone production of cell culture supernatant
was determined by Cortisol/Aldosterone HTRF kit after for about 15
hours incubation at RT (protect from light). IC50 values were
calculated from the percent inhibition observed for each test
compound at 10 concentrations.
[0478] The assay plate was read using Envision (Perkin Elmer,
Waltham, Mass.) at 665 nm and 590 nm (using Filter Barcode of 217#,
205#; Mirror Barcode of 446#).
The Envision setting parameters were as follows:
TABLE-US-00014 Envision Parameters: Light source: Laser Top mirror
(Barcode): 446# Bottom mirror (Barcode): None Emission Filter
(Barcode): 217# 2.sup.nd emission Filter (Barcode): 205#
Measurement height (mm): 6.5 Delay (.mu.s): 50 Window time (.mu.s):
400 Number of sequential windows: 1 Time between flashes 16600
Number of flashes 10 Number of flashes for 2.sup.nd detector 10
[0479] Data are analyzed using Assay Data Analyzer. All ratio data
(665 nm/590 nm) are back calculated according to the standard
curve, resulting in Cortisol/Aldosterone concentrations. IC.sub.50
values are reported as the Inflection Point (IP) of a four
parameter fit of the titration data.
[0480] The following equation was used to calculate the %
inhibition:
% Activity=100.times.{1-(Sample_back calculated
Cortisol/Aldosterone concentration-LC_back calculated
Cortisol/Aldosterone concentration)/(HC_back calculated
Cortisol/Aldosterone concentration-LC_back calculated
Cortisol/Aldosterone concentration)}
Curve Fitting: Four Parameter Logistic:
[0481] y = n + m - n 1 + ( x ) p ##EQU00001##
Example 22
[0482] The table below provides data for compounds of Formula (I)
obtained using the assays described in Examples 18 and 19,
above.
TABLE-US-00015 Cmpd No. 3A4(LPV) CYP1A2 CYP2C9 CYP2C19 CYP2D6
CYP11B1 CYP11B2 1 1.4 >10000 2299 2534 2782 1765 1716 2 1
>10000 3219 1829 8011 215 77 3 2.7 >10000 1470 >10000 2700
>10000 >10000 4 <0.1 >10000 1843 721 5248 225 445 5 3.8
>10000 4460 3853 >10000 2004 4771 6 1.4 >10000 1937
>10000 >10000 1558 3878 7 1.7 >10000 3393 >10000
>10000 4089 16330 8 1.8 >10000 3497 >10000 >10000
>10000 4005 9 2.8 >10000 4118 >10000 >10000 2045 3922
10 <0.98 >10000 2684 >10000 >10000 1913 >10000 11
<0.98 >10000 2148 8018 >10000 1105 3394 12 1.0 >10000
1748 >10000 2851 1464 1694 13 1.4 >10000 7407 >10000 9618
1561 8584 14 1.4 >10000 9759 >10000 1539 1055 1152 15 1.2
>10000 2461 >10000 3562 1708 3625 16 5.2 1495 9121 8038
>10000 >10000 4601 17 1.7 2186 2450 2254 3382 >10000 9354
18 1.1 >10000 2295 2164 5003 2594 4584 19 1.7 >10000 1412
7953 7009 1850 1927 20 4.1 2769 4500 4109 >10000 1015 2236 21
1.9 >10000 1158 10000 6176 3918 >10000 22 1.3 8657 5695 2291
3655 1162 1353 23 1.6 >10000 5009 >10000 4650 1221 4573 24
1.9 >10000 1352 >10000 3199 4265 >10000 25 1.9 >10000
9728 >10000 8349 6929 >10000 26 1.5 >10000 4274 7209
>10000 3041 9224 27 2.6 >10000 1766 6478 3848 1575 2269 28
4.4 >10000 6612 3682 6495 3553 4643 29 2.9 >10000 >10000
>10000 >10000 1442 4366 30 3.6 >10000 >10000 >10000
4920 4515 2903 31 4.4 >10000 >10000 >10000 >10000
>10000 >10000 32 1.2 >10000 1560 3444 1298 1579 1029 33
2.3 >10000 >10000 7515 4803 4750 1605 34 1.0 >10000 2951
>10000 >10000 1032 2979 35 3.8 >10000 >10000 >10000
8893 2184 4998 36 4.3 >10000 >10000 >10000 4077 1350 3834
37 4.1 5808 6102 >10000 >10000 3815 193 38 2.5 >10000 1220
4185 7130 2137 1309 39 8.0 3730 4700 2650 2180 2475 2466 40 0.8
>10000 357 3045 2888 1148 3900 41 2.1 >10000 2256 4949 2298
nd nd 42 32 >10000 >10000 >10000 >10000 7800 >10000
43a 6.0 >10000 >10000 >10000 2900 nd nd 43b 2.0 >10000
>10000 9200 3600 nd nd 44 1.1 >10000 3565 8386 2408 nd nd 45a
<0.98 >10000 336 1132 5684 nd nd 45b <0.98 >10000 1452
4494 7854 nd nd 46a <0.98 >10000 >10000 >10000
>10000 nd nd 46b <0.98 >10000 >10000 >10000
>10000 nd nd 47 13 >10000 >10000 >10000 5844 nd nd 48
9.4 >10000 >10000 8065 2846 nd nd nd = no data
Example 24
In Vivo Effects of the Compounds of the Invention on the
Pharmacokinetics of a Therapeutic Compound Metabolized by CYP3A4 in
Sprague-Dawley Rats
[0483] The ability of the compounds of the present invention to
enhance the exposure of two known HIV protease inhibitors that are
metabolized by CYP3A4, Lopinavir (LPV) and Atazanavir (ATV), was
evaluated in rats. Fasted male Sprague-Dawley rats were co-dosed
with 10 mg/kg PO dose of a compound of Formula (I) and 10 mg/kg of
either LPV or ATV. The mean AUC values are listed in the Table
below and are compared to dosing with and without the PKE.
TABLE-US-00016 LPV Ratio ATV Ratio Compound of AUC.sub.0-inf (+/-)
AUC.sub.0-inf (+/-) Formula (I) (uM*h) PKE (uM*h) PKE none 2.2 n/a
1.2 n/a 2 22 10 3.4 2.8 4 14.3 6.5 2.4 2 5 26 11.8 2.4 2 44 14.2
6.5 -- --
[0484] Co-administration of compounds 2, 4, 5 or 44 resulted in an
increase in mean LPV exposure of 6-10.times.. The mean increase in
exposure when these compounds were co-dosed with ATV was
2-2.8.times.. These results show that the compounds of the present
invention are efficient and potent enhancer of the pharmacokinetics
of both Lopinavir and Atazanavir in vivo.
Example 25
In Vivo Effects of the Compounds of the Present Invention on the
Pharmacokinetics of Therapeutic Compound Metabolized by CYP3A4 in
Male Cynomolgus Monkeys
[0485] The ability of the compounds of the present invention to
enhance the exposure of two different marketed HIV protease
inhibitors, Lopinavir (LPV) and Atazanavir (ATV), was evaluated in
non-human primates. Fasted male cynomolgus monkeys were co-dosed
with 3 mg/kg PO dose of selected compounds of Formula (I) and 3
mg/kg of either LPV or ATV. The mean AUC values are listed in the
Table below.
TABLE-US-00017 LPV Ratio ATV Ratio Compound of AUC.sub.0-inf (+/-)
AUC.sub.0-inf (+/-) Formula (I) (uM*h) PKE (uM*h) PKE none 0.01 n/a
0.005 n/a 2 12.2 1220 1.0 200 4 7.9 790 1.9 380 5 6.2 620 2.4 480
44 5.6 560 nd nd
[0486] Co-administration of compounds 2, 4, 5 or 44 resulted in an
increase in mean LPV exposure of 620-1220.times.. The mean increase
in exposure when these compounds were co-dosed with ATV was
200-480.times.. These results show that the compounds of the
present invention are efficient and potent enhancers of the
pharmacokinetics of both Lopinavir and Atazanavir in cynomolgus
monkeys.
[0487] The present invention is not to be limited by the specific
embodiments disclosed in the examples that are intended as
illustrations of a few aspects of the invention and any embodiments
that are functionally equivalent are within the scope of this
invention. Indeed, various modifications of the invention in
addition to those shown and described herein will become apparent
to those skilled in the art and are intended to fall within the
scope of the appended claims.
[0488] A number of references have been cited herein, the entire
disclosures of which are incorporated herein by reference.
* * * * *